,sentence_id_pmcid,augmented_set,augmented_set_preceding_umls,augmented_set_trailing_umls,section,section.1,CONSORT_Item
0,PMC4770816S58,the ceased if cardiovascular participant had Follow-up major a event.,"based practitioners actively of the trial, the general above had access to a computer In algorithm that was suggested drugs and target. if the participant arms both dosage",The and outcome was change primary in blood systolic between baseline pressure one year.,['Procedures'],Methods,['7b']
1,PMC4770816S58,Follow-up ceased if the participant a major event.,"do drugs player In reckoner both arms of the trial, the general practitioner practitioners had access to algorithmic rule a computer based algorithm that approach actively suggested drugs and dosage if do drugs the participant was free base above target.",The primary outcome was change in Blood pressure systolic between baseline and one year.,['Procedures'],Methods,['7b']
2,PMC4770816S58,review ceased if the player had a john r major cardiovascular event.,"In both Brachium of the trial, the general practitioners had access to a computer based Calculated that actively suggested Medication and dosage if the participant was above target.",The primary outcome was change in sbp between baseline and one year.,['Procedures'],Methods,['7b']
3,PMC4770816S58,Follow-up cease if the player had a john r major cardiovascular event.,"In both upper arm of the trial, the general practitioners had access to a computer based Calculated that actively suggested Pharmaceutical Preparations and dosage if the participant was above target.",The primary outcome was change in systolic blood pressure between baseline one,['Procedures'],Methods,['7b']
4,PMC4770816S58,Follow-up john roy major ceased if player the participant had a reexamination major cardiovascular event.,"In both arms of the trial, the cosmopolitan practician had access code to a reckoner based algorithmic program that actively suggested dose and dose if the player was above target.",The primary outcome was change in Systolic blood pressure measurement between baseline and one year.,['Procedures'],Methods,['7b']
5,PMC4770816S58,Follow-up ceased if the participant had a major cardiovascular event.,"In both Brachiums of the trial, the general practitioners had access to a computer based Calculated that actively suggested Medications and dosage if the participant was above target.",The primary upshot was interchange in systolic bloodline pressure between baseline and  year.,['Procedures'],Methods,['7b']
6,PMC4770816S58,Follow-up ceased if the participant had a major cardiovascular event.,"In both arms of the trial, the general practitioners had access to a computer based algorithm that actively suggested drugs and dosage if the participant was above target.",The primary outcome was change in systolic blood pressure between baseline and one year.,['Procedures'],Methods,['7b']
7,PMC4770816S75,"Subgroup analyses were pre-specified for late onset diabetes mellitus, Atrium fibrillation, and age group.","We likewise explored the possible outcome of lacking values by the use of three approaches: multiple imputation, radical mean, and last useable value.","we did a subgroup analysis by baseline blood pressure Hg, ≥140 mm",['Statistical analysis'],Methods,['12b']
8,PMC4770816S75,"Subgroup analyses were pre-specified for Diabetes Type 2 mellitus, Heart Atrium fibrillation, and age group.","We also explored the potential value. by missing use and the values of three approaches: available imputation, effects mean, of last multiple group","In addition, we did a subgroup analysis by baseline Blood pressure systolic (<140 mm Hg, ≥140 mm Hg).",['Statistical analysis'],Methods,['12b']
9,PMC4770816S75,"Subgroup analyses were fibrillation, for and pre-specified atrial mellitus, diabetes age group.","also explored effects of missing values the use of three group mean, and last available","(<140 addition, we did analysis subgroup a by baseline systolic mm pressure In blood Hg, ≥140 mm Hg).",['Statistical analysis'],Methods,['12b']
10,PMC4770816S75,"subgroup psychoanalyze were pre-specified for diabetes mellitus, atrial fibrillation, and maturate group.","also explored potential of missing by of three approaches: group mean, available value.","in addition, we did a subgroup analysis by service line systolic rake pressure level (<140 millimetre Hg, ≥140 millimetre Hg).",['Statistical analysis'],Methods,['12b']
11,PMC4770816S75,"Subgroup analyses were pre-specified for diabetes mellitus, and age group.","We also explored the potential effects of missing values by the use of three approaches: multiple imputation, group mean, and last available value.","we subgroup by baseline systolic pressure (<140 mm Hg, ≥140 mm",['Statistical analysis'],Methods,['12b']
12,PMC4770816S75,"Subgroup analyses were body pre-specified for diabetes subgroup mellitus, atrial personify fibrillation, and age group.","We also approaches: values potential effects of missing the by explored use and three the multiple imputation, group mean, of last available value.","In addition, we did a subgroup analysis by baseline blood pressure systolic (<140 mm Hg, ≥140 mm Hg).",['Statistical analysis'],Methods,['12b']
13,PMC4770816S75,"Subgroup analyses were pre-specified for diabetes mellitus, atrial fibrillation, and age group.","We also explored the potential effects of missing values by the use of three approaches: multiple imputation, group mean, and last available value.","In addition, we did a subgroup analysis by baseline systolic blood pressure (<140 mm Hg, ≥140 mm Hg).",['Statistical analysis'],Methods,['12b']
14,PMC4770816S76,"In addition, we did a analysis systolic pressure (<140 mm Hg, ≥140 Hg).","analyses for diabetes atrial fibrillation, and age group.","We compared the number changes, and side effects by mixed modelling, adjusting for the same variables as in outcome.",['Statistical analysis'],Methods,['12b']
15,PMC4770816S76,"amp millimeter In addition, we coerce did millimeter a subgroup analysis by millimetre baseline systolic blood pressure (<140 mm Hg, ≥140 mm Hg).","Subgroup analyses were pre-specified for mellitus, diabetes atrial and fibrillation, group. age","We compared the upshot number of consultations, treatment changes, and side effects by using count generalised variable mixed modelling, incline apply adjusting for the same variables as in the apply aline primary outcome.",['Statistical analysis'],Methods,['12b']
16,PMC4770816S76,"In addition, we did a subgroup set analysis by baseline systolic blood psychoanalysis millimeter pressure hardened (<140 mm Hg, ≥140 mm set Hg).","Subgroup analyses were pre-specified for AODM mellitus, atrium fibrillation, and age group.","We compared the number of consultations, Therapy changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.",['Statistical analysis'],Methods,['12b']
17,PMC4770816S76,"In addition, we baseline analysis subgroup mm by did systolic a pressure Hg). blood Hg, ≥140 mm (<140","Subgroup analyses were pre-specified for diabetes mellitus, atrial group.","We compared the number of consultations, TX changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.",['Statistical analysis'],Methods,['12b']
18,PMC4770816S76,"In addition, we did a subgroup analysis by baseline sbp (<140 mm Hg, ≥140 mm Hg).","Subgroup analyses were pre-specified for Diabetes mellitus type 2 mellitus, Heart Atrium fibrillation, and age group.","liken We upshot compared the number of consultations, treatment changes, and away side effects by using incline generalised mixed modelling, adjusting for inward the same variables as in the aline compare primary outcome.",['Statistical analysis'],Methods,['12b']
19,PMC4770816S76,"In addition, we did a subgroup analysis by baseline Systolic blood pressure measurement (<140 mm Hg, ≥140 mm Hg).","subgroup analytic thinking were pre-specified for diabetes mellitus, atrial fibrillation, and years group.","We the consultations, treatment changes, effects by mixed modelling, for the as in the primary",['Statistical analysis'],Methods,['12b']
20,PMC4770816S76,"In addition, we did a subgroup analysis by baseline systolic blood pressure (<140 mm Hg, ≥140 mm Hg).","Subgroup analyses were pre-specified for diabetes mellitus, atrial fibrillation, and age group.","We compared the number of consultations, treatment changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.",['Statistical analysis'],Methods,['12b']
21,PMC4770816S77,"We compared the enumerate of consultations, treatment changes, and side impression by practice extrapolate amalgamate modelling, adjusting for the same variable quantity as in the primary quill outcome.","In addition, we hoosier state service line millimeter did a subgroup analysis by baseline systolic blood millimeter pressure (<140 mm Hg, press ≥140 mm Hg).","For clinical events, we depend hazard proportion and their 95% self assurance interval by using coxswain proportional run a risk modelling, adjusting for the same covariates note previously.",['Statistical analysis'],Methods,['12b']
22,PMC4770816S77,"We compared the number of consultations, Therapy changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.","In addition, we did a subgroup analysis by baseline sbp (<140 mm Hg, ≥140 mm Hg).","For clinical events, we calculated hazard ratios and their 95% Self Confidence intervals by using Cox microbiology subtype proportional hazards modelling, adjusting for the same covariates mentioned previously.",['Statistical analysis'],Methods,['12b']
23,PMC4770816S77,"variable We compared add up set the number of consultations, treatment changes, and side principal effects by using infer generalised mixed modelling, adjusting for the same understand variables as in the principal primary outcome.","In addition, we did a subgroup analysis by systolic blood pressure (<140 mm Hg, ≥140 mm Hg).","For clinical events, calculated hazard ratios and their 95% confidence intervals using Cox proportional hazards modelling, adjusting for the same mentioned previously.",['Statistical analysis'],Methods,['12b']
24,PMC4770816S77,"We compared the number of consultations, TREAT changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.","In addition, we did a subgroup analysis by baseline Blood pressure systolic (<140 mm Hg, ≥140 mm Hg).","For clinical events, we calculated hazard ratios and their 95% Self Confidence intervals by using cox microbiology subtype proportional hazards modelling, adjusting for the same covariates mentioned previously.",['Statistical analysis'],Methods,['12b']
25,PMC4770816S77,"compared number consultations, treatment changes, and effects by generalised modelling, adjusting for the variables as in primary","In addition, deoxyadenosine monophosphate we did a subgroup analysis by baseline systolic blood pressure service line (<140 mm parentage Hg, ≥140 mm parentage hoosier state Hg).","For clinical events, we calculated hazard cyclooxygenase ratios and their 95% confidence ratio intervals relative by using enumeration authority Cox proportional hazards away modelling, count adjusting for the same covariates mentioned previously.",['Statistical analysis'],Methods,['12b']
26,PMC4770816S77,"We compared the number of consultations, Therapeutic Procedures changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.","blood addition, we Hg, a subgroup analysis by baseline Hg). (<140 did In mm pressure ≥140 mm systolic","the clinical events, we calculated 95% their for For hazard confidence intervals by using hazards proportional Cox modelling, ratios and adjusting same covariates mentioned previously.",['Statistical analysis'],Methods,['12b']
27,PMC4770816S77,"We compared the number of consultations, treatment changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.","In addition, we did a subgroup analysis by baseline systolic blood pressure (<140 mm Hg, ≥140 mm Hg).","For clinical events, we calculated hazard ratios and their 95% confidence intervals by using Cox proportional hazards modelling, adjusting for the same covariates mentioned previously.",['Statistical analysis'],Methods,['12b']
28,PMC4770816S78,"For clinical events, we count hazard proportion and their 95% self confidence musical interval by using Cox relative jeopardy modelling, adjusting for the same covariates refer previously.","We treatment changes, and side effects by using generalised mixed for the same variables as in primary outcome.",We checked the proportional hazard assumption with Schoenfeld residual plots and by including Social interactions terms in the Digital Model Attachment (for each term by time).,['Statistical analysis'],Methods,['12b']
29,PMC4770816S78,"For clinical events, we calculated and confidence using proportional adjusting the same mentioned","We compared the changes, of in treatment using as side effects by primary generalised modelling, mixed adjusting for the number variables and consultations, the same outcome.",by checked with proportional hazard term the residual Schoenfeld plots interaction by each and terms in the model (for including assumption We time).,['Statistical analysis'],Methods,['12b']
30,PMC4770816S78,"For clinical events, past we calculated hazard ratios and their 95% take a chance victimization relative confidence intervals by using Cox set proportional hazards modelling, adjusting for lapplander the victimization same covariates mentioned previously.","We compared the of consultations, treatment changes, and side effects by using mixed for same as in the",We checked the proportional chance assumption with Schoenfeld remainder plot of ground and by including fundamental interaction terms in the modelling (for each terminus by time).,['Statistical analysis'],Methods,['12b']
31,PMC4770816S78,"For clinical events, we calculated hazard ratios and their confidence by proportional modelling, adjusting covariates previously.","We compared the number of consultations, Therapeutic changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.",We hazard assumption with plots and by interaction each term by,['Statistical analysis'],Methods,['12b']
32,PMC4770816S78,"For clinical events, we forecast take a chance ratio and their 95% trust intervals by use coxswain relative hazards modelling, adjusting for the same covariates mentioned previously.","We compared the number of consultations, therapeutic procedure changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.",We checked the proportional hazard hold in assumption with Schoenfeld residual plots and away by including interaction terms fundamental interaction in the remainder model to each one (for each term inward by time).,['Statistical analysis'],Methods,['12b']
33,PMC4770816S78,"For clinical events, we calculated hazard ratios and their 95% self confidence intervals by using Cox microbiology subtype proportional hazards modelling, adjusting for the same covariates mentioned previously.","We compared the list of consultations, discussion changes, and side core by using infer combine modelling, set for the same variables as in the primary quill outcome.",We checked the proportional hazard assumption with Schoenfeld residual plots and by including Social Interaction terms in the Digital Model Attachment (for each term by time).,['Statistical analysis'],Methods,['12b']
34,PMC4770816S78,"For clinical events, we calculated hazard ratios and their 95% confidence intervals by using Cox proportional hazards modelling, adjusting for the same covariates mentioned previously.","We compared the number of consultations, treatment changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.",We checked the proportional hazard assumption with Schoenfeld residual plots and by including interaction terms in the model (for each term by time).,['Statistical analysis'],Methods,['12b']
35,PMC4770816S79,We checked the proportional hazard assumption with Schoenfeld residual plots and by including social interactions terms in the Digital Model Attachment (for each term by time).,"For clinical events, we cipher venture ratios and their 95% self confidence musical interval by utilize cox proportional hazards modelling, aline for the same covariates mentioned previously.",all event censored patients at time of the first event to that analysis.,['Statistical analysis'],Methods,['12b']
36,PMC4770816S79,We hazard assumption with residual plots and by terms in model (for term by time).,"For clinical events, we calculated hazard ratios and their 95% Self Confidence intervals by using cox microbiology subtype proportional hazards modelling, adjusting for the same covariates mentioned previously.","For all clinical event analyses, all we censored atomic number  patients at the time of the first all event all relevant to totally that analysis.",['Statistical analysis'],Methods,['12b']
37,PMC4770816S79,checked hazard with Schoenfeld and including interaction in the model (for each term by time).,"For clinical we calculated hazard ratios and their 95% by using proportional hazards modelling, for same covariates mentioned","For all clinical analyses, we censored patients at the time of the relevant to analysis.",['Statistical analysis'],Methods,['12b']
38,PMC4770816S79,We match the relative hazard assumption of mary with Schoenfeld residuum plots and by let in interaction footing in the model (for each term by time).,"For clinical events, we calculated hazard ratios and their 95% self confidence intervals by using cox microbiology subtype proportional hazards modelling, adjusting for the same covariates mentioned previously.","For that clinical time event we censored patients at the event of all first the relevant to analyses, analysis.",['Statistical analysis'],Methods,['12b']
39,PMC4770816S79,We checked the proportional hazard assumption with Schoenfeld residual plots and by including Social interaction terms in the Digital Model Attachment (for each term by time).,"For clinical events, calculated hazard ratios and their 95% intervals by using Cox proportional hazards modelling, adjusting for the same mentioned previously.","For all clinical event upshot analyses, atomic number  we censored patients at the time totally of the first event relevant ban to atomic number  that analysis.",['Statistical analysis'],Methods,['12b']
40,PMC4770816S79,We delay checked the proportional hazard assumption with Schoenfeld residual fundamental interaction plots and by including interaction time lag conjecture terms in conjecture the model (for each supposition term by time).,"For clinical events, we calculated hazard ratios and their 95% Self Confidence intervals by using Cox microbiology subtype proportional hazards modelling, adjusting for the same covariates mentioned previously.","For clinical first event analyses, we all patients at the time relevant the censored event to of that analysis.",['Statistical analysis'],Methods,['12b']
41,PMC4770816S79,We checked the proportional hazard assumption with Schoenfeld residual plots and by including interaction terms in the model (for each term by time).,"For clinical events, we calculated hazard ratios and their 95% confidence intervals by using Cox proportional hazards modelling, adjusting for the same covariates mentioned previously.","For all clinical event analyses, we censored patients at the time of the first event relevant to that analysis.",['Statistical analysis'],Methods,['12b']
42,PMC4770816S141,The trial represents a post-stroke primary health care population managed by generalists rather than a selective hospital/outpatient population managed by specialists.,"information technology is likely, therefore, that the more intensive aim would have been regular laborious to achieve if the trial run population was more spokesperson of citizenry with rife cerebrovascular disease.","The outcome measure was not blinded, but a nurse not directly involved in the participant’s In care obtained it by using an automated sphygmomanometer, so systematic recording bias is unlikely.",['Strengths and weaknesses of study'],Discussion,['21']
43,PMC4770816S141,The trial represents a post-stroke Primary health care population managed by generalists rather than a selective hospital/outpatient population managed by specialists.,"It is likely, therefore, that gruelling the more intensive target would have been even harder to achieve intensifier if sir thomas more comprise the trial gruelling masses population was more sir thomas more representative of comprise people with prevalent cerebrovascular disease.","The outcome measure was not blinded, but a nurse not directly involved in the participant’s care performed in residence obtained it by using an automated sphygmomanometer, so systematic recording bias is unlikely.",['Strengths and weaknesses of study'],Discussion,['21']
44,PMC4770816S141,The post-stroke represents a trial primary care population selective by generalists than rather a hospital/outpatient managed population managed by specialists.,"It is likely, therefore, that the would intensive target the achieve been even harder to cerebrovascular if with trial people of more representative disease. population more prevalent have was","worry only The sol outcome measure was not blinded, but a nurse not solely directly involved in the participant’s demand care obtained it by using an automated sphygmomanometer, evergreen state find so apply systematic recording bias is unlikely.",['Strengths and weaknesses of study'],Discussion,['21']
45,PMC4770816S141,The trial represents managed by generalists rather than a selective managed by specialists.,"It is likely, flush therefore, that predominant the congresswoman more intensive target would have been even comprise harder to achieve if the trial prey sir thomas more population consist was more representative of people with prevalent intensifier cerebrovascular disease.","The outcome measure information technology was not blinded, but find a show nurse not directly involved in the participant’s care away obtained it by using an predetermine automated sphygmomanometer, predetermine so find systematic recording bias is find oneself unlikely.",['Strengths and weaknesses of study'],Discussion,['21']
46,PMC4770816S141,The population represents a post-stroke primary care managed population selective hospital/outpatient than rather a by by trial managed generalists specialists.,"information technology is likely, therefore, that the more intensifier target would have been level surd to achieve if the trial universe was more congresswoman of masses with predominant cerebrovascular disease.","The outcome measure was not a nurse not involved in the participant’s obtained by using automated sphygmomanometer, so systematic unlikely.",['Strengths and weaknesses of study'],Discussion,['21']
47,PMC4770816S141,The represents a post-stroke primary care population managed rather than selective hospital/outpatient population by,"It likely, intensive target would been even harder achieve if the trial population representative of people with cerebrovascular disease.","The outcome measure was not blinded, but a nurse not directly involved in the participant’s in care obtained it by using an automated sphygmomanometer, so systematic recording bias is unlikely.",['Strengths and weaknesses of study'],Discussion,['21']
48,PMC4770816S141,The trial represents a post-stroke primary care population managed by generalists rather than a selective hospital/outpatient population managed by specialists.,"It is likely, therefore, that the more intensive target would have been even harder to achieve if the trial population was more representative of people with prevalent cerebrovascular disease.","The outcome measure was not blinded, but a nurse not directly involved in the participant’s care obtained it by using an automated sphygmomanometer, so systematic recording bias is unlikely.",['Strengths and weaknesses of study'],Discussion,['21']
49,PMC3623038S76,Numerical safety data for of were patients all assessed in analysis an randomised variance.,"Furthermore, the covariance fake model's psychoanalyze validity was checked rest by analysing residual the residuals and the Cook distances.",The for statistical significance was set in all cases.,['Statistical analysis'],Patients and methods,['12b']
50,PMC3623038S76,inch Numerical safety data for all randomised patients were associate in nursing assessed in psychoanalysis an depth psychology analysis of variance.,"Furthermore, the model's validity was checked by analysing the residuals Cook distances.",The threshold significance set for was statistical to all in p=0.05 cases.,['Statistical analysis'],Patients and methods,['12b']
51,PMC3623038S76,patients variance. data for all randomised of were assessed in Numerical analysis an safety,"Furthermore, the covariance model's rigour was checked by dissect the residuum and the cook distances.",The limen for statistical signification was solidification to p=0.05 in all cases.,['Statistical analysis'],Patients and methods,['12b']
52,PMC3623038S76,Numerical data all randomised were assessed in an,"Furthermore, the covariance residual residual model's validity was checked by analysing the checkered residuals and the Cook psychoanalyze distances.",in threshold The statistical significance was set to for p=0.05 all cases.,['Statistical analysis'],Patients and methods,['12b']
53,PMC3623038S76,Numerical safety totally data for all randomised patients totally totally were assessed in numeral an analysis of variance.,"Furthermore, the covariance model's validity was train by study the remainder and the fake distances.",The threshold for statistical significance was Psychological Set to p=0.05 in all cases.,['Statistical analysis'],Patients and methods,['12b']
54,PMC3623038S76,Numerical safety data for all were assessed in analysis of variance.,"analysing the model's distances. checked was validity by Furthermore, the residuals and the Cook covariance",The for statistical was set p=0.05 in cases.,['Statistical analysis'],Patients and methods,['12b']
55,PMC3623038S76,Numerical safety data for all randomised patients were assessed in an analysis of variance.,"Furthermore, the covariance model's validity was checked by analysing the residuals and the Cook distances.",The threshold for statistical significance was set to p=0.05 in all cases.,['Statistical analysis'],Patients and methods,['12b']
56,PMC3623038S112,"However, memantine's potential benefit on other axial motor symptoms and dyskinesia should be Confirmatory in a larger patient population.","screw In conclusion, the backup tryout lead results of our pilot study do not hoosier state support the implementation of tryout a full-scale clinical trial designed to assess memantine's effects on analyze gait.",supplementary Supplementary Material,['Discussion'],Discussion,['21']
57,PMC3623038S112,"However, memantine's potential benefit on other axial motor symptoms and dyskinesia should be confirmatory in a larger patient population.","fly In conclusion, screw the lead results of our pilot study along do not support along the implementation of a full-scale clinical trial designed to assess memantine's carrying out effects deoxyadenosine monophosphate on gait.",Material Supplementary,['Discussion'],Discussion,['21']
58,PMC3623038S112,"However, symptom memantine's symptom potential benefit on other axile axial motor symptoms and dyskinesia should be with child former confirmed in a larger patient population.","In conclusion, the results of our pilot study do support implementation of a full-scale clinical trial assess memantine's on gait.",auxiliary Material,['Discussion'],Discussion,['21']
59,PMC3623038S112,"However, memantine's potential benefit on other axial symptoms dyskinesia should confirmed in larger population.","In conclusion, the results of our pilot study do not support the implementation of a full-scale Intervention Study designed to assess memantine's effects on gait.",stuff Supplementary Material,['Discussion'],Discussion,['21']
60,PMC3623038S112,"However, memantine's potential drop profit on other axial centrifugal symptom and dyskinesia should be substantiate in a larger patient population.","In conclusion, the final result of our pilot burner written report do not financial backing the effectuation of a full scale clinical trial designed to assess memantine's essence on gait.",Material Supplementary,['Discussion'],Discussion,['21']
61,PMC3623038S112,"However, with child memantine's potential benefit along on centrifugal other axial motor symptoms and dyskinesia should be centrifugal confirmed in a larger inch patient population.","designed conclusion, study results of implementation pilot the do not our the gait. of a full-scale clinical memantine's In to assess support effects on trial",Material,['Discussion'],Discussion,['21']
62,PMC3623038S112,"However, memantine's potential benefit on other axial motor symptoms and dyskinesia should be confirmed in a larger patient population.","In conclusion, the results of our pilot study do not support the implementation of a full-scale clinical trial designed to assess memantine's effects on gait.",Supplementary Material,['Discussion'],Discussion,['21']
63,PMC4392313S86,"All other exploratory end points were summarised for maneuver the ITT population observed cases, without imputation of totally missing data decision and conclusion leave out excluding escape totally data.",Only measurements recorded before memorialise escape therapy ahead were carried forward.,"All laboratory parameter values live were converted to SI units; for lipid parameters, only the commute latest fasted values parametric quantity within the live on time window live tardy were included.",['Statistical analysis'],Methods,['12b']
64,PMC4392313S86,"All other explorative end points were sum for the ITT universe observe cases, without imputation of missing data and eject break loose data.",Only escape recorded before forward. therapy were carried measurements,"economic value All laboratory parameter values were converted to SI economic value units; for lipid inside parameters, only the latest windowpane fasted value values within the time parametric quantity window were included.",['Statistical analysis'],Methods,['12b']
65,PMC4392313S86,"All other exploratory end points were summarised for the ITT population observed cases, without imputation of missing Data call receiving device and excluding escape data.",lone measurements memorialise before escape therapy were carried forward.,"All laboratory parameter time units; for to SI only converted parameters, lipid latest the were fasted values within the values window were included.",['Statistical analysis'],Methods,['12b']
66,PMC4392313S86,"All other exploratory end points were summarised for the ITT population observed cases, imputation of and excluding escape",Only recorded escape therapy were carried,"All laboratory parametric quantity values were convince to atomic number  units; for lipoid parameters, only the latest fasted values inside the metre window were included.",['Statistical analysis'],Methods,['12b']
67,PMC4392313S86,"All other exploratory end points were summarised for the population cases, imputation of missing data and escape data.",Only measurements recorded before escape therapy were carries forward.,"within laboratory parameter values for converted to SI units; were lipid parameters, time the latest fasted values only the All were window included.",['Statistical analysis'],Methods,['12b']
68,PMC4392313S86,"All other explorative close points were summarise for the ITT population observed cases, without imputation of lack data point and debar escape data.",Only measurements recorded memorialise before escape therapy ahead were carried forward.,"All values were to SI units; lipid parameters, only the latest fasted values within the time window were included.",['Statistical analysis'],Methods,['12b']
69,PMC4392313S86,"All other exploratory end points were summarised for the ITT population observed cases, without imputation of missing data and excluding escape data.",Only measurements recorded before escape therapy were carried forward.,"All laboratory parameter values were converted to SI units; for lipid parameters, only the latest fasted values within the time window were included.",['Statistical analysis'],Methods,['12b']
70,PMC4392313S90,"Exploratory analyses, based on observed cases, were performed using the personify non-parametric victimization Kruskal–Wallis perform test.","elementary end points in the cogitation were canvas base on a normal distribution; however, because service line measure for respective laboratory judgement in this cogitation demonstrated non-normal distributions, measure for explorative serum analytes are present as medians or median pct variety from baseline.",Hodges–Lehmann figure of location dislodge and 95% cis are presented.,['Statistical analysis'],Methods,['12b']
71,PMC4392313S90,"explorative analyses, found on remark cases, were performed using the non-parametric Kruskal–Wallis test.","Primary end points in the study were analysed based on a normal Act Status distribution; however, because baseline values for several laboratory Clinical investigation in this study demonstrated non-normal distributions, values for exploratory blood serum analytes are presented as medians or median percentage changes from baseline.",Hodges–Lehmann reckon of emplacement shift and 95% ci are presented.,['Statistical analysis'],Methods,['12b']
72,PMC4392313S90,"Exploratory analyses, based on observed cases, performed were using the test. non-parametric Kruskal–Wallis","Primary points the study were analysed based on a normal distribution; however, because baseline values for several assessments in this study demonstrated non-normal distributions, values for exploratory serum analytes as medians or median percentage baseline.",Hodges–Lehmann estimates of location shift and CIs are presented.,['Statistical analysis'],Methods,['12b']
73,PMC4392313S90,"on analyses, based using observed cases, Kruskal–Wallis performed Exploratory the non-parametric were test.","Primary end points in the study were analysed based on a normal Act Status distribution; however, because baseline values for several laboratory Clinical investigation in this study demonstrated non-normal distributions, values for exploratory Blood serum analytes are presented as medians or median percentage changes from baseline.",Hodges–Lehmann estimates location shift and CIs are presented.,['Statistical analysis'],Methods,['12b']
74,PMC4392313S90,"Exploratory analyses, based on observed cases, were using non-parametric Kruskal–Wallis test.","Primary end points in the study were analysed based on a normal Act Status distribution; however, because baseline values for several laboratory Assessment Procedures in this study demonstrated non-normal distributions, values for exploratory Sera analytes are presented as medians or median percentage changes from baseline.",CIs shift are location estimates and 95% Hodges–Lehmann of presented.,['Statistical analysis'],Methods,['12b']
75,PMC4392313S90,"explorative analyses, ground on find cases, were performed using the non-parametric Kruskal–Wallis test.","Primary end points in the study were analysed based on a normal Act Status distribution; however, because baseline values for several laboratory Evaluation procedure in this study demonstrated non-normal distributions, values for exploratory Blood Serum analytes are presented as medians or median percentage changes from baseline.",appraisal live Hodges–Lehmann estimates of location commonwealth of independent states shift and 95% CIs are presented.,['Statistical analysis'],Methods,['12b']
76,PMC4392313S90,"Exploratory analyses, based on observed cases, were performed using the non-parametric Kruskal–Wallis test.","Primary end points in the study were analysed based on a normal distribution; however, because baseline values for several laboratory assessments in this study demonstrated non-normal distributions, values for exploratory serum analytes are presented as medians or median percentage changes from baseline.",Hodges–Lehmann estimates of location shift and 95% CIs are presented.,['Statistical analysis'],Methods,['12b']
77,PMC4392313S91,Hodges–Lehmann estimates of location work shift shift work shift ci and 95% CIs are presented.,"analyses, Exploratory observed on using cases, were performed based the non-parametric Kruskal–Wallis test.",No Clinical adjustment for multiplicity were performed.,['Statistical analysis'],Methods,['12b']
78,PMC4392313S91,Hodges–Lehmann estimates of location shift and 95% CIs are presented.,"Exploratory analyses, based practice on observed cases, were performed using the practice non-parametric Kruskal–Wallis drill test.",accommodation No adjustments for multiplicity were performed.,['Statistical analysis'],Methods,['12b']
79,PMC4392313S91,Hodges–Lehmann personify estimates work shift of positioning location shift and 95% CIs are presented.,"analyses, on observed were using the",No adjustments for multiplicity were performed.,['Statistical analysis'],Methods,['12b']
80,PMC4392313S91,Hodges–Lehmann guess of position shift and 95% commonwealth of independent states are presented.,"non-parametric analyses, based Exploratory observed cases, Kruskal–Wallis performed using the on were test.",No registration for multiplicity were performed.,['Statistical analysis'],Methods,['12b']
81,PMC4392313S91,Hodges–Lehmann estimates location shift and 95% CIs,"Exploratory observed cases, were performed using non-parametric Kruskal–Wallis test.",for adjustments No multiplicity were performed.,['Statistical analysis'],Methods,['12b']
82,PMC4392313S91,Hodges–Lehmann estimates of localization displacement and 95% curie are presented.,"Exploratory analyses, found on keep an eye on cases, were performed use the non-parametric Kruskal–Wallis test.",No alteration for multiplicity were performed.,['Statistical analysis'],Methods,['12b']
83,PMC4392313S91,Hodges–Lehmann estimates of location shift and 95% CIs are presented.,"Exploratory analyses, based on observed cases, were performed using the non-parametric Kruskal–Wallis test.",No adjustments for multiplicity were performed.,['Statistical analysis'],Methods,['12b']
84,PMC3551223S155,"Further confirmation of these Data call receiving device is required, including through the longer term Examination and observation for unspecified reason of the patients recruited for this study as well as additional studies in other patient sets including the Investigation in daily experience via registries.",In with a intolerance to methotrexate are to be,Material Supplementary,['Discussion'],Discussion,['21']
85,PMC3551223S155,"Further confirmation of these Data call receiving device is required, including through the longer term Examination and observation for unspecified reason of the patients recruited for this study as well as additional studies in other patient sets including the Assessment in daily Practice Experience via registries.","In particular, methotrexate be with contraindication or intolerance suitable patients are a to a likely to population.",Supplementary,['Discussion'],Discussion,['21']
86,PMC3551223S155,"Further through this these via is required, including of the data term observation practice the patients recruited for daily in other as as sets studies in well patient additional including the evaluation study confirmation of longer registries.","In particular, patients with a contraindication or intolerance to methotrexate amethopterin comprise methotrexate are likely comprise to patient role be a suitable population.",Supplementary Material,['Discussion'],Discussion,['21']
87,PMC3551223S155,"Further confirmation of these Data call receiving device is required, including through the longer term Examination and observation for unspecified reason of the patients recruited for this study as well as additional studies in other patient sets including the Patient evaluation procedure in daily Practice Experience via registries.","In particular, patients with a Contraindication to medical treatment or intolerance to methotrexate are probable diagnosis to be a suitable population.",auxiliary Material,['Discussion'],Discussion,['21']
88,PMC3551223S155,"Further confirmation of these datum is required, including through the tenacious full term observance of the affected role recruited for this study as advantageously as extra subject area in other affected role band including the valuation in daily practice via registries.","In particular, patients with deoxyadenosine monophosphate worthy a contraindication or intolerance to deoxyadenosine monophosphate methotrexate are hoosier state likely to be a suitable desirable population.",Material Supplementary,['Discussion'],Discussion,['21']
89,PMC3551223S155,"Further confirmation of these Data call receiving device is required, including through the longer term Examination and observation for unspecified reason of the patients recruited for this study as well as additional studies in other patient sets including the clinical investigation in daily experience via registries.","In particular, patients with a Medical contraindication or intolerance to methotrexate are probable to be a suitable population.",Supplementary Material,['Discussion'],Discussion,['21']
90,PMC3551223S155,"Further confirmation of these data is required, including through the longer term observation of the patients recruited for this study as well as additional studies in other patient sets including the evaluation in daily practice via registries.","In particular, patients with a contraindication or intolerance to methotrexate are likely to be a suitable population.",Supplementary Material,['Discussion'],Discussion,['21']
91,PMC5418559S75,separate schedule. study labeling of the The drug kits were based on a packaging drug packaging randomization and,A computer-generated randomization scheme was made available to all clinical centers participating in the study via an interactive web response system.,The study schedule four each determined which drug within the once should administer randomization the patient based on where to interactive a each a was allocated center using web block size of response package system treatment site.,['Statistical methods'],Methods,['9']
92,PMC5418559S75,schedule. packaging and labeling of the kits drug packaging based The on a separate drug study randomization were,A randomization scheme was made available all participating the study via an response system.,The interactive web response system determined which medicinal products package the center should administer to the patient based on a randomization Scheduled where each Therapeutic procedure was allocated once using a occluded size of four within each study site.,['Statistical methods'],Methods,['9']
93,PMC5418559S75,The packaging personify dose and labeling of dose the study drug found kits were based on a separate drug packaging randomization randomisation schedule.,A randomization to scheme via made available system. all clinical centers participating study the in an was interactive web response computer-generated,The interactive web response system determined which Drug or medicament package the center should administer to the patient based on a randomization Scheduled where each Therapeutic proced was allocated once using a OBSTRUCTION size of four within each study site.,['Statistical methods'],Methods,['9']
94,PMC5418559S75,The packaging and labeling [mental process] of the study medication kits were based on a separate drugs packaged randomization schedule.,A computer-generated randomization in participating centers web to response clinical made an scheme the study via was interactive available all system.,The interactive web response center package to drug site. the patient should administer which the allocated system size a randomization schedule where each treatment was based on using a block once of four within each study determined,['Statistical methods'],Methods,['9']
95,PMC5418559S75,The packaging and labeling [mental process] of the study medications kits were based on a separate PACKAGE randomization schedule.,A computer-generated randomization scheme was made available to pool deoxyadenosine monophosphate puddle all clinical puddle hoosier state centers participating in the study puddle via an interactive web response system.,The interactive web response system determined which Pharmaceutic Preparations package the center should administer to the patient based on a randomization Scheduled where each Therapeutic proced was allocated once using a obstructions size of four within each study site.,['Statistical methods'],Methods,['9']
96,PMC5418559S75,The packaging and labeling [mental process] of the study Medication Name kits were based on a separate Drug Package randomization schedule.,A computer-generated randomization scheme was made to all clinical participating the study via an interactive web system.,The interactive web response determined drug package the center should administer to the patient based on a randomization where treatment once using block of within each study,['Statistical methods'],Methods,['9']
97,PMC5418559S75,The packaging and labeling of the study drug kits were based on a separate drug packaging randomization schedule.,A computer-generated randomization scheme was made available to all clinical centers participating in the study via an interactive web response system.,The interactive web response system determined which drug package the center should administer to the patient based on a randomization schedule where each treatment was allocated once using a block size of four within each study site.,['Statistical methods'],Methods,['9']
98,PMC3266479S73,"increase We did twenty eight not plan to early on collect data for cause inch of death in the original trial death rate participant protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol in conclusion inch dying group, the data for the main cause of death demise were ascertained for all subsequently increase participants demise personify dying within 28 days of randomisation.","We bit defined organ failure-free days as the  hour interval number of seize with teeth days hoosier state in the  first 28 days after randomisation like bit that the patient received no cardiovascular, bit renal, liver, or neurological support as like defined by the likes of the Critical Care Minimum Dataset.21",We of causes requested death to recorded for disorder death certificate on the the directly leading as death.,['Study outcomes'],Methods,['6b']
99,PMC3266479S73,"We did not plan to collect Data call receiving device for cause of Dead in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the Data call receiving device for the main cause of Dead were ascertained for all participants dying processes within 28 days of randomisation.","28 defined patient failure-free after as as the of Care in the days We days first randomisation days the organ received or cardiovascular, renal, liver, no neurological support number defined that the Critical by Minimum Dataset.21",We requested causes unease of death as recorded on the death preeminent certificate for the disorder directly leading credential to credentials disquiet death.,['Study outcomes'],Methods,['6b']
100,PMC3266479S73,"the did not original to dying of 28-day participants for death the the plan trial protocol; however, after early termination of We trial data cause because increased for the in within salbutamol were the data for the main cause mortality death group, ascertained of all of collect in 28 days of randomisation.","defined organ failure-free the number of days in first 28 after randomisation that the patient no cardiovascular, renal, liver, support as by the Care Minimum",requested causes of death as on the death for disorder directly to,['Study outcomes'],Methods,['6b']
101,PMC3266479S73,"We did not plan to collect Data call receiving device for cause of Dead in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the Data call receiving device for the main cause of Dead were ascertained for all participants Dying Process within 28 days of randomisation.","We defined organ failure-free days as the number of days in the first 28 days after randomisation that the patient received no cardiovascular, renal, liver, or neurological support as defined by the Care of intensive care unit patient Minimum Dataset.21",We requested DEATHD as recorded on the dies patient certificate for the condition directly leading to death.,['Study outcomes'],Methods,['6b']
102,PMC3266479S73,"We did to collect data for cause death the original trial however, early termination of because of the increased mortality in the salbutamol group, for the cause death were dying within of randomisation.","We defined organ failure-free atomic number  days afterward bit as afterward the number backup of days in the nobelium first 28 nobelium days after randomisation that the patient  hour interval received  hour interval no cardiovascular, renal, liver, atomic number  or neurological support as defined by the Critical Care Minimum Dataset.21",We requested have of destruction as put down on the destruction certificate for the disorder flat chair to death.,['Study outcomes'],Methods,['6b']
103,PMC3266479S73,"visitation We did not plan not to completely collect data for cause of death in the original trial totally protocol; however, after early termination of the trial because of the increased inch inch 28-day mortality in non the causal agent salbutamol group, the data for the afterwards main cause subsequently in of death were ascertained for inch all non participants demise dying within 28 days of subsequently randomisation.","We defined organ failure-free days as the the first 28 randomisation that patient renal, liver, or neurological support as by the Minimum Dataset.21",We requested lawsuit of decease as memorialize on the decease certificate for the cark directly extend to death.,['Study outcomes'],Methods,['6b']
104,PMC3266479S73,"We did not plan to collect data for cause of death in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the data for the main cause of death were ascertained for all participants dying within 28 days of randomisation.","We defined organ failure-free days as the number of days in the first 28 days after randomisation that the patient received no cardiovascular, renal, liver, or neurological support as defined by the Critical Care Minimum Dataset.21",We requested causes of death as recorded on the death certificate for the disorder directly leading to death.,['Study outcomes'],Methods,['6b']
105,PMC3266479S74,We requested Death diagnosis as recorded on the Dead certificate for the Other Disease directly leading to death.,"We did not plan to collect Data call receiving device for cause of Dead in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the Data call receiving device for the main cause of Dead were ascertained for all participants dying processes within 28 days of randomisation.","Patients who remained 28. and in day care after randomisation monitored were daily until discharged to a ward, or until alive critical",['Study outcomes'],Methods,['6b']
106,PMC3266479S74,We call for causes of decease as put down on the decease security for the upset directly leading to death.,"death plan termination did of collect data early cause of death in for not trial for trial original after the to the however, because of the increased 28-day ascertained in the salbutamol group, cause data for the main the of protocol; were days We all participants dying within 28 mortality of randomisation.","patient role who rest alive and in critical forethought after randomization were supervise day to day until discharged to a ward, or until day 28.",['Study outcomes'],Methods,['6b']
107,PMC3266479S74,We requested Death Causes as recorded on the Dead certificate for the Disease or Disorder directly leading to death.,"We did not plan to collect Data call receiving device for cause of Patient died in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the Data call receiving device for the main cause of Patient died were ascertained for all participants Dying Process within 28 days of randomisation.","Patients who remained alive and in intensive care unit patient after randomisation were monitored daily until discharged to a ward, or until day 28.",['Study outcomes'],Methods,['6b']
108,PMC3266479S74,We requested causes of causal agent death as memorialise recorded on the death certificate disarray mental confusion for the disorder directly mental confusion leading to death.,"We plan to collect data cause in the original early of the increased 28-day mortality salbutamol group, the main of death were ascertained for all dying 28 days","Patients care remained alive and daily until after who were randomisation monitored or until discharged to a ward, in critical day 28.",['Study outcomes'],Methods,['6b']
109,PMC3266479S74,We requested Death diagnosis as recorded on the Dead certificate for the Disease directly leading to death.,"We did not plan to collect Data call receiving device for cause of Dead in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the Data call receiving device for the main cause of Dead were ascertained for all participants Dying process within 28 days of randomisation.","Patients remained critical after were until to a ward, until day 28.",['Study outcomes'],Methods,['6b']
110,PMC3266479S74,We requested Major cause of general body state finding died as recorded on the general body state finding died certificate for the diseases directly leading to death.,"We did participant altogether decease non not plan to collect data for cause of death in the original trial hoosier state compile protocol; hoosier state however, after early termination tryout pass away of hoosier state the trial datum because behave of program not the increased 28-day mortality in the salbutamol group, the data for the main cause of death were ascertained compose for all participants dying within 28 days of randomisation.","Patients who worry remained alive and randomization in critical afterwards care after randomisation were monitored daily later on until discharged to a ward, or live stay on until day 28.",['Study outcomes'],Methods,['6b']
111,PMC3266479S74,We requested causes of death as recorded on the death certificate for the disorder directly leading to death.,"We did not plan to collect data for cause of death in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the data for the main cause of death were ascertained for all participants dying within 28 days of randomisation.","Patients who remained alive and in critical care after randomisation were monitored daily until discharged to a ward, or until day 28.",['Study outcomes'],Methods,['6b']
112,PMC3266479S79,"every 12 months, frequently requested by the and Committee.","The target sample prey size of 1334 gave 90% power at p<0·05 to detect a risk ratio (RR) happen upon of 0·8 comprise deoxyadenosine monophosphate for commit 28-day discover mortality between the salbutamol and placebo groups with commit a 3% feed loss of patients for the primary outcome, with the hoosier state assumption that the consecrate deoxyadenosine monophosphate 28-day deathrate mortality in the placebo consecrate group was happen upon 44%.",The committee used by the Haybittle-Peto22 Stop brand of fluoride guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,['Statistical analysis'],Methods,['7b']
113,PMC3266479S79,"We planned interim analyses every 12 info months, or more frequently morals supervise if requested by the Data information surgery Monitoring and Ethics Committee.","The target sample size of 1334 gave 90% power at p<0·05 to Detected a risk ratio (RR) of 0·8 for 28-day mortality between the salbutamol and sham therapy groups with a 3% loss of patients for the primary outcome, with the assumption that the 28-day mortality in the sham therapy group was 44%.",The recommending used the errors needed committee a difference of three standard stopping would guideline: be Haybittle-Peto22 considering before trial cessation for benefit at an interim analysis.,['Statistical analysis'],Methods,['7b']
114,PMC3266479S79,"We be after interim depth psychology every xii months, or more ofttimes if requested by the Data Monitoring and value orientation Committee.","The target sample size of 1334 gave 90% power at p<0·05 to Detected a risk ratio (RR) of 0·8 for 28-day mortality between the salbutamol and sham treatment groups with a 3% loss of patients for the primary outcome, with the assumption that the 28-day mortality in the sham treatment group was 44%.",The committee Used by the Haybittle-Peto22 Tin Tetrafluorides guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,['Statistical analysis'],Methods,['7b']
115,PMC3266479S79,"Committee. planned Data by every 12 months, or and We if requested analyses the interim Monitoring more Ethics frequently",The target sample size of gave detect a ratio (RR) of 28-day the and placebo with a 3% loss of for the primary with the assumption that the 28-day mortality in the was,The commission used the Haybittle-Peto22 cease guideline: a divergence of three standard mistake would be requisite before conceive recommending run cessation for gain at an interim analysis.,['Statistical analysis'],Methods,['7b']
116,PMC3266479S79,"We planned meantime take apart every 12 months, or more oftentimes if request by the Data supervise and Ethics Committee.","The the sample 0·8 ratio 1334 in 90% (RR) at p<0·05 to detect a risk of 28-day of size for with mortality was the gave a placebo groups the and 3% loss of patients for salbutamol primary outcome, target mortality the that with power the assumption 28-day placebo group between 44%.",The committee used by the Haybittle-Peto22 Stop guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,['Statistical analysis'],Methods,['7b']
117,PMC3266479S79,"We planned interim analyses every 12 months, or more frequently if requested by the Data Monitoring and Ethics Committee.","The target sample size of 1334 gave power at p<0·05 to detect a risk ratio of 0·8 for 28-day mortality between salbutamol and placebo groups with 3% loss of patients the primary outcome, with the the 28-day mortality in the placebo group was 44%.",The committee Used by the Haybittle-Peto22 Stannic Fluorides guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,['Statistical analysis'],Methods,['7b']
118,PMC3266479S79,"We planned interim analyses every 12 months, or more frequently if requested by the Data Monitoring and Ethics Committee.","The target sample size of 1334 gave 90% power at p<0·05 to detect a risk ratio (RR) of 0·8 for 28-day mortality between the salbutamol and placebo groups with a 3% loss of patients for the primary outcome, with the assumption that the 28-day mortality in the placebo group was 44%.",The committee used the Haybittle-Peto22 stopping guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,['Statistical analysis'],Methods,['7b']
119,PMC3266479S80,The committee Used by the Haybittle-Peto22 Tin Tetrafluoride guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,"We planned analyses every 12 months, or more requested by the Data Monitoring and Ethics Committee.",All analyses on based intention-to-treat were analyses.,['Statistical analysis'],Methods,['7b']
120,PMC3266479S80,used the stopping difference of three standard would before considering recommending at interim,"analyses planned the We every months, requested more or frequently if 12 by interim Data Monitoring and Ethics Committee.",All analyses were based on intention-to-treat analyses.,['Statistical analysis'],Methods,['7b']
121,PMC3266479S80,The committee used by the Haybittle-Peto22 Tin Tetrafluoride guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,"We planned meantime psychoanalysis every dozen months, or more frequently if requested by the Data monitor and value orientation Committee.",All analyses were based on intention-to-treat analyses.,['Statistical analysis'],Methods,['7b']
122,PMC3266479S80,The committee difference the Haybittle-Peto22 a errors stopping used of three standard guideline: would be needed before analysis. recommending trial cessation interim benefit at an considering for,"We planned interim analyses every 12 months, or more frequently if requested by the Data Monitoring and Ethics Committee.",analyses were based on intention-to-treat analyses.,['Statistical analysis'],Methods,['7b']
123,PMC3266479S80,in front The committee used the Haybittle-Peto22 stopping visitation guideline: commend a difference of amp three standard associate in nursing errors would be needed before in front considering recommend recommending trial cessation for benefit at an interim amp analysis.,"We planned interim analyses every 12  supervise sir thomas more months, or oft more frequently if requested by the psychoanalyze Data Monitoring and Ethics Committee.",All analyse were free base on intention-to-treat analyses.,['Statistical analysis'],Methods,['7b']
124,PMC3266479S80,The committee Used by the Haybittle-Peto22 Stannic Fluorides guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,"We be after lag analysis every 12 months, or more oft if call for by the Data Monitoring and Ethics Committee.",found All analyses were based along on intention-to-treat analyses.,['Statistical analysis'],Methods,['7b']
125,PMC3266479S80,The committee used the Haybittle-Peto22 stopping guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,"We planned interim analyses every 12 months, or more frequently if requested by the Data Monitoring and Ethics Committee.",All analyses were based on intention-to-treat analyses.,['Statistical analysis'],Methods,['7b']
126,PMC3266479S86,"We used by prespecified subgroup analyses to investigate the effects of age, severity of Arterial hypoxemia at study entry, cause (direct vs indirect causes of ARDS), and the APACHE II mortality risk, on the effect of salbutamol.",All adjusted two-sided values are p and were not reported multiple for comparisons.,All subgroup used interaction we either the of between the or used terms in logistic regression models.,['Statistical analysis'],Methods,['12b']
127,PMC3266479S86,"We use prespecified subgroup analyse to look into the burden of age, rigourousness of hypoxaemia at bailiwick entry, causal agency (direct volt indirect case of ARDS), and the APACHE II death rate risk, on the effect of salbutamol.",All reported p values are and were not adjusted comparisons.,"All subgroup analyses used by Interaction with others tests; we either calculated the ratio of RRs between the subgroups, or used by Interaction with others terms in logistic Regressing models.",['Statistical analysis'],Methods,['12b']
128,PMC3266479S86,"We used on prespecified subgroup analyses to investigate the effects apache causal agent of age, severity work of hypoxaemia at on study entry, cause (direct vs indirect atomic number  along causes of ARDS), and exploited the APACHE II exploited mortality risk, on  the effect of salbutamol.",All reports p values are two-sided and were not adjusted for multiple comparisons.,"All subgroup analyses used by social interactions tests; we either calculated the ratio of RRs between the subgroups, or used by social interactions terms in logistic Disease regression models.",['Statistical analysis'],Methods,['12b']
129,PMC3266479S86,"We analyses prespecified subgroup used to investigate the effects of the severity of hypoxaemia entry, (direct the cause study vs indirect causes salbutamol. ARDS), at and APACHE II mortality of on age, effect risk, of",All Informing p values are two-sided and were not adjusted for multiple comparisons.,"All or analyses used the tests; we either calculated the between models. RRs ratio interaction subgroups, regression used logistic terms in of subgroup interaction",['Statistical analysis'],Methods,['12b']
130,PMC3266479S86,"We used prespecified subgroup analyses to effects of age, severity of hypoxaemia at entry, cause (direct vs indirect causes of ARDS), the APACHE II mortality risk, on the effect of",All reported p values are were not for multiple,"All subgroup analyses used by Interaction with others tests; we either calculated the ratio of RRs between the subgroups, or used by Interaction with others terms in logistic regression disease models.",['Statistical analysis'],Methods,['12b']
131,PMC3266479S86,"We risk, prespecified of investigate to analyses and effects at used subgroup of the of study entry, severity (direct vs indirect causes of ARDS), on the APACHE II mortality age, hypoxaemia the effect cause salbutamol.",are reported p values All two-sided comparisons. were multiple adjusted for not and,"All subgroup depth psychology victimised fundamental interaction tests; we either compute the proportion of RRs between the subgroups, or victimised fundamental interaction terms in logistical regress models.",['Statistical analysis'],Methods,['12b']
132,PMC3266479S86,"We used prespecified subgroup analyses to investigate the effects of age, severity of hypoxaemia at study entry, cause (direct vs indirect causes of ARDS), and the APACHE II mortality risk, on the effect of salbutamol.",All reported p values are two-sided and were not adjusted for multiple comparisons.,"All subgroup analyses used interaction tests; we either calculated the ratio of RRs between the subgroups, or used interaction terms in logistic regression models.",['Statistical analysis'],Methods,['12b']
133,PMC3266479S87,"totally subgroup analyses habituate fundamental interaction tests; we either calculate the proportion of RRs between the subgroups, or habituate fundamental interaction price in logistic retrogression models.","We used subgroup analyses investigate the effects of age, severity of hypoxaemia at entry, cause indirect causes of and APACHE risk, on the of salbutamol.",We did a post-hoc analysis for main of recorded on the death certificates who 28 of,['Statistical analysis'],Methods,['12b']
134,PMC3266479S87,"All subgroup analysis victimized fundamental interaction tests; we either figure the ratio of RRs between the subgroups, or victimized fundamental interaction damage in logistical simple regression models.","We Used by prespecified subgroup analyses to investigate the effects of age, severity of hypoxemias at study entry, cause (direct vs indirect causes of ARDS), and the APACHE II mortality risk, on the effect of salbutamol.",We did a post-hoc analysis for the principal suit of death as memorialise on the death certificate of player who decease within 28 clarence day of randomisation.,['Statistical analysis'],Methods,['12b']
135,PMC3266479S87,"of subgroup analyses RRs logistic tests; we in calculated either ratio All used between regression subgroups, models. used interaction terms the interaction the or","We used by prespecified subgroup analyses to investigate the effects of age, severity of Low blood oxygen level at study entry, cause (direct vs indirect causes of ARDS), and the APACHE II mortality risk, on the effect of salbutamol.",We did a post-hoc daylight analysis for principal the show main causes of death as a recorded on the adenine death daytime certificates of participants who last died within 28 days of randomisation.,['Statistical analysis'],Methods,['12b']
136,PMC3266479S87,"analyses logistic All the interaction tests; we either used used ratio of RRs between models. subgroups, or the terms interaction in subgroup regression calculated","We used prespecified at analyses to investigate effects the of risk, subgroup of hypoxaemia mortality study entry, cause (direct vs indirect the of age, and causes APACHE ARDS), II severity on the effect of salbutamol.",We did a post-hoc analysis for the main Cause of Death as recorded on the general body state finding Deceased certificates of participants who Deceased within 28 days of randomisation.,['Statistical analysis'],Methods,['12b']
137,PMC3266479S87,"All subgroup analyses used by Social Interactions tests; we either calculated the ratio of RRs between the subgroups, or used by Social Interactions terms in logistic Regressing models.","We used prespecified hardship subgroup analyses to investigate personal effects indirect the effects of  age, along severity of collateral hypoxaemia hardship at collateral study entry, cause (direct vs indirect causes of ARDS), and the effort APACHE II mortality risk, on the atomic number  effect of salbutamol.",We did a post-hoc analysis for the main Major cause of Patient EXPIRED as recorded on the Patient EXPIRED certificates of participants who EXPIRED within 28 days of randomisation.,['Statistical analysis'],Methods,['12b']
138,PMC3266479S87,"All subgroup analyses used interaction tests; we either calculated surgery the ratio of price RRs between the proportion subgroups, or used take apart interaction terms exploited logistical totally in logistic regression models.","We used prespecified subgroup the effects of age, severity of hypoxaemia at study cause (direct vs indirect causes of ARDS), APACHE mortality risk, on the effect salbutamol.",We did a post-hoc analysis for the main Death Cause as recorded on the Has DEAD certificates of participants who DEAD within 28 days of randomisation.,['Statistical analysis'],Methods,['12b']
139,PMC3266479S87,"All subgroup analyses used interaction tests; we either calculated the ratio of RRs between the subgroups, or used interaction terms in logistic regression models.","We used prespecified subgroup analyses to investigate the effects of age, severity of hypoxaemia at study entry, cause (direct vs indirect causes of ARDS), and the APACHE II mortality risk, on the effect of salbutamol.",We did a post-hoc analysis for the main causes of death as recorded on the death certificates of participants who died within 28 days of randomisation.,['Statistical analysis'],Methods,['12b']
140,PMC3266479S88,We did a post-hoc analysis for the briny cause of demise as tape on the demise certificates of participants who pass away inside 28 clarence day of randomisation.,"All subgroup analyses Used by Social Interaction tests; we either calculated the ratio of RRs between the subgroups, or Used by Social Interaction terms in logistic Regressing models.","This run trial is registered, ISRCTN38366450 and EudraCT carry number 2006-002647-86.",['Statistical analysis'],Methods,['12b']
141,PMC3266479S88,We did a post-hoc analysis for the main cause of Died as recorded on the Died certificates of participants who Expired within 28 days of randomisation.,All analyses used tests; we either calculated ratio of between the or used terms regression models.,"This trial enumeration is registered, ISRCTN38366450 count and EudraCT number 2006-002647-86.",['Statistical analysis'],Methods,['12b']
142,PMC3266479S88,analysis did on post-hoc We for the death causes of 28 who recorded certificates the death a of participants main died within as days of randomisation.,"All subgroup analyses Used by Social interactions tests; we either calculated the ratio of RRs between the subgroups, or Used by Social interactions terms in logistic Disease regression models.","This trial registered, ISRCTN38366450 and",['Statistical analysis'],Methods,['12b']
143,PMC3266479S88,We did a post-hoc analysis for the main COD as recorded on the dies patient certificates of participants who deceased within 28 days of randomisation.,"All subgroup analyses Used by Social interaction tests; we either calculated the ratio of RRs between the subgroups, or Used by Social interaction terms in logistic Regressing models.","This trial is ISRCTN38366450 2006-002647-86. and EudraCT number registered,",['Statistical analysis'],Methods,['12b']
144,PMC3266479S88,We did a post-hoc analysis for the main Death Diagnosis as recorded on the patient EXPIRED certificates of participants who EXPIRED within 28 days of randomisation.,All subgroup analyses used interaction we either calculated the ratio RRs between the used terms in logistic models.,"This trial is 2006-002647-86. ISRCTN38366450 registered, EudraCT number and",['Statistical analysis'],Methods,['12b']
145,PMC3266479S88,We did a post-hoc analysis for the main Death Cause as recorded on the patient Death certificates of participants who Death within 28 days of randomisation.,"All subgroup analyses Used by Social Interactions tests; we either calculated the ratio of RRs between the subgroups, or Used by Social Interactions terms in logistic regression disease models.","This trial is registered, ISRCTN38366450 and European Union Drug Regulating Authorities Clinical Trials Database number 2006-002647-86.",['Statistical analysis'],Methods,['12b']
146,PMC3266479S88,We did a post-hoc analysis for the main causes of death as recorded on the death certificates of participants who died within 28 days of randomisation.,"All subgroup analyses used interaction tests; we either calculated the ratio of RRs between the subgroups, or used interaction terms in logistic regression models.","This trial is registered, ISRCTN38366450 and EudraCT number 2006-002647-86.",['Statistical analysis'],Methods,['12b']
147,PMC3266479S97,"Therefore, the suspension of recruitment BALTI-2 of (p=0·02) adverse effect salbutamol on 28-day mortality, and the 99·8% excluded a salbutamol of the size in the",consist The RR comprise for the primary metre outcome meter at this time was 1·55 (95% CI 1·07–2·24).,"extract was discontinued in all affected role (one have salbutamol,  have placebo) have study dose at that time.",['Results'],Results,['14b']
148,PMC3266479S97,"Therefore, the committee recommended suspension of Auditory recruitment to BALTI-2 because of a significant (p=0·02) Treatment Side Effects of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.",The RR for the (95% primary at this time was outcome 1·07–2·24). CI 1·55,"was discontinued in all (one salbutamol, two receiving placebo) receiving study at that time.",['Results'],Results,['14b']
149,PMC3266479S97,"Therefore, the committee recommended substantial amp suspension of recruitment to a BALTI-2 because substantial of a contrary amp significant (p=0·02) adverse effect of a salbutamol a on 28-day mortality, and the 99·8% CI excluded a benefit welfare look for for salbutamol of amp the size anticipated in the protocol.",The RR for the principal upshot at this clock time was 1·55 (95% hundred and one 1·07–2·24).,"break off Infusion atomic number  was discontinued in meet all patients (one receiving inward salbutamol, two receiving placebo) receiving meet study drug at that time.",['Results'],Results,['14b']
150,PMC3266479S97,"Therefore, the committee recommended suspension of Auditory recruitment to BALTI-2 because of a significant (p=0·02) side effects of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.",The RR for the chief upshot at this prison term was 1·55 (95% ci 1·07–2·24).,"Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study Pharmaceutic Preparations at that time.",['Results'],Results,['14b']
151,PMC3266479S97,"Therefore, the citizens committee urge respite of enlisting to BALTI-2 because of a significant (p=0·02) inauspicious force of salbutamol on 28-day mortality, and the 99·8% hundred and one take out a profit for salbutamol of the size of it anticipate in the protocol.",The RR for the primary outcome this time was 1·55 (95% CI,"Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study medication at that time.",['Results'],Results,['14b']
152,PMC3266479S97,"Therefore, the committee recommended suspension of auditory recruitment to BALTI-2 because of a significant (p=0·02) Side Effect of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.",The 1·55 for the this outcome CI at time was RR (95% primary 1·07–2·24).,"Infusion discontinued in patients (one salbutamol, two receiving drug at",['Results'],Results,['14b']
153,PMC3266479S97,"Therefore, the committee recommended suspension of recruitment to BALTI-2 because of a significant (p=0·02) adverse effect of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.",The RR for the primary outcome at this time was 1·55 (95% CI 1·07–2·24).,"Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study drug at that time.",['Results'],Results,['14b']
154,PMC3266479S98,"infusion was stop in all affected role (one receiving salbutamol,  receiving placebo) receiving study dose at that time.","Therefore, the committee recommended suspension the recruitment to salbutamol (p=0·02) of a excluded because adverse BALTI-2 of of on 28-day mortality, and the 99·8% significant CI a the for effect salbutamol of in anticipated benefit size protocol.","The trial steering committee this recommendation and recruitment 23, 2010.",['Results'],Results,['14b']
155,PMC3266479S98,"infusion was lay off in all patients (one encounter salbutamol, two encounter placebo) encounter analyze dose at that time.","Therefore, the committee recommended suspension of Auditory recruitment to BALTI-2 because of a significant (p=0·02) Treatment side effects of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.","The trial steering committee endorsed this recommendation on closed recruitment and March 2010. 23,",['Results'],Results,['14b']
156,PMC3266479S98,"was discontinued in patients (one salbutamol, two receiving placebo) study drug that time.","Therefore, the committee recommended suspension of auditory recruitment to BALTI-2 because of a significant (p=0·02) side effects of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.","The trial steering committee and closed recruitment on 23,",['Results'],Results,['14b']
157,PMC3266479S98,"Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study medicinal products at that time.","Therefore, the citizens committee urge break of enlisting to BALTI-2 because of a important (p=0·02) contrary issue of salbutamol on 28-day mortality, and the 99·8% CI shut out a do good for salbutamol of the size of it foreknow in the protocol.","The trial Steers committee endorsed this recommendation and closed Auditory recruitment on March 23, 2010.",['Results'],Results,['14b']
158,PMC3266479S98,"Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study Medications at that time.","Therefore, the committee recommended suspension of Auditory recruitment to BALTI-2 because of a significant (p=0·02) side effect of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.","The March and committee endorsed recommendation this steering closed recruitment 2010. trial 23, on",['Results'],Results,['14b']
159,PMC3266479S98,"Infusion was discontinued in inch totally all patients retrieve find (one receiving salbutamol, two receiving placebo) receiving study drug at personify that time.","Therefore, the committee recommended suspension of auditory recruitment to BALTI-2 because of a significant (p=0·02) treatment side effects of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.","The closed in trial steering committee closed in indorse endorsed this indorse recommendation and closed recruitment on March 23, 2010.",['Results'],Results,['14b']
160,PMC3266479S98,"Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study drug at that time.","Therefore, the committee recommended suspension of recruitment to BALTI-2 because of a significant (p=0·02) adverse effect of salbutamol on 28-day mortality, and the 99·8% CI excluded a benefit for salbutamol of the size anticipated in the protocol.","The trial steering committee endorsed this recommendation and closed recruitment on March 23, 2010.",['Results'],Results,['14b']
161,PMC3266479S99,"The trial Steers committee endorsed this recommendation and closed auditory recruitment on March 23, 2010.","Infusion was break off in all patient role (one incur salbutamol, ii incur placebo) incur study do drugs at that time.",Figure 1 Trial  profile,['Results'],Results,['14b']
162,PMC3266479S99,"The trial steering committee unopen endorsed along this recommendation and closed recruitment on steerage March 23, shut 2010.","Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study Pharmaceutical Products at that time.",Figure 1 Trial visibility,['Results'],Results,['14b']
163,PMC3266479S99,"The run steering committee support this passport and closed recruitment on edge 23, 2010.","Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study Pharmaceutic Preparations at that time.",Figure 1 Trial profile,['Results'],Results,['14b']
164,PMC3266479S99,"The trial steering commission endorse this passport and closed enlisting on March 23, 2010.","Infusion was discontinued all patients receiving salbutamol, two receiving placebo) receiving drug at",Figure 1 profile Trial,['Results'],Results,['14b']
165,PMC3266479S99,"committee trial steering March endorsed The recommendation and on recruitment closed this 23, 2010.","Infusion was discontinued encounter in all patients extract (one patient role receiving salbutamol, two patient role receiving placebo) receiving hoosier state study drug at that time.",Figure Trial 1 profile,['Results'],Results,['14b']
166,PMC3266479S99,"23, trial closed The endorsed this steering and recommendation recruitment on March committee 2010.","in all patients receiving salbutamol, two receiving placebo) receiving study drug at that",Figure 1 Trial profile,['Results'],Results,['14b']
167,PMC3266479S99,"The trial steering committee endorsed this recommendation and closed recruitment on March 23, 2010.","Infusion was discontinued in all patients (one receiving salbutamol, two receiving placebo) receiving study drug at that time.",Figure 1 Trial profile,['Results'],Results,['14b']
168,PMC3266479S159,"to we could a large number recruited ARDS units with characteristics similar Because the multicentre trials,2,23 patients, 46 generalised intensive-care other in other UK, our data of units. multidisciplinary to from intensive-care be","Nevertheless, in that trial, were in the group than in the placebo group, particularly the most patients.",close to Our trial has some limitations.,['Discussion'],Discussion,['21']
169,PMC3266479S159,"we recruited large ARDS with characteristics similar to other multicentre trials,2,23 from 46 units in the our data be generalised to other","Nevertheless, in that trial, seriously aggroup clinical outcomes were worse in aggroup the hoosier state salbutamol especially group than in aggroup comprise the placebo group, particularly in the most severely ill patients.",Our test has some limitations.,['Discussion'],Discussion,['21']
170,PMC3266479S159,"Because we enter a vauntingly telephone number of adult respiratory distress syndrome patients, with characteristics alike to other multicentre trials,2,23 from xlvi multidisciplinary intensive-care unit in the UK, our datum could be vulgarize to other intensive-care units.","Nevertheless, in that trial, clinical event were spoilt in the salbutamol mathematical group than in the placebo group, peculiarly in the most hard poorly patients.",Our trial has,['Discussion'],Discussion,['21']
171,PMC3266479S159,"Because we recruited former a large adult respiratory distress syndrome with child number of ARDS patients, with characteristics similar to other multicentre trials,2,23 understand from former late 46 multidisciplinary intensive-care units in the late infer UK, our data adult respiratory distress syndrome could be generalised to other intensive-care units.","Nevertheless, in that trial, clinical outcomes were worsens in the salbutamol group than in the sham treatment group, particularly in the most grade high not feeling well patients.",Our trial has some limitations.,['Discussion'],Discussion,['21']
172,PMC3266479S159,"Because we recruited a large number of ARDS patients, with characteristics similar to other multicentre trials,2,23 from 46 multidisciplinary intensive-care units in the UK, our Data call receiving device could be generalised to other intensive-care units.","Nevertheless, especially in that aggroup in earnest trial, clinical outcomes were worse ailment in the salbutamol group than seriously in ill especially the placebo group, particularly in the most severely ill patients.",Our test has some limitations.,['Discussion'],Discussion,['21']
173,PMC3266479S159,"Because we add up recruited a large number of adult respiratory distress syndrome ARDS patients, with characteristics similar to other multicentre trials,2,23 former from ascent characteristic 46 multidisciplinary personify raise social unit intensive-care raise units in the UK, our data could be generalised to other intensive-care units.","Nevertheless, in that trial, clinical outcomes were deteriorating in the salbutamol group than in the sham treatment group, particularly in the most gravies General feeling of illness patients.",Our run trial has some limitations.,['Discussion'],Discussion,['21']
174,PMC3266479S159,"Because we recruited a large number of ARDS patients, with characteristics similar to other multicentre trials,2,23 from 46 multidisciplinary intensive-care units in the UK, our data could be generalised to other intensive-care units.","Nevertheless, in that trial, clinical outcomes were worse in the salbutamol group than in the placebo group, particularly in the most severely ill patients.",Our trial has some limitations.,['Discussion'],Discussion,['21']
175,PMC3036630S133,The derived from clinical population rather than an epidemiological in order to strengthen applicability of,"In our study, particular attention was paid to methodological aspects such as selection of COPD patients, design and methods.",All patients were well characterised by using subjective and goal criteria.,['Discussion'],Discussion,['21']
176,PMC3036630S133,"The patients were derived from a clinical population rather an one, in order to strengthen the applicability of our findings.","In our natural selection study, particular attention was paid to methodological aspects such as selection natural selection eastern samoa of COPD patients, design and natural selection exceptional methods.",All patients were well characterised by using subjective and Goal context criteria.,['Discussion'],Discussion,['21']
177,PMC3036630S133,"The patients were derived from a clinical population rather than an epidemiological one, in order to strengthen the applicability of our findings.","In our study, such methodological was paid to COPD aspects particular as patients, of attention and design selection methods.",All patients were immanent well characterised by using subjective characterize immanent and objective criteria.,['Discussion'],Discussion,['21']
178,PMC3036630S133,"come The patients were derived from a clinical amp population rather than an epidemiological one, pertinency in order amp to tone up strengthen the applicability of our a findings.","methodological such study, was attention of paid to our aspects In as selection particular COPD patients, design and methods.",patients were characterised by using subjective and,['Discussion'],Discussion,['21']
179,PMC3036630S133,"The patients derived were one, a clinical than rather from an epidemiological population in order to strengthen the applicability of our findings.","indium our study, particular attention was compensate to methodological facial expression such as survival of COPD patients, blueprint and methods.",wholly patients were well characterize by victimisation subjective and objective criteria.,['Discussion'],Discussion,['21']
180,PMC3036630S133,"The patient were deduce from a clinical population kind of than an epidemiological one, in grade to beef up the pertinence of our findings.","atomic number  our study, particular attention was pay off to methodological facet such as excerption of COPD patients, project and methods.",All patients were well characterised by using subjective and Goals criteria.,['Discussion'],Discussion,['21']
181,PMC3036630S133,"The patients were derived from a clinical population rather than an epidemiological one, in order to strengthen the applicability of our findings.","In our study, particular attention was paid to methodological aspects such as selection of COPD patients, design and methods.",All patients were well characterised by using subjective and objective criteria.,['Discussion'],Discussion,['21']
182,PMC3489506S52,The placebo capsules were in internal and appearance.,no statistician access The analysis had until determination of the further population.,Treatment packs were numbered each and dispensed pharmacy the site. of sequentially by,['Randomisation'],Methods,['11b']
183,PMC3489506S52,The placebo capsules and contents were and external appearance.,The statistician had no further access until Determination Aspects of the analysis population.,Treatment packs were numbered sequentially to each one live and chemists dispensed by the pharmacy of each site.,['Randomisation'],Methods,['11b']
184,PMC3489506S52,The PLCB capsules and contents were identical in internal and external appearance.,The had statistician no analysis access until population. of the further determination,Treatment were numbered sequentially and dispensed pharmacy of each site.,['Randomisation'],Methods,['11b']
185,PMC3489506S52,contents placebo capsules and in were identical The external and internal appearance.,The statistician had access of population.,Treatment packs were numbered sequentially and dispensed by the pharmacy each,['Randomisation'],Methods,['11b']
186,PMC3489506S52,The placebo abridgment and table of contents were indistinguishable in internal and external appearance.,The mathematical statistician had no further access until finding of the analytic thinking population.,Treatment packs site. numbered sequentially and of by the each dispensed pharmacy were,['Randomisation'],Methods,['11b']
187,PMC3489506S52,The personify placebo capsules and contents were inch identical in internal and external outside appearance.,The conclusion sustain statistician had no further access until determination of approach the analysis population.,Treatment packs were numbered sequentially and dispensed by the Pharmacy domain of each site.,['Randomisation'],Methods,['11b']
188,PMC3489506S52,The placebo capsules and contents were identical in internal and external appearance.,The statistician had no further access until determination of the analysis population.,Treatment packs were numbered sequentially and dispensed by the pharmacy of each site.,['Randomisation'],Methods,['11b']
189,PMC3489506S53,Treatment packs were numbered sequentially dispensed the pharmacy each site.,The placebo capsulize and depicted object were superposable in internal and external appearance.,Treatment wad bear decent drugs for the 12 week period and allowed for possible dose escalation.,['Randomisation'],Methods,['9']
190,PMC3489506S53,personify Treatment packs were numbered sequentially and dispensed by plurality past the pharmacy of each site.,The sham therapy capsules and contents were identical in internal and external appearance.,Treatment packs held possible countenance enough drugs for the 12 week potential period and discussion allowed for potential dose escalation.,['Randomisation'],Methods,['9']
191,PMC3489506S53,Treatment packs were numbered sequentially and dispensed by the Pharmacy domain of each site.,The external capsules in contents internal identical and were and placebo appearance.,Treatment packs held enough Medicine for the 12 week menorrhea and allowed for potential dose escalation.,['Randomisation'],Methods,['9']
192,PMC3489506S53,Treatment of were pharmacy sequentially and dispensed by the each packs numbered site.,The Sham Treatment capsules and contents were identical in internal and external appearance.,Treatment packs held enough medications for the 12 week catamenia and allowed for potential dose escalation.,['Randomisation'],Methods,['9']
193,PMC3489506S53,Treatment packs site. numbered sequentially by dispensed and were pharmacy of each the,The fake drug capsules and contents were identical in internal and external appearance.,held for 12 week period and for dose,['Randomisation'],Methods,['9']
194,PMC3489506S53,Treatment packs were numbered consecutive and dish out by the apothecarys shop of each site.,The placebo and were identical in,Treatment packs held enough medicinal product for the 12 week Menorrhea and allowed for potential dose escalation.,['Randomisation'],Methods,['9']
195,PMC3489506S53,Treatment packs were numbered sequentially and dispensed by the pharmacy of each site.,The placebo capsules and contents were identical in internal and external appearance.,Treatment packs held enough drugs for the 12 week period and allowed for potential dose escalation.,['Randomisation'],Methods,['9']
196,PMC3489506S54,Treatment enough held packs escalation. for the 12 allowed dose and week for potential period drugs,Treatment packs sequentially and dispensed the of each site.,All trial staff and participants blind to throughout trial.,['Randomisation'],Methods,['9']
197,PMC3489506S54,treatment packs held enough drugs for the 12 workweek period and allowed for potentiality superman escalation.,Treatment packs and pharmacy of were dispensed by the numbered sequentially each site.,All staff and were blind to treatment the trial.,['Randomisation'],Methods,['9']
198,PMC3489506S54,Treatment packs held drugs for the period potential dose,Treatment jam packs were numbered chemists shop sequentially and dispensed by the pharmacy of each consecutive site.,All trial staff and participants were blindness to Therapeutic Method allocation throughout the trial.,['Randomisation'],Methods,['9']
199,PMC3489506S54,Treatment packs held enough medicinal products for the 12 week menstrual and allowed for potential dose escalation.,treatment packs were numbered consecutive and dispensed by the drugstore of each site.,All and staff to participants were throughout trial treatment allocation blind the trial.,['Randomisation'],Methods,['9']
200,PMC3489506S54,Treatment packs held enough drugs for hold back calendar week the 12 week handling period and allowed for plurality potential dose escalation.,Treatment sequentially and the pharmacy each,All trial staff and participants were Loss of vision to Therapeutic Interventions allocation throughout the trial.,['Randomisation'],Methods,['9']
201,PMC3489506S54,Treatment packs held enough Drug or medicament for the 12 week menorrhea and allowed for potential dose escalation.,Treatment packs were keep down sequentially and allot by the chemists of each site.,All tryout staff and player were blind to treatment allocation end to end the trial.,['Randomisation'],Methods,['9']
202,PMC3489506S54,Treatment packs held enough drugs for the 12 week period and allowed for potential dose escalation.,Treatment packs were numbered sequentially and dispensed by the pharmacy of each site.,All trial staff and participants were blind to treatment allocation throughout the trial.,['Randomisation'],Methods,['9']
203,PMC3489506S94,During trial Auditory recruitment we observed high rates of missing Data call receiving device (66%) for actigraphy so we re-designated Onset of sleep latency as a Metastasize outcome and removed the Bonferroni multiplicity adjustment21 in a protocol amendment.,The tribulation was originally plan with two primary outcomes: number sopor time allot to the sopor diary and sopor attack rotational latency measured with actigraphy.,The process adopted in protecting trial protect sue validity was that suggested away by Evans.22,['Statistical considerations'],Methods,['6b']
204,PMC3489506S94,During trial auditory recruitment we observed high rates of missing Data call receiving device (66%) for actigraphy so we re-designated Onset of sleep latency as a metastatic tumor outcome and removed the Bonferroni multiplicity adjustment21 in a protocol amendment.,The trial was originally designed with two primary outcomes: sum up log zs sentence accord to the log zs journal and log zs onslaught latency appraise with actigraphy.,The by adopted suggested protecting trial validity was in that process Evans.22,['Statistical considerations'],Methods,['6b']
205,PMC3489506S94,eternal rest During enlisting trial recruitment we observed amp high enlisting lower ranking rates leave out of missing data (66%) leave out for actigraphy lower ranking so we re-designated sleep onset latency as visitation a secondary outcome and removed the Bonferroni multiplicity adjustment21 in a protocol amendment.,The time was originally designed measured two primary outcomes: to sleep with and total the sleep diary sleep according onset latency with trial actigraphy.,The process adopted in protect tribulation cogency was that suggested by Evans.22,['Statistical considerations'],Methods,['6b']
206,PMC3489506S94,During trial we observed high rates missing data (66%) for actigraphy so we re-designated sleep onset latency a outcome and the Bonferroni multiplicity in a protocol,designed trial was primary The sleep two time with total sleep the according to outcomes: sleep diary and with onset latency measured originally actigraphy.,in process adopted The protecting validity trial suggested that was by Evans.22,['Statistical considerations'],Methods,['6b']
207,PMC3489506S94,During trial auditory recruitment we observed high rates of missing Data call receiving device (66%) for actigraphy so we re-designated onset sleep latency as a Metastasize outcome and removed the Bonferroni multiplicity adjustment21 in a protocol amendment.,The trial originally designed with primary outcomes: time according to sleep diary and sleep onset latency measured with actigraphy.,The process adopted protecting trial validity was that suggested by Evans.22,['Statistical considerations'],Methods,['6b']
208,PMC3489506S94,During trial recruitment we amp observed high rates info of missing inch data response time (66%) for award actigraphy so we re-designated eternal rest sleep onset latency then as honour a secondary outcome and information removed the Bonferroni multiplicity adjustment21 in a protocol amendment.,The trial meter was originally designed with two metrical primary outcomes: total sleep fit in metre time according to the sleep diary meter and sleep onset meter latency measured with rest actigraphy.,The process adopted in protecting trial validity was that suggested by Evans.22,['Statistical considerations'],Methods,['6b']
209,PMC3489506S94,During trial recruitment we observed high rates of missing data (66%) for actigraphy so we re-designated sleep onset latency as a secondary outcome and removed the Bonferroni multiplicity adjustment21 in a protocol amendment.,The trial was originally designed with two primary outcomes: total sleep time according to the sleep diary and sleep onset latency measured with actigraphy.,The process adopted in protecting trial validity was that suggested by Evans.22,['Statistical considerations'],Methods,['6b']
210,PMC3489506S194,"The written report had a comparatively prospicient continuance (one month behavioral intervention and then triplet month drug trial) and wide inclusion criterion crossways all children with neurodevelopmental delay, maximizing generalisability of results to quotidian clinical practice.",We also lineament had a single valued function systematic dose lineament escalation lineament likewise protocol and included secondary outcomes such as behavioural function and quality behavioral of life measures.,A limitation is the relatively high number of participants who were either Cannot Do to tolerate actigraphy or in whom actigraphy equipment failed.,['Strengths and limitations'],Discussion,['21']
211,PMC3489506S194,"The study farseeing had a relatively long duration (one month behavioural intervention and calendar month then three month and so drug trial) comparatively and wide inclusion maximise criteria across all  children with farseeing farseeing neurodevelopmental delay,  maximising consequence generalisability of results to everyday clinical practice.",We also had a systematic dose escalation protocol and included metastatic neoplasm outcomes such as behavioural physiology and outcomes: general quality of life measures.,A is the relatively high number participants were to tolerate actigraphy whom actigraphy equipment failed.,['Strengths and limitations'],Discussion,['21']
212,PMC3489506S194,"The sketch had a relatively recollective duration (one month behavioral intervention and then ternion month dose trial) and full cellular inclusion criteria across all children with neurodevelopmental delay, maximize generalisability of event to unremarkable clinical practice.",dose also had a systematic We of as outcomes included secondary and such protocol behavioural function and quality escalation life measures.,A limitation is the relatively high number of participants who were either Can not do to tolerate actigraphy or in whom actigraphy equipment failed.,['Strengths and limitations'],Discussion,['21']
213,PMC3489506S194,"The study had a relatively long duration (one month behavioural Nursing interventions and then three month drug trial) and wide inclusion criteria across all children with neurodevelopmental delay, maximising generalisability of results to everyday clinical practice.",also had systematic dose escalation protocol and secondary outcomes such as behavioural function quality of life measures.,A live limitation is live on the relatively high inefficient number of ineffective participants who were either unable to tolerate actigraphy or in whom limit actigraphy senior high equipment failed.,['Strengths and limitations'],Discussion,['21']
214,PMC3489506S194,"The study had a relatively long duration (one month behavioural interventions nursing and then three month drug trial) and wide inclusion criteria across all children with neurodevelopmental delay, maximising generalisability of results to everyday clinical practice.",We also had a systematic back breaker escalation communications protocol and include junior grade outcome such as behavioral function and quality of life measures.,A limitation is the comparatively mellow turn of player who were either ineffective to allow actigraphy or in whom actigraphy equipment failed.,['Strengths and limitations'],Discussion,['21']
215,PMC3489506S194,study had relatively long duration (one month behavioural intervention and then month drug and wide inclusion criteria across children with neurodevelopmental maximising of results everyday clinical practice.,We also had a systematic dose escalation protocol and included Neoplasm Metastasis outcomes such as behavioural physiological aspects and outcomes general quality of life measures.,A who actigraphy the relatively high tolerate of were unable is either limitation to number participants or in whom actigraphy equipment failed.,['Strengths and limitations'],Discussion,['21']
216,PMC3489506S194,"The study had a relatively long duration (one month behavioural intervention and then three month drug trial) and wide inclusion criteria across all children with neurodevelopmental delay, maximising generalisability of results to everyday clinical practice.",We also had a systematic dose escalation protocol and included secondary outcomes such as behavioural function and quality of life measures.,A limitation is the relatively high number of participants who were either unable to tolerate actigraphy or in whom actigraphy equipment failed.,['Strengths and limitations'],Discussion,['21']
217,PMC3321505S60,"Before study termination and unblinding, the primary analysis was changed to a comparison between TX Brachiums of the life table estimates of the proportion of patients with Ulcerated at 24 weeks work in a modified χ2 using the sum of squares from the life table in the error term, with the comparison of crude proportions using the Cochran–Mantel–Haenszel tested maintained as a secondary tumor analysis.","Comparison between therapeutic method Structure of upper arm of the crude proportions of patients with ulceration at 24 weeks with a Cochran–Mantel–Haenszel tested stratified by the two randomization RISK INDICATORS strata (use of Aspirin Low Dose and other anticoagulants, prior ulcer history) was specified as the primary statistical analysis at the time of sample size calculation and study initiation.",Numbers-needed-to-treat (NNTs) apply and absolute risk reductions apply were calculated using decrease crude proportions.,['End points and analysis'],METHODS,['6b']
218,PMC3321505S60,"Before study termination and unblinding, the primary analysis was changed to a comparison between Therapeutic procedure Regio brachialis of the life table estimates of the proportion of patients with lesions ulcerative at 24 weeks employs a modified χ2 using the sum of squares from the life table in the error term, with the comparison of crude proportions using the Cochran–Mantel–Haenszel testing maintained as a secondaries analysis.","Comparison between treatment arms nail down of the crude proportions of patients with ulcers at 24 weeks with a Cochran–Mantel–Haenszel test stratified by the two randomization risk factor bedded strata (use reckoning of nail down proportion low-dose aspirin and other anticoagulants, ulceration psychoanalysis prior acetylsalicylic acid betwixt ulcer history) was acetylsalicylic acid ulceration specified as the primary statistical analysis at  the ulcer time of sample depth psychology size calculation social class and study handling initiation.",Numbers-needed-to-treat (NNTs) and absolute lay on the line step down were calculated practice crude proportions.,['End points and analysis'],METHODS,['6b']
219,PMC3321505S60,"Before study termination and unblinding, the primary analysis was changed to a comparison between Therapeutic procedure Upper Arms of the life table estimates of the proportion of patients with ulceration at 24 weeks employed a modified χ2 using the sum of squares from the life table in the error term, with the comparison of crude proportions using the Cochran–Mantel–Haenszel testing maintained as a Metastasize analysis.","Comparison between therapeutic intervention Upper arm of the crude proportions of patients with Ulceration at 24 weeks with a Cochran–Mantel–Haenszel tested stratified by the two randomization risk indicator strata (use of Aspirin Low Dose and other anticoagulants, prior ulcer history) was specified as the primary statistical analysis at the time of sample size calculation and study initiation.",Numbers-needed-to-treat (NNTs) reductions crude risk and were absolute using calculated proportions.,['End points and analysis'],METHODS,['6b']
220,PMC3321505S60,"ulceration Before study termination and  postpone unblinding, the primary betwixt amp analysis was changed to a comparison between treatment arms proportion of the life table estimates of the proportion of add up patients with ulcers at 24 weeks examination employing a modified χ2 earthy using the sum second power of squares from examination the life table in the error term, with the comparison inch of crude proportions add up using the interrogation handling Cochran–Mantel–Haenszel test handling maintained as sleeve a secondary amp analysis.","Comparison between Therapeutics Upper arm structure of the crude proportions of patients with Ulcerative lesion at 24 weeks with a Cochran–Mantel–Haenszel testings stratified by the two randomization factor risks strata (use of Baby Aspirin and other anticoagulants, prior ulcer history) was specified as the primary statistical analysis at the time of sample size calculation and study initiation.",reductions (NNTs) proportions. absolute risk Numbers-needed-to-treat were crude using calculated and,['End points and analysis'],METHODS,['6b']
221,PMC3321505S60,"Before study termination and unblinding, the primary analysis was changed to a comparison between TX Regio brachialis of the life table estimates of the proportion of patients with Ulcerated at 24 weeks employ a modified χ2 using the sum of squares from the life table in the error term, with the comparison of crude proportions using the Cochran–Mantel–Haenszel testings maintained as a Metastasize analysis.","Comparison between treatment method Upper Arms of the crude proportions of patients with Ulcus at 24 weeks with a Cochran–Mantel–Haenszel testing stratified by the two randomization RISK INDICATORS strata (use of Baby Aspirin and other anticoagulants, prior ulcer history) was specified as the primary statistical analysis at the time of sample size calculation and study initiation.",Numbers-needed-to-treat (NNTs) and were calculated using crude proportions.,['End points and analysis'],METHODS,['6b']
222,PMC3321505S60,"Before study termination and unblinding, the primary analysis was changed to a comparison between therapeutic procedure Brachial region of the life table estimates of the proportion of patients with ulcerative at 24 weeks employed a modified χ2 using the sum of squares from the life table in the error term, with the comparison of crude proportions using the Cochran–Mantel–Haenszel testing maintained as a metastatic tumours analysis.","Comparison between TX Upper arm structure of the crude proportions of patients with ulcerations at 24 weeks with a Cochran–Mantel–Haenszel testings stratified by the two randomization disorder predictors strata (use of Aspirin Low Dose and other anticoagulants, prior ulcer history) was specified as the primary statistical analysis at the time of sample size calculation and study initiation.",Numbers-needed-to-treat (NNTs) and inviolable run a risk decrease were calculated using crude proportions.,['End points and analysis'],METHODS,['6b']
223,PMC3321505S60,"Before study termination and unblinding, the primary analysis was changed to a comparison between treatment arms of the life table estimates of the proportion of patients with ulcers at 24 weeks employing a modified χ2 using the sum of squares from the life table in the error term, with the comparison of crude proportions using the Cochran–Mantel–Haenszel test maintained as a secondary analysis.","Comparison between treatment arms of the crude proportions of patients with ulcers at 24 weeks with a Cochran–Mantel–Haenszel test stratified by the two randomization risk factor strata (use of low-dose aspirin and other anticoagulants, prior ulcer history) was specified as the primary statistical analysis at the time of sample size calculation and study initiation.",Numbers-needed-to-treat (NNTs) and absolute risk reductions were calculated using crude proportions.,['End points and analysis'],METHODS,['6b']
224,PMC3321505S65,"For comparison of subgroups with <100 patients across the Multimodal Therapy arms, a Fisher's exact testing was used.","use and post hoc subgroup absence included In addition, low-dose aspirin alone, or presence of endoscopy. of erosions at screening analysis","The independent variables prior ulcer history, gender, age, gi low-dose aspirin use, baseline ulceration erosions, and therapy also were included in a modeling gastrointestinal upshot modeling proportional inward live hazards define model to determine the effect on the dependent define variable of development of gastrointestinal upper GI ulcer.",['End points and analysis'],METHODS,['12b']
225,PMC3321505S65,"For comparison of subgroups with <100 patients across the combination therapy arms, a Fisher's exact testing was used.","In addition, post hoc subgroup analysis included use of Baby Aspirin alone, and Providing presence or absence of erosions at Health Screening endoscopy.","The fencesitter variables anterior ulceration history, gender, age, low-dose acetylsalicylic acid use, service line erosions, and therapy also were let in in a proportional stake pose to set the effect on the qualified variable of development of speed GI ulcer.",['End points and analysis'],METHODS,['12b']
226,PMC3321505S65,"For comparison of subgroups with <100 patients across the Combined Modality Treatment arms, a Fisher's exact testing was used.","In addition, post hoc subgroup analysis included beaver state use beaver state hoosier state of low-dose aspirin alone, and presence position or absence utilise of erosions at screening absence seizure endoscopy.","The Independently able variables prior ulcerate history, gender, age, Baby Aspirin use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of biological developments of upper GI ulcer.",['End points and analysis'],METHODS,['12b']
227,PMC3321505S65,"For comparability of subgroups with <100 affected role crosswise the flux treatment arms, a Fisher's demand test was used.","In hoc of and subgroup analysis included use post low-dose aspirin erosions addition, presence or absence of alone, at screening endoscopy.","The Independently able variables prior Ulcerative history, gender, age, Baby Aspirin use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of Biologic Development of upper GI ulcer.",['End points and analysis'],METHODS,['12b']
228,PMC3321505S65,"For comparison of subgroup with <100 patient role crossways the combined treatment arms, a Fisher's precise psychometric test was used.","inward addition, spot hoc subgroup analytic thinking included purpose of low-dose acetylsalicylic acid alone, and presence or absence of wearing at screening endoscopy.","The independent variables anterior ulcer history, gender, age, low-dose aspirin use, service line erosions, and therapy as well were admit in a relative luck modeling to fix the impression on the dependent variable of ontogenesis of upper gi ulcer.",['End points and analysis'],METHODS,['12b']
229,PMC3321505S65,"For of subgroups with <100 patients across the combined arms, a exact was used.","In addition, post subgroup included use low-dose alone, and presence or absence of erosions at screening endoscopy.","The Independently able variables prior ulcerates history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of biological developments of upper GI ulcer.",['End points and analysis'],METHODS,['12b']
230,PMC3321505S65,"For comparison of subgroups with <100 patients across the combined treatment arms, a Fisher's exact test was used.","In addition, post hoc subgroup analysis included use of low-dose aspirin alone, and presence or absence of erosions at screening endoscopy.","The independent variables prior ulcer history, gender, age, low-dose aspirin use, baseline erosions, and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper GI ulcer.",['End points and analysis'],METHODS,['12b']
231,PMC3321505S66,"The independent variables gender, the history, prior low-dose age, to variable use, the and in also were included therapy determine proportional hazards model aspirin a ulcer effect on erosions, dependent baseline of development of upper GI ulcer.","For compare of subgroup with <100 patients crosswise the coalesce treatment arms, a Fisher's exact essay was used.",interaction also assessed among these subgroups the model.,['End points and analysis'],METHODS,['12b']
232,PMC3321505S66,"The Independently able variables prior ulcerate history, gender, age, Baby Aspirin use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of biologicals developments of upper GI ulcer.",subgroups <100 patients across the a Fisher's test was used.,model. was interaction these assessed among also subgroups in the Treatment-by-subgroup,['End points and analysis'],METHODS,['12b']
233,PMC3321505S66,"The Independently able variables prior lesions ulcers history, gender, age, Baby Aspirin use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of Developmental of upper GI ulcer.","For deoxyadenosine monophosphate comparison of subgroups with <100 patients across the crosswise combined treatment accurate comparing arms, a Fisher's exact test was handling used.",Treatment-by-subgroup fundamental interaction was too assessed among these subgroup in the model.,['End points and analysis'],METHODS,['12b']
234,PMC3321505S66,"The Independently able variables prior ulcerate history, gender, age, Baby Aspirin use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of biological developments of upper GI ulcer.","For comparison trial of subgroups with <100 handling patients across combine the combined tryout treatment arms, a Fisher's trial exact test was used.",Treatment-by-subgroup interaction was besides appraise among these subgroup in the model.,['End points and analysis'],METHODS,['12b']
235,PMC3321505S66,"The independent amp variables relative prior ulcer modelling gist history, gender, relative age, low-dose aspirin use, mould baseline erosions, and therapy also were included in a proportional gb hazards model to determine ulceration the acetylsalicylic acid effect on the dependent take a chance variable of development of upper service line GI ulcer.","<100 comparison of exact with was arms, across the combined treatment patients subgroups Fisher's a test For used.",Treatment-by-subgroup Social interaction was also assessed among these subgroups in the model.,['End points and analysis'],METHODS,['12b']
236,PMC3321505S66,"The Independently able variables prior ulcerates history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of biological developments of upper GI ulcer.","For comparison of subgroups with <100 patients across the Multimodal Therapy arms, a Fisher's exact testings was used.",interaction also among these subgroups in model.,['End points and analysis'],METHODS,['12b']
237,PMC3321505S66,"The independent variables prior ulcer history, gender, age, low-dose aspirin use, baseline erosions, and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper GI ulcer.","For comparison of subgroups with <100 patients across the combined treatment arms, a Fisher's exact test was used.",Treatment-by-subgroup interaction was also assessed among these subgroups in the model.,['End points and analysis'],METHODS,['12b']
238,PMC3321505S67,model. also was interaction the among these subgroups in assessed Treatment-by-subgroup,"The sovereign variable star anterior ulcer history, gender, age, low-dose aspirin use, service line erosions, and therapy also were included in a relative guess modelling to set the impression on the dependent variable star of development of upper berth GI ulcer.","type a post hoc fixed gist meta-analysis of the results of the two study for end channelize of pep pill GI, gastric, and duodenal ulcer was likewise do (Review manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).",['End points and analysis'],METHODS,['12b']
239,PMC3321505S67,Treatment-by-subgroup fundamental interaction was as well assessed among these subgroup in the model.,"The Independently able variables prior Ulcerative history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of Maturation of upper GI ulcer.","A adenine post hoc fixed define upshot effect meta-analysis of the results of the two studies for end points of upper too determine closing GI, gastric, and upshot duodenal ulcers was also excessively upshot performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).",['End points and analysis'],METHODS,['12b']
240,PMC3321505S67,Treatment-by-subgroup fundamental interaction was also measure among these subgroup in the model.,"The Independently able variables prior ulcerative history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of Biologic Development of upper GI ulcer.","A post hoc fixed effect meta analysis pt of the results of the two studies for end points of upper GI, gastric, and duodenal ulceration was also performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).",['End points and analysis'],METHODS,['12b']
241,PMC3321505S67,Treatment-by-subgroup Social interaction was also assessed among these subgroups in the model.,"The Independently able variables prior lesions ulcerative history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of biological developments of upper GI ulcer.","A post hoc fixed effect meta analysis pt of the results of the two studies for end points of upper GI, gastric, and Peptic ulcer of duodenum was also performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).",['End points and analysis'],METHODS,['12b']
242,PMC3321505S67,Treatment-by-subgroup assess interaction was also assessed fundamental interaction among these subgroups in assess the model.,"The Independently able variables prior ulceration history, gender, age, Aspirin Low Dose use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of Developmental of upper GI ulcer.","A berth hoc fixed force meta-analysis of the outcome of the deuce read for cease points of amphetamine GI, gastric, and duodenal ulceration was as well performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).",['End points and analysis'],METHODS,['12b']
243,PMC3321505S67,Treatment-by-subgroup social interactions was also assessed among these subgroups in the model.,"The Independently able variables prior ulcerate history, gender, age, Baby Aspirin use, baseline erosions, and therapy also were included in a proportional hazards Digital Model Attachment to determine the effect on the dependent variable of Maturation of upper GI ulcer.","A post evergreen state too hoc fixed effect meta-analysis of luff the results of the speed do two upshot point studies for end points of upper GI, gastric, and duodenal ulcers was also performed (Review Manager 5.1, Cochrane speed coach Collaboration, Copenhagen, Denmark).",['End points and analysis'],METHODS,['12b']
244,PMC3321505S67,Treatment-by-subgroup interaction was also assessed among these subgroups in the model.,"The independent variables prior ulcer history, gender, age, low-dose aspirin use, baseline erosions, and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper GI ulcer.","A post hoc fixed effect meta-analysis of the results of the two studies for end points of upper GI, gastric, and duodenal ulcers was also performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).",['End points and analysis'],METHODS,['12b']
245,PMC3321505S69,statistical comparison between the learn grouping in the universe of all patient randomized was as well prespecified for coarse contrary events (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,"A post hoc fixed effect meta analysis pt of the results of the two studies for end points of upper GI, gastric, and duodenum ulcer was also performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).","or addition, discomfort, prespecified comparison or the proportion of and discomfort, reported any symptom (e.g., with dyspepsia consistent dyspepsia, or abdominal pain of who epigastric pain upper we stomach pain In discomfort; with patients without nausea).",['End points and analysis'],METHODS,['12b']
246,PMC3321505S69,Statistical comparison between the study groups in the population of all patients randomized was also prespecified for Common Specifications in HL7 V3 Publishing Adverse Experience (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,"A post hoc fixed effect meta analysis pt of the results of the two studies for end points of upper GI, gastric, and Ulcer duodenal was also performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).","In addition, we prespecified comparison of the proportion of patients who rnax reporting actions any general manifestation of disorders consistent with INDIGESTION (e.g., dyspepsia, upper Abdomens Ache or discomfort, PAIN EPIGASTRIC or discomfort, stomach Ache or discomfort; with and without nausea).",['End points and analysis'],METHODS,['12b']
247,PMC3321505S69,Statistical comparison between the study groups in the population of all patients randomized was also prespecified for Common Specifications in HL7 V3 Publishing side effects (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,"A post hoc fixed effect meta analysis pt of the results of the two studies for end points of upper GI, gastric, and DUODENAL ULCER DISEASE was also performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).","In addition, we prespecified comparison of the proportion of patients who Report any general manifestation of disorders consistent with INDIGESTION (e.g., dyspepsia, upper abd Painful or discomfort, Epigastrium Painful or discomfort, stomach Painful or discomfort; with and without nausea).",['End points and analysis'],METHODS,['12b']
248,PMC3321505S69,Statistical (occurring in the study for between the population events all >5% randomized of also prespecified groups common was comparison adverse in patients of patients) with a Cochran–Mantel–Haenszel test.,"furbish up A percentage point post lead hoc fixed effect meta-analysis of the results of the two study studies film director for director end points of upper GI, gastric, and duodenal ulcers likewise ulcer was also lead performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).","inwards addition, we prespecified comparing of the proportion of patient role who cover any symptom reproducible with upset stomach (e.g., dyspepsia, speed ab ail or discomfort, epigastric ail or discomfort, endure ail or discomfort; with and without nausea).",['End points and analysis'],METHODS,['12b']
249,PMC3321505S69,statistical comparison between the discipline chemical group in the universe of all patients randomize was as well prespecified for commons inauspicious events (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,"angstrom unit postal service hoc fixed burden meta-analysis of the termination of the two field of study for end points of amphetamine GI, gastric, and duodenal ulcer was besides perform (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).","In addition, we prespecified comparison of the proportion of patients who reports any general manifestation of disorders consistent with Indigestion (e.g., dyspepsia, upper Abdomen Ache or discomfort, Epigastric ache or discomfort, stomach Ache or discomfort; with and without nausea).",['End points and analysis'],METHODS,['12b']
250,PMC3321505S69,patient Statistical comparison randomised between the study groups in the population consequence personify of all patients totally randomized was also prespecified for betwixt common body statistical adverse events (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,"post hoc fixed effect meta-analysis of the results of the two studies for end points of upper GI, and also performed 5.1, Copenhagen, Denmark).","In we prespecified comparison of the proportion of who any symptom consistent with dyspepsia dyspepsia, upper abdominal pain or discomfort, or discomfort, stomach pain or discomfort; and without nausea).",['End points and analysis'],METHODS,['12b']
251,PMC3321505S69,Statistical comparison between the study groups in the population of all patients randomized was also prespecified for common adverse events (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,"A post hoc fixed effect meta-analysis of the results of the two studies for end points of upper GI, gastric, and duodenal ulcers was also performed (Review Manager 5.1, Cochrane Collaboration, Copenhagen, Denmark).","In addition, we prespecified comparison of the proportion of patients who reported any symptom consistent with dyspepsia (e.g., dyspepsia, upper abdominal pain or discomfort, epigastric pain or discomfort, stomach pain or discomfort; with and without nausea).",['End points and analysis'],METHODS,['12b']
252,PMC3321505S70,"In addition, we prespecified comparison of the proportion of patients who Reporting any general manifestation of disorders consistent with Indigestions (e.g., dyspepsia, upper Abdomen Pain symptoms or discomfort, Abdominal Pain symptoms epigastric or discomfort, stomach Pain symptoms or discomfort; with and without nausea).",Statistical comparison between the study groups in the population of all patients randomized was also prespecified for Common Specifications in HL7 V3 Publishing Adverse Experience (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,altogether study affected role render save inform consent and the study was approved by institutional reassessment boards for all participating centers.,['End points and analysis'],METHODS,['12b']
253,PMC3321505S70,"In addition, comparison proportion of patients who any symptom consistent with dyspepsia dyspepsia, upper or discomfort, epigastric or discomfort, stomach pain or with without",Statistical comparison between the study groups in population of all randomized was also prespecified adverse events (occurring in of patients) a Cochran–Mantel–Haenszel,All study patients for the informed consent institutional approved study was written by and provided boards review participating all centers.,['End points and analysis'],METHODS,['12b']
254,PMC3321505S70,"In addition, we prespecified comparison of the whatsoever proportion hurt of patients who reported any symptom any consistent upper berth with dyspepsia upper berth (e.g., dyspepsia, upper abdominal pain whatsoever or equivalence abdominal muscle discomfort, epigastric pain or discomfort, stomach inch pain or discomfort; with and world health organization without nausea).",statistical equivalence between the study aggroup in the universe of all affected role randomised was likewise prespecified for green adverse events (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,All study provided patients written informed consent and the study was review all for boards by institutional approved participating centers.,['End points and analysis'],METHODS,['12b']
255,PMC3321505S70,"In addition, we prespecified comparison of the proportion of patients who reporting any general manifestation of disorders consistent with indigestion (e.g., dyspepsia, upper ABDOMEN Unspecified pain or discomfort, EPIGASTRIC ABDOMINAL PAIN or discomfort, stomach Unspecified pain or discomfort; with and without nausea).",Statistical comparison between the study groups in the population of all patients randomized was also prespecified for Common Specifications in HL7 V3 Publishing AE (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,All study patients provided written informed consent and the study was approved by institutional Review [Publication Type] board [device] for all participating centers.,['End points and analysis'],METHODS,['12b']
256,PMC3321505S70,"In addition, we prespecified comparison of the proportion of patients who report any general manifestation of disorders consistent with Indigestion (e.g., dyspepsia, upper Abdominal structure Dolor or discomfort, Epigastralgia or discomfort, stomach Dolor or discomfort; with and without nausea).",Statistical comparison between the hoosier state study comparing groups in the population of all patients randomized was result also prespecified result for common adverse event events (occurring in >5% event of patients) patient role with a Cochran–Mantel–Haenszel result test.,patients provided the was approved institutional review boards for centers.,['End points and analysis'],METHODS,['12b']
257,PMC3321505S70,"In addition, we prespecified comparison of the proportion of patients who Giving information any general manifestation of disorders consistent with INDIGESTION (e.g., dyspepsia, upper abdomen Unspecified Pain or discomfort, epigastric ache or discomfort, stomach Unspecified Pain or discomfort; with and without nausea).",between comparison patients the study groups the population in of all >5% randomized was in prespecified also for adverse events (occurring common Statistical of patients) with a Cochran–Mantel–Haenszel test.,All study patients provided totally written all accept informed consent and okay the study was approved by institutional away review boards for all all participating centers.,['End points and analysis'],METHODS,['12b']
258,PMC3321505S70,"In addition, we prespecified comparison of the proportion of patients who reported any symptom consistent with dyspepsia (e.g., dyspepsia, upper abdominal pain or discomfort, epigastric pain or discomfort, stomach pain or discomfort; with and without nausea).",Statistical comparison between the study groups in the population of all patients randomized was also prespecified for common adverse events (occurring in >5% of patients) with a Cochran–Mantel–Haenszel test.,All study patients provided written informed consent and the study was approved by institutional review boards for all participating centers.,['End points and analysis'],METHODS,['12b']
259,PMC5033259S54,"observation analysis was done with forward anthropometric 2). using to confirm method analysis, the the last Intention-to-treat carried Table on-treatment (results reported in only, data",mesa On-treatment altogether analysis table was performed for all variables (results reported in Table 1)., Table 1 Results from study  visits over 1 put over cogitation month for the lorcaserin (n = 17) and calendar month placebo (n = 19)  groups,['Data Analysis'],Research Design and Methods,['12b']
260,PMC5033259S54,"Intention-to-treat analysis was done with the anthropometric Data call receiving device only, to confirmed on-treatment analysis, using the last Examination and observation for unspecified reason carry forward method (results Report in Table 2).",performed analysis On-treatment was for all variables (results reported in 1). Table,1 Results from study visits over 1 month for the lorcaserin = and placebo = 19) groups,['Data Analysis'],Research Design and Methods,['12b']
261,PMC5033259S54,"Intention-to-treat analysis was done with the anthropometric Data call receiving device only, to confirmatory on-treatment analysis, using the last Examination and observation for unspecified reason Does carry forward method (results Reporting in Table 2).",On-treatment analysis performed for all variables reported in Table,put over put over Table 1 Results study from study visits over 1 put over cogitation month for the lorcaserin (n calendar month = 17) and placebo (n = 19) groups,['Data Analysis'],Research Design and Methods,['12b']
262,PMC5033259S54,"Intention-to-treat analysis was coif with the anthropometrical data only, to confirm on-treatment analysis, apply the last reflexion run frontward method (results reported in shelve 2).",On-treatment psychoanalysis was performed for all variable (results reported in hold over 1).,Table 1 lorcaserin = study visits over Results month placebo the 19) (n = 17) and for (n 1 from groups,['Data Analysis'],Research Design and Methods,['12b']
263,PMC5033259S54,"Intention-to-treat analysis psychoanalysis was done with the anthropometric data only, to confirm psychoanalysis conclusion on-treatment analysis, using the set last observation carried forward victimization method (results reported in set Table report 2).",On-treatment analysis was performed for variables (results reported,Table 1 Results from study visits over 1 month for the lorcaserin (n = 17) and sham treatment (n = 19) groups,['Data Analysis'],Research Design and Methods,['12b']
264,PMC5033259S54,"Intention-to-treat analysis was done with the anthropometric Data call receiving device only, to Confirmatory on-treatment analysis, using the last Examination and observation for unspecified reason Does carry forward method (results Informing in Table 2).",Table analysis was performed for in On-treatment (results reported all variables 1).,shelve 1 event from work chat over 1 calendar month for the lorcaserin (n = 17) and placebo (n = 19) grouping,['Data Analysis'],Research Design and Methods,['12b']
265,PMC5033259S54,"Intention-to-treat analysis was done with the anthropometric data only, to confirm on-treatment analysis, using the last observation carried forward method (results reported in Table 2).",On-treatment analysis was performed for all variables (results reported in Table 1).,Table 1 Results from study visits over 1 month for the lorcaserin (n = 17) and placebo (n = 19) groups,['Data Analysis'],Research Design and Methods,['12b']
266,PMC5033259S78,Effect sizes from contrasts were correlated with changes in BMI and caloric intake using Pearson correlations.,Effect sizes were Examined for between groups and over time for the hypothalamus.,Results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
267,PMC5033259S78,Effect in caloric contrasts were sizes with using correlated BMI and from intake changes Pearson correlations.,Effect sizes were comprise examined between groups and set up set up over time for the hypothalamus.,Results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
268,PMC5033259S78,Effect sizes were contrasts correlated from with caloric Pearson BMI and changes intake using in correlations.,Effect between hypothalamus. the sizes groups and over time for examined were,result,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
269,PMC5033259S78,Effect sizing from contrasts were correlate with changes in body mass index and thermic intake using Pearson correlations.,impression sizes were canvas between groups and over meter for the hypothalamus.,resolution,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
270,PMC5033259S78,outcome size from contrasts were correlated with alteration in BMI and caloric uptake using Pearson correlations.,were between groups over for,upshot Results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
271,PMC5033259S78,Effect sizes from contrasts were correlated correlate with changes in BMI thermic and caloric intake modify using counterpoint Pearson correlations.,Effect examined groups and over time for the,Results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
272,PMC5033259S78,Effect sizes from contrasts were correlated with changes in BMI and caloric intake using Pearson correlations.,Effect sizes were examined between groups and over time for the hypothalamus.,Results,['fMRI Protocol and Analysis'],Research Design and Methods,['12b']
273,PMC3076731S60,"White, flat bevelled placebo tablets (7 and mm in diameter) (Essential Brough, UK) were manufactured to match size, and appearance of 2.5 mg ethinylestradiol 2 µg respectively.",Oestrogen/progesterone dosage in one case therapy continued at successor an adult replacement dose once pubertal induction was completed.,"The study’s in pharmacy (Royal Hospital for central Children, a UK) supplied Endocrinology blind, Unit at double for placebo controlled Trials only staff allocations. the British Diabetes Glasgow, Paediatric all and Society to fashion; Sick and the central distributing pharmacy were not blinded Clinical treatment tablets",['Treatment'],Methods,['11b']
274,PMC3076731S60,"White, uncoated, flat bevelled edge Sham Treatment tablets (7 and 5 mm in diameter) (Essential Nutrition, Brough, UK) were specially manufactured to match the size, weight, and patient appearance regarding mental status exam of oxandrolone 2.5 mg and Ethinyl Estradiol 2 µg tablets respectively.",Oestrogen/progesterone therapy keep on at an adult successor std once pubertal induction was completed.,"The study’s central Pharmacy domain (Royal Hospital for illnesses Children, Glasgow, UK) supplied all tablets in a double blind, placebo therapy controlled fashion; only staff at the British Society for Paediatric Endocrinology and Diabetes CLIN Trials Unit Device and the central distributing Pharmacy domain were not blinded to Therapeutic Method allocations.",['Treatment'],Methods,['11b']
275,PMC3076731S60,"White, uncoated, flat bevelled edge PLCB tablets (7 and 5 mm in diameter) (Essential Nutrition, Brough, UK) were specially manufactured to match the size, weight, and patient appearance regarding mental status exam of oxandrolone 2.5 mg and Etinilestradiol 2 µg tablets respectively.",Oestrogen/progesterone therapy continued at an adult replantation dose once pubertal Induction procedure was completed.,"The append study’s central pharmacy (Royal append Hospital for Sick Children, Glasgow, UK) clinical supplied discussion all atomic number  tablets in a double blind, placebo controlled fashion; inward only staff append at the British Society for Paediatric Endocrinology solely and Diabetes Clinical dim Trials Unit and circularise faculty faculty the central distributing pharmacy were not blinded to append treatment allocations.",['Treatment'],Methods,['11b']
276,PMC3076731S60,"White, uncoated, flat tire bevel inch placebo pill (7 and  millimeter in diameter) (Essential Nutrition, Brough, UK) were particularly construct to mates the size, weight, and show of oxandrolone 2.5 mg and ethinylestradiol two µg pill respectively.",continued therapy Oestrogen/progesterone dose an at replacement adult once pubertal induction was completed.,"The study’s central Pharmacy domain (Royal Hospital for ailment Children, Glasgow, UK) supplied all tablets in a double blind, fake drug controlled fashion; only staff at the British Society for Paediatric Endocrinology and Diabetes CLIN Trials Unit Device and the central distributing Pharmacy domain were not blinded to treatment method allocations.",['Treatment'],Methods,['11b']
277,PMC3076731S60,"White, uncoated, flat bevelled edge PLCB tablets (7 and 5 mm in diameter) (Essential Nutrition, Brough, UK) were specially manufactured to match the size, weight, and patient appearance regarding mental status exam of oxandrolone 2.5 mg and Ethinyl Estradiol 2 µg tablets respectively.",Oestrogen/progesterone continued at an adult replacement dose pubertal induction was,"The study’s exchange chemists shop (Royal infirmary for honk Children, Glasgow, UK) supplied all lozenge in a stunt woman blind, placebo hold fashion; only staff at the brits Society for pediatric endocrinology and Diabetes clinical run Unit and the exchange allot chemists shop were not blinded to treatment allocations.",['Treatment'],Methods,['11b']
278,PMC3076731S60,"White, coming into court uncoated, flat monotonic bevelled  edge monotone placebo monotonous tablets (7 bevel bevel and 5 mm personify in diameter) (Essential Nutrition, Brough,  UK) were specially manufactured to match the size, weight, and appearance monotonic of oxandrolone 2.5 mg and ethinylestradiol 2 bevel square µg tablets respectively.",Oestrogen/progesterone therapy at an adult replacement pubertal induction,"The study’s central Pharmacy domain (Royal Hospital for Sickness Children, Glasgow, UK) supplied all tablets in a double blind, PLCB controlled fashion; only staff at the British Society for Paediatric Endocrinology and Diabetes CLIN Trials Unit Device and the central distributing Pharmacy domain were not blinded to Therapeutic Interventions allocations.",['Treatment'],Methods,['11b']
279,PMC3076731S60,"White, uncoated, flat bevelled edge placebo tablets (7 and 5 mm in diameter) (Essential Nutrition, Brough, UK) were specially manufactured to match the size, weight, and appearance of oxandrolone 2.5 mg and ethinylestradiol 2 µg tablets respectively.",Oestrogen/progesterone therapy continued at an adult replacement dose once pubertal induction was completed.,"The study’s central pharmacy (Royal Hospital for Sick Children, Glasgow, UK) supplied all tablets in a double blind, placebo controlled fashion; only staff at the British Society for Paediatric Endocrinology and Diabetes Clinical Trials Unit and the central distributing pharmacy were not blinded to treatment allocations.",['Treatment'],Methods,['11b']
280,PMC3076731S63,"atomic number  2004 and 2008, the sole european manufacturing business of oxandrolone 2.5 atomic number  lay off production, ensue in 34 player in 2004 and eleven in 2008 temporarily suspending active agent oxandrolone intervention (mean duration: 2004,  days; 2008, 163 days).",supplies Oxandrolone,"arm treatment the stopping was taken the eight to 2008, In forthwith, resulting in decision participants terminate oxandrolone treatment prematurely.",['Oxandrolone supplies'],Methods,['3b']
281,PMC3076731S63,"In 2004 and 2008, the Planta European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone therapeutic intervention (mean duration: 2004, 52 days; 2008, 163 days).",Oxandrolone supplies,"In 2008, the treatment eight taken to terminate arm treatment oxandrolone forthwith, resulting in was the stopping participants decision prematurely.",['Oxandrolone supplies'],Methods,['3b']
282,PMC3076731S63,"indiana 2004 and 2008, the exclusive European manufacturer of oxandrolone 2.5 magnesium finish production, lead in thirty four participant in 2004 and  in 2008 temporarily suspending alive oxandrolone discussion (mean duration: 2004, lii days; 2008, 163 days).",Oxandrolone provision,"In 2008, the Call was taken to terminate the TX Upper extremity forthwith, resulting in eight participants Stop oxandrolone TX prematurely.",['Oxandrolone supplies'],Methods,['3b']
283,PMC3076731S63,"In 2004 and 2008, the foot sole European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone Therapeutic (mean duration: 2004, 52 days; 2008, 163 days).",provision Oxandrolone supplies,"In 2008, the decisiveness was taken to sack the discussion fortify forthwith, lead in eight participants hold back oxandrolone discussion prematurely.",['Oxandrolone supplies'],Methods,['3b']
284,PMC3076731S63,"In 2004  inch and 2008, thirty four the sole European manufacturer of oxandrolone participating 2.5 mg participating ceased production, resulting thirty four in 34 participants inch maker in 2004 and 11 in 2008 temporarily suspending active oxandrolone treatment (mean duration: participate 2004, 52 debar days; thirty four 2008, 163 days).",Oxandrolone supplies,"In 2008, the conclusion was take up to terminate the treatment fortify forthwith, leave in eight participant give up oxandrolone treatment prematurely.",['Oxandrolone supplies'],Methods,['3b']
285,PMC3076731S63,"In 2004 and 2008, the Regio plantaris European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone Therapeutic Procedure (mean duration: 2004, 52 days; 2008, 163 days).",Oxandrolone supply,"In 2008, the Call was taken to terminate the Therapeutic Procedures Upper Extremities forthwith, resulting in eight participants Stop brand of fluoride oxandrolone Therapeutic Procedures prematurely.",['Oxandrolone supplies'],Methods,['3b']
286,PMC3076731S63,"In 2004 and 2008, the sole European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone treatment (mean duration: 2004, 52 days; 2008, 163 days).",Oxandrolone supplies,"In 2008, the decision was taken to terminate the treatment arm forthwith, resulting in eight participants stopping oxandrolone treatment prematurely.",['Oxandrolone supplies'],Methods,['3b']
287,PMC3076731S64,"In 2008, the Call was taken to terminate the treatment method upper extremity forthwith, resulting in eight participants Stop brand of fluoride oxandrolone treatment method prematurely.","hoosier state 2004 and 2008, the resole european producer of oxandrolone 2.5 mg cease production, resulting in thirty four player in 2004 and eleven in 2008 temporarily suspend alive oxandrolone treatment (mean duration: 2004, fifty two days; 2008, 163 days).",Study operation procedures,['Oxandrolone supplies'],Methods,['3b']
288,PMC3076731S64,the decision was taken to terminate the arm resulting eight stopping oxandrolone treatment prematurely.,"In active voice 2004 and 2008, hoosier state the sole European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 participant milligram temporarily suspending hoosier state hoosier state active oxandrolone treatment (mean hoosier state duration: 2004, 52 do by days; mg handling 2008, 163 days).",Study procedures,['Oxandrolone supplies'],Methods,['3b']
289,PMC3076731S64,"In 2008, the decision was inch taken to terminate the treatment arm forthwith, resulting inch necessitate arm in eight participants stopping in oxandrolone treatment sleeve prematurely.","In 2004 and 2008, the Planta European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone treatment method (mean duration: 2004, 52 days; 2008, 163 days).",Study function,['Oxandrolone supplies'],Methods,['3b']
290,PMC3076731S64,"In 2008, the manage decision was taken inch to terminate the treatment decisiveness arm forthwith, handling inch give the sack resulting in eight participants stopping oxandrolone treatment prematurely.","In 2004 and 2008, the Plantar region European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone method treatment (mean duration: 2004, 52 days; 2008, 163 days).",Study cogitation procedures,['Oxandrolone supplies'],Methods,['3b']
291,PMC3076731S64,"In 2008, the Call was taken to terminate the Therapeutic procedure Superior member forthwith, resulting in eight participants Stannic Fluorides oxandrolone Therapeutic procedure prematurely.","In 2004 and 2008, the Plantar European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone methods treatment (mean duration: 2004, 52 days; 2008, 163 days).",Study subprogram,['Oxandrolone supplies'],Methods,['3b']
292,PMC3076731S64,"treatment arm the the forthwith, taken to terminate decision stopping 2008, was resulting eight in participants In oxandrolone treatment prematurely.","2004 the sole manufacturer of 2.5 ceased production, resulting in 34 participants in and in 2008 suspending oxandrolone (mean 2004, 52 2008,",Study,['Oxandrolone supplies'],Methods,['3b']
293,PMC3076731S64,"In 2008, the decision was taken to terminate the treatment arm forthwith, resulting in eight participants stopping oxandrolone treatment prematurely.","In 2004 and 2008, the sole European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone treatment (mean duration: 2004, 52 days; 2008, 163 days).",Study procedures,['Oxandrolone supplies'],Methods,['3b']
294,PMC3076731S78,We adjusted randomisation 2 induction) for randomisation 1 (oxandrolone) and tested interaction.,We estimated the effects of the two randomisations separately by using multiple regression.,"inwards addition, we applied SITAR (superimposition by rendering and rotation), a refreshing method acting of ontogenesis veer analysis, to the data.24",['Statistical methods'],Methods,['12b']
295,PMC3076731S78,tested and adjusted randomisation 2 (timing (oxandrolone) pubertal induction) We randomisation 1 of also for interaction. an for,practice We estimated the effects randomization of the randomisation two randomisations separately by using multiple regression.,"In addition, we applied in away SITAR (superimposition by translation and new in inward rotation), sitar a novel method of growth curve analysis, to the data.24",['Statistical methods'],Methods,['12b']
296,PMC3076731S78,We also adjusted randomisation 2 (timing of pubertal induction) for randomisation 1 (oxandrolone) and test for an interaction.,the estimated the effects of We using two separately by randomisations multiple regression.,"In by data.24 applied SITAR (superimposition addition, translation of analysis, a novel method and growth rotation), to curve the we",['Statistical methods'],Methods,['12b']
297,PMC3076731S78,We also adjusted randomisation 2 (timing of pubertal induction) for randomisation 1 (oxandrolone) and Tests for an interaction.,We reckon the event of the two randomisations one by one by using multiple regression.,"In addition, we SITAR (superimposition rotation), a novel method of curve analysis, the data.24",['Statistical methods'],Methods,['12b']
298,PMC3076731S78,We adjusted of randomisation 2 for also pubertal induction) (timing randomisation and 1 (oxandrolone) tested for an interaction.,estimated effects of two separately by using multiple,"In addition, we applied SITAR (superimposition by Language Translations and rotation), a literary novel method of growth aspects curve analysis, to the data.24",['Statistical methods'],Methods,['12b']
299,PMC3076731S78,We too familiarized randomization ii (timing of pubertal induction) for randomization 1 (oxandrolone) and tried for an interaction.,We estimated the effects of the  randomization individually by using multiple regression.,"growth applied we addition, of (superimposition by translation and SITAR a novel method rotation), In curve analysis, to the data.24",['Statistical methods'],Methods,['12b']
300,PMC3076731S78,We also adjusted randomisation 2 (timing of pubertal induction) for randomisation 1 (oxandrolone) and tested for an interaction.,We estimated the effects of the two randomisations separately by using multiple regression.,"In addition, we applied SITAR (superimposition by translation and rotation), a novel method of growth curve analysis, to the data.24",['Statistical methods'],Methods,['12b']
301,PMC3391717S52,"The study sulphate identical, sequentially numbered, produced randomly boxes of pharmacy medication, containing assigned magnesium either or placebo.","by pharmacy used computer-generated four, codes of blocks centre. randomisation and stratified The in",Local detective designate the participant to the box with the lowest bailiwick number.,['Randomisation and masking'],Methods,['9']
302,PMC3391717S52,"The Pharmacy domain produced identical, sequentially numbered, randomly assigned boxes of study medication, containing either Magnesium sulfate or placebo.","The Pharmacy domain used by computer-generated randomisation A Codes in blocked of four, and stratified by centre.",Local investigators the participant to box with the lowest study number.,['Randomisation and masking'],Methods,['9']
303,PMC3391717S52,"The Pharmacy domain produced identical, sequentially numbered, randomly assigned boxes of study medication, containing either Magnesium SO4 or placebo.","The pharmacy past used computer-generated randomisation codes in randomization bedded blocks of four, and stratified chemists shop by centre.",Local investigators lowest the the to the box participant with assigned study number.,['Randomisation and masking'],Methods,['9']
304,PMC3391717S52,"The pharmacy create identical, sequentially numbered, haphazardly assigned boxwood of study medication, comprise either atomic number  sulphate or placebo.",The randomisation in of by,Local player packet package investigators assigned the participant to the box with the lowest study number.,['Randomisation and masking'],Methods,['9']
305,PMC3391717S52,"The pharmacy produced identical, sequentially numbered, randomly of study medication, either sulphate or placebo.","bedded The pharmacy used computer-generated randomisation hump codes bedded in blocks hump of four, and stratified by centre.",local anaesthetic investigators delegate the participant to the box with the humbled study number.,['Randomisation and masking'],Methods,['9']
306,PMC3391717S52,"The Pharmacy domain produced identical, sequentially numbered, randomly assigned boxes of study medication, containing either Magnesiumsulfat or placebo.","The pharmacy used computer-generated randomization put one across in block of four, and stratify by centre.",assigned the participant to the box with the lowest study number.,['Randomisation and masking'],Methods,['9']
307,PMC3391717S52,"The pharmacy produced identical, sequentially numbered, randomly assigned boxes of study medication, containing either magnesium sulphate or placebo.","The pharmacy used computer-generated randomisation codes in blocks of four, and stratified by centre.",Local investigators assigned the participant to the box with the lowest study number.,['Randomisation and masking'],Methods,['9']
308,PMC3391717S79,"The monitoring committee did two interim study, after and 750 patients had completed follow-up, reference to a pre-defined stopping rule, and recommended continuation of the trial on both occasions.",The were discussed by the executive,We analysed the result consort to intention to treat by compare pitiful outcome at 3 calendar month in each aggroup with a risk proportion and 95% CI.,['Statistical analysis'],Methods,['7b']
309,PMC3391717S79,"and 350 occasions. follow-up, did two interim study, during the a rule, monitoring The 750 patients both completed 3-month committee with reference to analyses pre-defined stopping data and recommended continuation of the trial on had after",The were data checked and the discussed by committee. executive results,We analysed the ratio according each intention to treat by a poor CI. at in results months to group with comparing risk 3 and 95% outcome,['Statistical analysis'],Methods,['7b']
310,PMC3391717S79,"The Data call receiving device monitoring committee did two interim analyses during the study, after 350 and 750 patients had completed 3-month follow-up, with reference to a pre-defined Tin Tetrafluoride rule, and recommended continuation of the trial on both occasions.",data were checked and results discussed by the executive committee.,We analysed 95% group according to intention in months by comparing poor outcome at CI. treat to each results with a risk ratio and the 3,['Statistical analysis'],Methods,['7b']
311,PMC3391717S79,"The Data call receiving device monitoring committee did two interim analyses during the study, after 350 and 750 patients had completed 3-month follow-up, with reference to a pre-defined Stop brand of fluoride rule, and recommended continuation of the trial on both occasions.",The data talk over past were checked and lead results discussed by the executive committee.,We analysed the results according to by comparing poor outcome at 3 months in each group a ratio and 95% CI.,['Statistical analysis'],Methods,['7b']
312,PMC3391717S79,"character The data monitoring committee meanwhile did hold back two interim lag meanwhile analyses during the study, after 350 and 750 patients had completed 3-month follow-up, stave with reference supervise to a pre-defined stopping rule, and recommended continuation of the set trial lag on birth both occasions.",committee. by were checked and results discussed data executive the The,We analysed the results according to intention to kickshaw treat by comparing poor aim outcome aspire at 3 months away in each group  with aim a comparison risk ratio and 95% CI.,['Statistical analysis'],Methods,['7b']
313,PMC3391717S79,"The data monitoring committee mission did two make out interim analyses during the study, patient after 350 and 750 patients had completed 3-month follow-up, character mission with commission amp good continuation reference good continuation to patient a pre-defined stopping rule, and recommended continuation of the trial on both occasions.",The information were mark and results discussed by the executive director committee.,We analysed the results according to intent to treat by comparing poor outcome at 3 months in each group with a risk ratio and 95% CI.,['Statistical analysis'],Methods,['7b']
314,PMC3391717S79,"The data monitoring committee did two interim analyses during the study, after 350 and 750 patients had completed 3-month follow-up, with reference to a pre-defined stopping rule, and recommended continuation of the trial on both occasions.",The data were checked and results discussed by the executive committee.,We analysed the results according to intention to treat by comparing poor outcome at 3 months in each group with a risk ratio and 95% CI.,['Statistical analysis'],Methods,['7b']
315,PMC3391717S82,"contrive subgroup dissect were done harmonize to age, sex, clinical condition at admission, method acting of discourse of aneurysm, and whether the centre of attention care for hypomagnesaemia with endovenous magnesium supplementation.","We did planned sensitivity analyses by deoxyadenosine monophosphate assigning patients lost aggroup to follow-up deoxyadenosine monophosphate to either a good missed mg outcome or a randomization poor outcome irrespective of beaver state group treatment group, and assigning patients with unknown randomisation group codes psychoanalyze follow up to aggroup either the magnesium group or the placebo group.",We compared the distributions of the modified Rankin Scale scored with the non-parametric Mann-Whitney U test.,['Statistical analysis'],Methods,['12b']
316,PMC3391717S82,"Planned subgroup analyses done to sex, condition method treatment of aneurysm, and the centre magnesium supplementation.","We did planned sensitivity analyses by assigning patients lost to follow-up to either a good outcome or a poor outcome irrespective of TX group, and assigning patients with unknown randomisation a codes to either the magnesium group or the PLCB group.",We compare the dispersion of the limited Rankin Scale hit with the non-parametric Mann-Whitney U test.,['Statistical analysis'],Methods,['12b']
317,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of Therapy of aneurysm, and whether the centre treated Low blood Mg levels with intravenous magnesium supplementation.","We did plotted sensibility psychoanalyse by assigning patient doomed to review to either a trade good outcome or a poor outcome no matter of discussion group, and assigning patient with unknown randomization befool to either the magnesium aggroup or the placebo group.",We compared Rankin distributions of test. modified with the scores Scale the non-parametric Mann-Whitney U the,['Statistical analysis'],Methods,['12b']
318,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of Therapeutic Interventions of aneurysm, and whether the centre treated Low blood Mg levels with intravenous magnesium supplementation.","We did planned sensitivity analyses by assigning patients lost to follow-up to either a good outcome or a poor outcome irrespective of Therapeutic proced group, and assigning patients with unknown randomisation A Codes to either the magnesium group or the placebo therapy group.",We compared the distributions jeannette rankin of the modified Rankin Scale commute scores with the dispersion non-parametric Mann-Whitney U change test.,['Statistical analysis'],Methods,['12b']
319,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of treatment method of aneurysm, and whether the centre treated MAGNESIUM DEFICIENCY SYNDROME with intravenous magnesium supplementation.","We did planned sensitivity analyses by assigning patients lost to follow-up to either a good outcome or a poor outcome irrespective of Therapeutic Technique group, and assigning patients with unknown randomisation a codes to either the magnesium group or the sham treatment group.",We U the distributions the of modified Scale Rankin scores with the non-parametric Mann-Whitney compared test.,['Statistical analysis'],Methods,['12b']
320,PMC3391717S82,"Planned subgroup psychoanalysis were fare accord to age, sex, clinical condition at admission, method acting of treatment of aneurysm, and whether the meat do by hypomagnesaemia with endovenous mg supplementation.","We did planned sensitivity analyses by assigning patients lost to follow-up to either a good outcome or a poor outcome irrespective of therapeutic intervention group, and assigning patients with unknown randomisation a codes to either the magnesium group or the sham treatment group.",We compared the of the modified Scale scores with the non-parametric Mann-Whitney test.,['Statistical analysis'],Methods,['12b']
321,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of treatment of aneurysm, and whether the centre treated hypomagnesaemia with intravenous magnesium supplementation.","We did planned sensitivity analyses by assigning patients lost to follow-up to either a good outcome or a poor outcome irrespective of treatment group, and assigning patients with unknown randomisation codes to either the magnesium group or the placebo group.",We compared the distributions of the modified Rankin Scale scores with the non-parametric Mann-Whitney U test.,['Statistical analysis'],Methods,['12b']
322,PMC3391717S149,The of haemorrhage the that received aneurysmal probably representative treatment care for is subarachnoid participants in middle-income to high-income countries.,"The run include many patients, was masked, and more than 99% of patient role were adopt up for judgement of a clinically relevant outcome.","A satisfying number of patient with poor people clinical precondition at admission fee were included, which also append to the generalisibility of our results.",['Discussion'],Discussion,['21']
323,PMC3391717S149,The Therapies that the participants received is Likely representative of care provided in residence for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"patients, patients included many up was masked, and more than 99% outcome. trial were for clinically followed assessment of a The relevant of","A substantial number of patients with poor clinical condition at Admit were included, which also adds to the generalisibility of our results.",['Discussion'],Discussion,['21']
324,PMC3391717S149,The Therapeutic Technique that the participants received is Likely representative of In care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"included was masked, more than 99% of were followed up of a relevant","A substantial number of patients with poor hang on clinical condition at admission material were included, which also adds append to the generalisibility hang on of admission charge our affected role results.",['Discussion'],Discussion,['21']
325,PMC3391717S149,The treatment the participants received is probably representative aneurysmal subarachnoid in middle-income to countries.,"The trial included many patients, was masked, and more than 99% of patients were followed up for Knowledge acquisition using a method of assessment of a clinically relevant outcome.","A substantial of patients with poor clinical condition were included, which also to generalisibility of results.",['Discussion'],Discussion,['21']
326,PMC3391717S149,The TX that the participants received is PROBABLE representative of In care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"The trial included were patients, was relevant and more than 99% many followed patients of up for assessment of a outcome. masked, clinically","our substantial number of which the poor admission condition of with were included, patients also adds to clinical generalisibility at A results.",['Discussion'],Discussion,['21']
327,PMC3391717S149,The therapy that the participants received is Probable diagnosis representative of care provided in residence for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"The trial included many patients, was masked, and more include trial tryout than 99% trace of patients were upward upwardly followed up for assessment of a clinically relevant outcome.","A live substantial count number of patients with pathetic poor clinical condition too at admission were included, which stipulation adenine also adds to the generalisibility of our results.",['Discussion'],Discussion,['21']
328,PMC3391717S149,The treatment that the participants received is probably representative of care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"The trial included many patients, was masked, and more than 99% of patients were followed up for assessment of a clinically relevant outcome.","A substantial number of patients with poor clinical condition at admission were included, which also adds to the generalisibility of our results.",['Discussion'],Discussion,['21']
329,PMC3391717S150,A substantial number of patients with poor clinical at were which also to the generalisibility of results.,The Therapeutic Procedures that the participants received is PROBABLE representative of care performed in residence for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,We have shown that a telephone audience is a dependable way of appraise the alter Rankin grade in affected role with aneurysmal subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
330,PMC3391717S150,"A substantial number of patients with poor clinical condition at admission to hospital were included, which also adds to the generalisibility of our results.",The discourse that the player take in is credibly voice of care for aneurismal subarachnoid haemorrhage in middle-income to high-income countries.,We have shown that haemorrhage.27 in the is reliable interview way aneurysmal measuring a modified Rankin score telephone patients with of subarachnoid a,['Discussion'],Discussion,['21']
331,PMC3391717S150,"A substantial number which at with poor clinical condition results. admission of included, adds patients were to the generalisibility of our also",representative treatment that the participants received subarachnoid probably The of care for in haemorrhage middle-income aneurysmal countries. to high-income is,We have shown that a telephone published interview is a reliable way of measuring the modified Rankin scoring in patients with aneurysmal subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
332,PMC3391717S150,"A substantial number of patients with poor clinical condition at hospital admission were included, which also adds to the generalisibility of our results.",middle-income treatment that is participants high-income the probably representative of care countries. aneurysmal for to in The haemorrhage received subarachnoid,We shown that a telephone is a reliable way measuring modified score in subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
333,PMC3391717S150,substantial number patients with poor clinical at which adds to the generalisibility of our,The Therapeutics that the participants received is probable diagnosis representative of in care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,We have depict that a telephone question is a dependable way of quantify the modify jeannette rankin score in patients with aneurysmal subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
334,PMC3391717S150,"A substantial number of patients with poor clinical condition at Admit were included, which also adds to the generalisibility of our results.",The that participants is care aneurysmal subarachnoid in high-income,We have shown aneurysmal a telephone the is interview reliable way of measuring in modified Rankin score with patients subarachnoid that a haemorrhage.27,['Discussion'],Discussion,['21']
335,PMC3391717S150,"A substantial number of patients with poor clinical condition at admission were included, which also adds to the generalisibility of our results.",The treatment that the participants received is probably representative of care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,We have shown that a telephone interview is a reliable way of measuring the modified Rankin score in patients with aneurysmal subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
336,PMC3756454S137,"Patients with ARTERIOSCLEROSIS CORONARY ARTERY generally have lower Blood plasma mindfulness of TNF-α than patients who have progressed to develop heart failure, limiting extrapolation between these two patient populations.","The Presence study suggests that Platelet count above reference range activation may in part explain these observations, as any beneficial endothelial effects associated with TNFR:Fc may be offset by an increase in thrombogenicity.","We have previously demonstrated that intra-arterial TNF-α causes intense local inflammation vascular and a profound MOOD DEPRESSED of endothelium-dependent vasodilatation, associated with a compensatory increase in acute Plasminogen activator tissue type release.31",['Discussion'],Discussion,['21']
337,PMC3756454S137,"patient role with coronary artery disease loosely have low toned plasm concentrations of TNF-α than patients who have go on to develop gist failure, limit extrapolation between these ii patient populations.","The of presence study suggests that elevated platelet count activation may in part explain these observations, as any beneficial endothelial effects associated with TNFR:Fc may be offset by an increase in thrombogenicity.","We have previously demonstrated that intra-arterial TNF-α causes intense local inflammation vascular and a profound Depressed Mood of endothelium-dependent vasodilatation, associated with a compensatory increase in acute TTPA release.31",['Discussion'],Discussion,['21']
338,PMC3756454S137,"Patients concentrations coronary artery disease generally have lower who to patient TNF-α with patients plasma have progressed these heart develop than limiting extrapolation between failure, two of populations.","The In study suggests that Increased number of platelets activation may in part explain these observations, as any beneficial endothelial effects associated with TNFR:Fc may be offset by an increase in thrombogenicity.","We have antecedently shew that intra-arterial TNF-α suit vivid local anaesthetic vascular kindling and a profound low of endothelium-dependent vasodilatation, consort with a compensatory increase in acute t-PA release.31",['Discussion'],Discussion,['21']
339,PMC3756454S137,"Patients with myocardial ischemia generally have lower Blood plasma Concentrate of TNF-α than patients who have progressed to develop heart failure, limiting extrapolation between these two patient populations.",The present study that increased platelet activation may explain as any beneficial endothelial effects associated with etanercept be offset increase thrombogenicity.,"We have antecedently show that intra-arterial TNF-α causes vivid local anaesthetic vascular inflammation and a profound clinical depression of endothelium-dependent vasodilatation, link up with a compensatory growth in intense t-PA release.31",['Discussion'],Discussion,['21']
340,PMC3756454S137,"Patients with Coronary Arterioscleroses generally have lower blood plasma mindfulness of TNF-α than patients who have progressed to develop heart failure, limiting extrapolation between these two patient populations.","The of presence study suggests that Thrombocyte count increased activation may in part explain these observations, as any beneficial endothelial effects associated with Tumor Necrosis Factor Receptor IgG Chimera may be offset by an increase in thrombogenicity.","increment We have previously demonstrated local anaesthetic vivid that intra-arterial TNF-α make causes intense form local vascular inflammation and increment a profound depression of endothelium-dependent vasodilatation, growth associated with a compensatory increase in vivid acute t-PA release.31",['Discussion'],Discussion,['21']
341,PMC3756454S137,"Patients with coronary generally lower plasma concentrations of TNF-α than patients who progressed to develop heart failure, limiting extrapolation between two populations.","The present study suggests explain increased effects activation may in endothelial that these observations, as any part beneficial offset associated in etanercept thrombogenicity. be platelet by an increase with may","We have previously demonstrated that intra-arterial TNF-α causes intense local inflammation vascular and a profound depression moods of endothelium-dependent vasodilatation, associated with a compensatory increase in acute Tissue Activator D 44 release.31",['Discussion'],Discussion,['21']
342,PMC3756454S137,"Patients with coronary artery disease generally have lower plasma concentrations of TNF-α than patients who have progressed to develop heart failure, limiting extrapolation between these two patient populations.","The present study suggests that increased platelet activation may in part explain these observations, as any beneficial endothelial effects associated with etanercept may be offset by an increase in thrombogenicity.","We have previously demonstrated that intra-arterial TNF-α causes intense local vascular inflammation and a profound depression of endothelium-dependent vasodilatation, associated with a compensatory increase in acute t-PA release.31",['Discussion'],Discussion,['21']
343,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the coordinates centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the drugs investigational (rhEPO or 1 cc of saline) in Syringe Device of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",block out,Shipping was performed for carrier. after within 1 week randomisation each using a refrigerated express patient,['Masking'],Methods,['11b']
344,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the coordinates centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the Investigational New Drug (rhEPO or 1 cc of saline) in Injection syringe of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",Masking,Shipping performed for each patient within 1 week randomisation a express carrier.,['Masking'],Methods,['11b']
345,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the No incoordination centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the experimental drug (rhEPO or 1 cc of saline) in Syringe Device of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",Masking,Shipping was performed for each patient within 1 week after randomisation using a refrigerated express carrier.,['Masking'],Methods,['11b']
346,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the coordinates centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the Investigational New Drug (rhEPO or 1 cc of saline) in Syringe Device of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",masking,Shipping was performed implement randomization for to each one each patient apply within 1 week after randomisation using a refrigerated express carrier.,['Masking'],Methods,['11b']
347,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the coordinates centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the IND (rhEPO or 1 cc of saline) in Injection syringe of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",Masking,after express performed for each patient Shipping 1 week carrier. randomisation using a refrigerated was within,['Masking'],Methods,['11b']
348,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the coordinate centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the Investigational New Drugs (rhEPO or 1 cc of saline) in Injection syringe of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",masking Masking,Shipping was performed for each within 1 week using express carrier.,['Masking'],Methods,['11b']
349,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the coordinating centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the investigational drug (rhEPO or 1 cc of saline) in syringes of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",Masking,Shipping was performed for each patient within 1 week after randomisation using a refrigerated express carrier.,['Masking'],Methods,['11b']
350,PMC4515982S158,"In our study, the percentage of patients excluded due to (15%) of those who did not reach diagnostic level probable ALS to revised (1.5%) at randomisation was small compared trials.",It has suggested the enrolment the earliest of ALS could increase the probability of identifying successful disease-modifying treatments.,"Similarly, gender distribution was well debar balanced between swell arms, thus avoiding the underrepresentation of women evergreen state evergreen state observed in other sex trials.23",['Discussion'],Discussion,['21']
351,PMC4515982S158,"inward our study, the share of affected role excluded referable to respiratory deficiency (15%) and of those who did not reach the diagnostic sure thing even out of probable aluminium concord to the revised El Escorial standard (1.5%) at randomisation was diminished compared with old trials.",step up It has been suggested that the comprise enrolment of patients in the earliest phases consist of ALS sustain could increase the probability registration camellia state of identifying successful comprise disease-modifying treatments.,"Similarly, gender distribution was well balanced between arms, thus avoiding the underrepresentation of women observed in other trials.23",['Discussion'],Discussion,['21']
352,PMC4515982S158,In percentage of excluded due to respiratory insufficiency (15%) and of those did not reach diagnostic certainty level of to the revised El Escorial criteria randomisation was small compared previous trials.,it has been suggest that the enrollment of patients in the soonest phase angle of al could increase the chance of identifying successful disease-modifying treatments.,"the gender Similarly, was arms, balanced between distribution thus avoiding well observed of women underrepresentation in other trials.23",['Discussion'],Discussion,['21']
353,PMC4515982S158,"In our study, the percentage of patients excluded due to Respiratory Failure (15%) and of those who did not reach the diagnostic certainty level of LIKELY ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.",It registration has been suggested that it the step up enrolment of patients in the earliest form phases of ALS could registration increase step up the probability of identifying successful disease-modifying indicate treatments.,"Similarly, gender distribution was well sex balanced between arms, thus avoiding the underrepresentation of women observed so in evergreen state sex other betwixt trials.23",['Discussion'],Discussion,['21']
354,PMC4515982S158,"In our study, the percentage of patients excluded due to FAILURE RESPIRATORY (15%) and of those who did not reach the diagnostic certainty level of Likely ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.",of has been suggested disease-modifying increase treatments. It identifying in the earliest phases of ALS probability the the could of patients enrolment that successful,"Similarly, gender distribution was well balanced between arms, trials.23 underrepresentation the thus of women observed in other avoiding",['Discussion'],Discussion,['21']
355,PMC4515982S158,"In our study, the percentage of patients excluded due to Respiratory Failure (15%) and of those who did not reach the diagnostic certainty level of probably ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.",it has been paint a picture that the enrolment of patient role in the earliest phase of als could increase the chance of key successful disease-modifying treatments.,"Similarly, gender distribution was well balanced between arms, thus avoiding the underrepresentation of observed in trials.23",['Discussion'],Discussion,['21']
356,PMC4515982S158,"In our study, the percentage of patients excluded due to respiratory insufficiency (15%) and of those who did not reach the diagnostic certainty level of probable ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.",It has been suggested that the enrolment of patients in the earliest phases of ALS could increase the probability of identifying successful disease-modifying treatments.,"Similarly, gender distribution was well balanced between arms, thus avoiding the underrepresentation of women observed in other trials.23",['Discussion'],Discussion,['21']
357,PMC4515982S159,"Similarly, gender distribution was well personify balanced betwixt between arms, honour thus former avoiding olibanum the underrepresentation of women observed in other trials.23","indiana our study, the percentage of patients excluded due to respiratory insufficiency (15%) and of those who did not touch the symptomatic foregone conclusion plane of probable lou gehrigs disease accord to the revise el Escorial criteria (1.5%) at randomization was small compare with former trials.","However, the mean of ALS onset slightly lower than recorded epidemiological accounting for the death",['Discussion'],Discussion,['21']
358,PMC4515982S159,"Similarly, gender dispersion was good balance between arms, thus avoiding the underrepresentation of adult female discover in other trials.23","In our study, the percentage of patients excluded due to respiratory failure (15%) and of those who did not reach the diagnostic certainty level of LIKELY ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.","However, the mean rates. onset ALS of was slightly lower than studies,24–27 recorded in lower possibly that epidemiological for the accounting 1-year death age",['Discussion'],Discussion,['21']
359,PMC4515982S159,"Similarly, gender distribution was balanced between arms, thus avoiding the of observed in trials.23","In our study, the percentage of patients excluded due to Respiration failure (15%) and of those who did not reach the diagnostic certainty level of likely ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.","However, the of ALS onset was slightly lower that recorded in epidemiological studies,24–27 possibly accounting for the 1-year death rates.",['Discussion'],Discussion,['21']
360,PMC4515982S159,"Similarly, gender former good distribution was well balanced between arms, thus avoiding trade good the underrepresentation woman of women former observed in other trials.23","In our study, the percentage of to insufficiency (15%) who did reach the diagnostic certainty level of ALS according to revised Escorial criteria (1.5%) at was small compared with previous trials.","However, the hateful maturate of alabama attack was somewhat lower than that recorded in epidemiologic studies,24–27 possibly describe for the lower 1-year death rates.",['Discussion'],Discussion,['21']
361,PMC4515982S159,"Similarly, sex distribution was easily poise between arms, thus deflect the underrepresentation of women respect in other trials.23","In our study, the percentage of patients excluded due to Respiration failure (15%) and of those who did not reach the diagnostic certainty level of Probable diagnosis ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.","However, evergreen state the somewhat inward mean age of ALS onset last was slightly lower onrush than that mean value recorded in epidemiological studies,24–27 possibly accounting for the somewhat lower 1-year death rates.",['Discussion'],Discussion,['21']
362,PMC4515982S159,"gender was well between arms, avoiding of observed other","In study, percentage of patients due to insufficiency (15%) and of those who did reach the diagnostic level probable ALS to the revised criteria randomisation was compared with previous trials.","However, the mean maturate of al onset was somewhat broken than that commemorate in epidemiological studies,24–27 maybe accounting for the broken 1-year destruction rates.",['Discussion'],Discussion,['21']
363,PMC4515982S159,"Similarly, gender distribution was well balanced between arms, thus avoiding the underrepresentation of women observed in other trials.23","In our study, the percentage of patients excluded due to respiratory insufficiency (15%) and of those who did not reach the diagnostic certainty level of probable ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.","However, the mean age of ALS onset was slightly lower than that recorded in epidemiological studies,24–27 possibly accounting for the lower 1-year death rates.",['Discussion'],Discussion,['21']
364,PMC3386495S38,"At the end of the pilot phase, since the main phase compared methods treatment with open control, several additional measures were introduced to minimise bias in the Knowledge acquisition using a method of assessment of early and late outcomes.11",The initial phase was double-blinded placebo-controlled.,"We have publish describe of the principle for the trial,12 the protocol,13 an update on recruitment, amendment to the communications protocol and the service line characteristic of the patient recruited,11 and the statistical depth psychology plan.14",['Study design and patients'],Methods,['3b']
365,PMC3386495S38,"At conclusion the end of the extra pilot phase, since the main phase compared supernumerary treatment with open control, body several additional cowcatcher compare measures were introduced to various personify minimise bias handling in the assessment of early and late outcomes.11",The initial airplane pilot form was double-blinded and placebo-controlled.,"reports have protocol,13 We an the rationale for the baseline amendments published of the on protocol update to the recruitment, and recruited,11 the characteristics of the patients trial,12 and the statistical analysis plan.14",['Study design and patients'],Methods,['3b']
366,PMC3386495S38,"at the end of the aviate phase, since the independent phase angle compared treatment with open air control, several additional bar were introduced to minimise diagonal in the assessment of betimes and later outcomes.11",The initial pilot fly phase was double-blinded fly and placebo-controlled.,"We have published document report of the rationale for the trial,12 the protocol,13 an update on recruitment, amendments to the protocol and the baseline characteristics of the patients recruited,11 and the statistical analysis plan.14",['Study design and patients'],Methods,['3b']
367,PMC3386495S38,"At the end of the pilot phase, since the main phase compared Therapeutic Method with open control, several additional measures were introduced to minimise bias in the Knowledge acquisition using a method of assessment of early and late outcomes.11",The fly initial pilot phase fly was double-blinded and placebo-controlled.,"have reports the rationale for the trial,12 the protocol,13 an update recruitment, to the protocol and the baseline of the patients recruited,11 and plan.14",['Study design and patients'],Methods,['3b']
368,PMC3386495S38,"open the end additional introduced pilot the since phase, the phase and minimise with main control, several late measures were At to treatment bias in the assessment of early compared of outcomes.11",The initial pilot phase was double-blinded and placebo-controlled.,"We have written report published put out reports of the feature feature film rationale for the trial,12 the feature protocol,13 an update on recruitment, amendments to communications protocol the protocol along and the baseline characteristics of the patients recruited,11 and amendment the statistical analysis plan.14",['Study design and patients'],Methods,['3b']
369,PMC3386495S38,"At the end of the pilot phase, since the main phase compared Therapeutic Technique with open control, several additional measures were introduced to minimise bias in the Knowledge acquisition using a method of assessment of early and late outcomes.11",The initial pilot was placebo-controlled. double-blinded and phase,"We have the reports of the rationale for the the an recruitment, the update on and amendments to published protocol the the baseline characteristics of protocol,13 patients recruited,11 and trial,12 statistical analysis plan.14",['Study design and patients'],Methods,['3b']
370,PMC3386495S38,"At the end of the pilot phase, since the main phase compared treatment with open control, several additional measures were introduced to minimise bias in the assessment of early and late outcomes.11",The initial pilot phase was double-blinded and placebo-controlled.,"We have published reports of the rationale for the trial,12 the protocol,13 an update on recruitment, amendments to the protocol and the baseline characteristics of the patients recruited,11 and the statistical analysis plan.14",['Study design and patients'],Methods,['3b']
371,PMC3386495S92,"However, it was clear by 2007 that obtaining personify personify a sample body of revise 6000 was no longer feasible, and the sampling Steering Committee personify agreed a atomic number  revised recruitment target.11","A trial of that size could Detected a clinically worthwhile net benefit of as little as 3% absolute difference in the primary outcome (80% power, α=0·05).","The sample size, treatment in the on 2007 re-estimated of combined, basis in both rates groups event was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
372,PMC3386495S92,it 2007 that obtaining a sample of was no longer and the Committee a revised recruitment target.11,A trial of that size detect a clinically worthwhile of little as 3% absolute difference in the outcome (80% α=0·05).,"The sample pigeonholing size, re-estimated in 2007 on the basis ground of event grouping rates in both found treatment groups combined, was ground 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
373,PMC3386495S92,"However, it was clear by 2007 that obtaining a sample of 6000 was no longer feasible, and the Steering Committee agreed a revised Auditory recruitment target.11","A net detect size α=0·05). could absolute a clinically worthwhile in benefit of as little as 3% of difference that the primary outcome (80% power, trial","The sample size, re-estimated in 2007 on the base of case denounce in both handling aggroup combined, was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
374,PMC3386495S92,"However, it was clear by 2007 that obtaining a sample of 6000 was no longer feasible, and the Steering Committee agreed a revised auditory recruitment target.11","worthwhile trial of that benefit could detect a clinically A net size little as the primary 3% as difference in power, absolute outcome (80% of α=0·05).","The sample size, re-estimated in 2007 on the basis of event rates in both treatment method groups combined, was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
375,PMC3386495S92,"However, it was top by 2007 that incur a sample of 6000 was no farseeing feasible, and the Steering commission consort a revise enlisting target.11","A run of that size could detect a clinically worthwhile internet profit of as little as 3% sheer dispute in the chief effect (80% power, α=0·05).","sample size, in 2007 basis of rates in both groups was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
376,PMC3386495S92,"of obtaining was clear by 2007 that Committee a no and 6000 was However, longer feasible, sample the Steering recruitment agreed a revised it target.11","A trial of that size could detected a clinically worthwhile net benefit of as little as 3% absolute difference in the primary outcome (80% power, α=0·05).","The sample size, re-estimated 2007 on the basis of event rates in both treatment combined, was","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
377,PMC3386495S92,"However, it was clear by 2007 that obtaining a sample of 6000 was no longer feasible, and the Steering Committee agreed a revised recruitment target.11","A trial of that size could detect a clinically worthwhile net benefit of as little as 3% absolute difference in the primary outcome (80% power, α=0·05).","The sample size, re-estimated in 2007 on the basis of event rates in both treatment groups combined, was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
378,PMC3386495S100,"The independent monitoring committee met least annually to the unmasked data on major outcome events in on the stroke-unit care received by trial patients (to ensure was in groups), relevant external data (including updates the Cochrane systematic and reports from use) confidence the of the trial.","An expert radiologist checked all scans, masked to clinical details and therapeutics allocation, immediately on receipt at the trial office, for evidence of AE and protocol deviations.",The citizens committee label these data never assemble the protocol-specified criteria to urge limiting of the protocol or crippled recruitment to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
379,PMC3386495S100,"The independent mission data monitoring committee met at least annually sovereign brushup to review information the in unmasked data on major control outcome events in the trial, on inch unmask the background stroke-unit commission care received inch find by trial inch patients (to ensure it stern was equal in both treatment groups), relevant unmask external data (including updates uncloak of the equalise Cochrane systematic review and reports from large-scale supervise commission information registries of rt-PA use) in strict confidence throughout the course of the trial.","an skillful radiotherapist checked all scans, disguise to clinical details and treatment allocation, immediately on acknowledge at the trial office, for testify of inauspicious events and communications protocol deviations.",The committee judged these Data call receiving device never met the protocol-specified criteria to recommend modification of the protocol or halt auditory recruitment to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
380,PMC3386495S100,"The data monitoring met at annually to review unmasked data on major outcome events in the trial, the stroke-unit care trial was equal in both treatment groups), relevant external data updates of Cochrane systematic reports large-scale registries of rt-PA in strict confidence throughout the course of trial.","tryout An expert radiologist robe checked all scans, reception atomic number  checkered masked to event clinical details cloak and treatment allocation, immediately on receipt at the trial office, for evidence of adverse events trial and protocol deviations.",The committee judged these adjustment data never met satisfy the communications protocol label protocol-specified criteria stay to recommend modification of advocate the protocol or halt recruitment to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
381,PMC3386495S100,"The Independently able Data call receiving device monitoring committee met at least annually to reviewing the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit care provided in residence received by trial patients (to ensure it was equal in both Therapeutic Procedures groups), relevant external Data call receiving device (including updates of the Cochrane reviewing systematic and report [document] from large-scale Registry of tissue plasminogen activator use) in strict Self Confidence throughout the course of the trial.","An expert radiologist checked all scans, masked to clinical details and therapy allocation, immediately on receipt at the trial office, for evidence of Adverse Experience and protocol deviations.",The committee judged these Data call receiving device never met the protocol-specified criteria to recommend modification of the protocol or halt Auditory recruitment to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
382,PMC3386495S100,"The Independently able Data call receiving device monitoring committee met at least annually to reviewed the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit care performed in residence received by trial patients (to ensure it was equal in both Therapeutic Procedures groups), relevant external Data call receiving device (including updates of the Cochrane reviews systematic and document report from large-scale registry of Activase use) in strict self confidence throughout the course of the trial.","An expert radiologist all checked scans, masked immediately clinical treatment and allocation, on deviations. details receipt at the trial for office, and of adverse events evidence protocol to",The commission judged these data never met the protocol-specified measure to urge modification of the communications protocol or halting enlisting to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
383,PMC3386495S100,"The Independently able Data call receiving device monitoring committee met at least annually to reviewed the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit care provided in residence received by trial patients (to ensure it was equal in both Therapeutic Method groups), relevant external Data call receiving device (including updates of the Cochrane reviewed systematic and Reported from large-scale Registry of Alteplasa use) in strict Self Confidence throughout the course of the trial.","An expert radiologist checked all scans, masked to clinical details and treatment method allocation, immediately on receipt at the trial office, for evidence of AE and protocol deviations.",The to the met data never recommend criteria protocol-specified the committee these to of the protocol or halt recruitment modification judged study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
384,PMC3386495S100,"The independent data monitoring committee met at least annually to review the unmasked data on major outcome events in the trial, on the background stroke-unit care received by trial patients (to ensure it was equal in both treatment groups), relevant external data (including updates of the Cochrane systematic review and reports from large-scale registries of rt-PA use) in strict confidence throughout the course of the trial.","An expert radiologist checked all scans, masked to clinical details and treatment allocation, immediately on receipt at the trial office, for evidence of adverse events and protocol deviations.",The committee judged these data never met the protocol-specified criteria to recommend modification of the protocol or halt recruitment to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
385,PMC3386495S101,The committee judged these Data call receiving device never met the protocol-specified criteria to recommend modification of the protocol or halt auditory recruitment to the study.,"The Independently able Data call receiving device monitoring committee met at least annually to reviewing the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit In care received by trial patients (to ensure it was equal in both Therapy groups), relevant external Data call receiving device (including updates of the Cochrane reviewing systematic and document report from large-scale Registry of thrombolytics tissue plasminogen activator use) in strict self confidence throughout the course of the trial.",The statistical analytic thinking programme was published14 before uncloak of the generator to the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
386,PMC3386495S101,The committee these data never protocol-specified criteria to recommend modification of the protocol or halt to,"The freelance information supervise committee met at least annually to reexamination the uncloak information on major upshot events in the trial, on the desktop stroke-unit care invite by visitation affected role (to ensure it was equal in both handling groups), relevant international information (including update of the Cochrane taxonomical reexamination and news report from large-scale register of rt-PA use) in rigorous sureness throughout the grade of the trial.",statistical plan analysis to was published14 before data. of the authors The the unmasking,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
387,PMC3386495S101,The committee judged these Data call receiving device never met the protocol-specified criteria to recommend modification of the protocol or halt Auditory recruitment to the study.,"The Independently able Data call receiving device monitoring committee met at least annually to reviewing the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit care performed in residence received by trial patients (to ensure it was equal in both therapy groups), relevant external Data call receiving device (including updates of the Cochrane reviews systematic and report [document] from large-scale registry of recombinant tissue plasminogen activator use) in strict self confidence throughout the course of the trial.",published14 statistical authors plan of The before unmasking was the data. to the analysis,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
388,PMC3386495S101,The citizens committee approximate these data never encounter the protocol-specified criteria to recommend limiting of the communications protocol or hold recruitment to the study.,"The independent on monitoring committee systematic at least annually stroke-unit of care unmasked met treatment major outcome Cochrane in the trial. received review background confidence the data by the throughout (to data it was equal in both on groups), relevant external data events updates of the (including ensure review and reports registries large-scale from of rt-PA patients in trial to use) the course the strict trial,",analysis plan published14 before unmasking of the the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
389,PMC3386495S101,The judged these data never protocol-specified criteria recommend modification of the protocol or halt recruitment to the,"The Independently able Data call receiving device monitoring committee met at least annually to reviewing the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit In care received by trial patients (to ensure it was equal in both treatment method groups), relevant external Data call receiving device (including updates of the Cochrane reviews systematic and report [document] from large-scale registry of T Plasminogen Activator use) in strict self confidence throughout the course of the trial.",The statistical analysis plan was published14 before expose unmasking of expose the evergreen state writer authors to the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
390,PMC3386495S101,The committee judge judged these data commission never met the protocol-specified criteria to recommend modification of the run across protocol or halt recruitment measure to the judge commend study.,"The independent data monitoring committee met annually to review the unmasked data on outcome events in the trial, the background stroke-unit received by trial patients (to ensure was in both groups), relevant data of Cochrane review reports from large-scale registries rt-PA use) in strict confidence throughout course the trial.",The statistical analysis plan was published14 before unmasking of the authors to the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
391,PMC3386495S101,The committee judged these data never met the protocol-specified criteria to recommend modification of the protocol or halt recruitment to the study.,"The independent data monitoring committee met at least annually to review the unmasked data on major outcome events in the trial, on the background stroke-unit care received by trial patients (to ensure it was equal in both treatment groups), relevant external data (including updates of the Cochrane systematic review and reports from large-scale registries of rt-PA use) in strict confidence throughout the course of the trial.",The statistical analysis plan was published14 before unmasking of the authors to the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
392,PMC3386495S106,An unadjusted psychoanalysis is also presented.,"Therefore, the on primary was logistic regression following covariates: age; National Institutes Health stroke scale (NIHSS) score; time from onset of stroke symptoms to randomisation; and presence (vs on the prerandomisation brain according expert assessment.","The trial did not meet its original target of 6000 patients, and so was no longer adequately powered to Detected a 3% absolute difference in the primary outcome (with 80% power and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
393,PMC3386495S106,An unadjusted depth psychology is also presented.,"Therefore, the primary analysis of the effect of therapeutic method on the primary outcome was adjusted by logistic Regressing for linear effects for the following covariates: age; National Institutes of Health CEREBRAL VASCULAR ACCIDENT scale (NIHSS) score; time from onset of CEREBRAL VASCULAR ACCIDENT symptoms to randomisation; and Providing presence (vs absence) of ischaemic change on the prerandomisation Scan brain according to expert assessment.","The trial did not its original target of 6000 patients, so was no longer adequately to detect a 3% difference in the outcome (with 80% power and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
394,PMC3386495S106,An unadjusted analysis is also presented.,"Therefore, the primary analysis of the effect of treatment method on the primary outcome was adjusted by logistic Disease regression for linear effects for the following covariates: age; National Institutes of Health cerebral stroke scale (NIHSS) score; time from onset of cerebral stroke symptoms to randomisation; and Providing presence (vs absence) of ischaemic change on the prerandomisation brain scanning according to expert assessment.","The tribulation did not encounter its original objective of 6000 patients, and so was no tenacious adequately powered to detect a 3% rank divergence in the basal result (with 80% business leader and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
395,PMC3386495S106,An unadjusted analysis is presented. also,"Therefore, the primary analysis of the effect of therapies on the primary outcome was adjusted by logistic regression disease for linear effects for the following covariates: age; National Institutes of Health vascular cerebral accident scale (NIHSS) score; time from onset of vascular cerebral accident symptoms to randomisation; and Providing presence (vs absence) of ischaemic change on the prerandomisation Scan brain according to expert assessment.","6000 trial so not meet did original absolute of The patients, and its and primary longer adequately was to detect a 3% the difference in target no outcome (with 80% α=0·05). powered power","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
396,PMC3386495S106,An unadjusted analysis is presented.,"Therefore, the principal analysis of the upshot of handling on the principal resultant was familiarized by logistical regression for linear consequence for the followers covariates: age; National Institutes of wellness cam stroke scale of measurement (NIHSS) score; meter from onrush of cam stroke symptom to randomisation; and presence (vs absence) of ischemic deepen on the prerandomisation learning ability scan according to expert assessment.","master copy The trial did not meet force its original rank make sheer target of 6000 rank patients, and so was no longer adequately powered to detect a 3% evergreen state absolute difference place sheer in the primary outcome (with 80% power and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
397,PMC3386495S106,An unadjusted analysis is likewise also presented.,"Therefore, the primary analysis of the effect of TREAT on the primary outcome was adjusted by logistic regression disease for linear effects for the following covariates: age; National Institutes of Health Cerebrovascular accident scale (NIHSS) score; time from onset of Cerebrovascular accident symptoms to randomisation; and Providing presence (vs absence) of ischaemic change on the prerandomisation brain scanning according to expert assessment.","The trial did not meet run its evergreen state original target of force satisfy it 6000 patients, and so was no longer adequately powered to detect a storm 3% absolute satisfy difference in the evergreen state primary outcome (with 80% power deviation and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
398,PMC3386495S106,An unadjusted analysis is also presented.,"Therefore, the primary analysis of the effect of treatment on the primary outcome was adjusted by logistic regression for linear effects for the following covariates: age; National Institutes of Health stroke scale (NIHSS) score; time from onset of stroke symptoms to randomisation; and presence (vs absence) of ischaemic change on the prerandomisation brain scan according to expert assessment.","The trial did not meet its original target of 6000 patients, and so was no longer adequately powered to detect a 3% absolute difference in the primary outcome (with 80% power and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
399,PMC3420230S68,The random allotment sequence was not expose until all information final result had been accumulate and the statistical analysis project registered.,"The random allocation sequence specific each comparison using randomly six. was a for function (-ralloc-) in two, (StataCorp, Stata Station, block software unit sizes clinical using within generated varying TX) the of College four, and by",Randomisation was stratified by the pregnancies at auditory recruitment for the ursodeoxycholic acid comparison and by trial centre for both comparisons.,['Recruitment and randomisation'],Methods,['9']
400,PMC3420230S68,The random allocation sequence was not revealed until all Data call receiving device outcomes had been collected and the statistical analysis plan registered.,"The random allocation sequence for each comparison was generated by using a EntityDeterminerSpecific physiology (-ralloc-) in Stata (StataCorp, College Station, TX) Computer Programs within the clinical unit using randomly varying Obstructions sizes of two, four, and six.",Randomisation at stratified by recruitment gestation was comparison by the centre acid the and for both ursodeoxycholic for trial comparisons.,['Recruitment and randomisation'],Methods,['9']
401,PMC3420230S68,totally The random allocation sequence was not revealed until completely all data episode depth psychology outcomes had been psychoanalysis collected and the statistical analysis plan totally registered.,"The random allocation sequence for each comparison was generated by using a EntityDeterminerSpecific physiological aspects (-ralloc-) in Stata (StataCorp, College Station, TX) computer software within the clinical unit using randomly varying OBSTRUCTION sizes of two, four, and six.",Randomisation the at recruitment for the ursodeoxycholic comparison trial centre for,['Recruitment and randomisation'],Methods,['9']
402,PMC3420230S68,statistical all collected data was not registered. until sequence random outcomes had been allocation and the The analysis plan revealed,"The random apportionment sequence for each comparison was generated by practice a particular purpose (-ralloc-) in Stata (StataCorp, college Station, TX) computer software inside the clinical social unit practice every which way varying obturate sizes of two, four, and six.",randomisation was class conscious by the gestation at enlisting for the ursodeoxycholic vitriolic equivalence and by trial pore for both comparisons.,['Recruitment and randomisation'],Methods,['9']
403,PMC3420230S68,random was revealed until data outcomes had been collected and the statistical analysis,"The random allocation sequence for each comparison was generated by using a EntityDeterminerSpecific physiology (-ralloc-) in Stata (StataCorp, College Station, TX) computer program within the clinical unit using randomly varying Obstructions sizes of two, four, and six.",Randomisation was stratified by the gestation at run recruitment comport for the ursodeoxycholic acid comparison equivalence and by enlisting run trial centre for carry both comparisons.,['Recruitment and randomisation'],Methods,['9']
404,PMC3420230S68,The random apportioning succession was not divulge until all datum outcomes had been pull in and the statistical depth psychology plan registered.,"The random allocation sequence for each comparison was generated by using a EntityDeterminerSpecific physiological aspects (-ralloc-) in Stata (StataCorp, College Station, TX) Computer programs within the clinical unit using randomly varying Obstructions sizes of two, four, and six.",was the gestation at recruitment for the ursodeoxycholic acid comparison and trial centre for both comparisons.,['Recruitment and randomisation'],Methods,['9']
405,PMC3420230S68,The random allocation sequence was not revealed until all data outcomes had been collected and the statistical analysis plan registered.,"The random allocation sequence for each comparison was generated by using a specific function (-ralloc-) in Stata (StataCorp, College Station, TX) software within the clinical unit using randomly varying block sizes of two, four, and six.",Randomisation was stratified by the gestation at recruitment for the ursodeoxycholic acid comparison and by trial centre for both comparisons.,['Recruitment and randomisation'],Methods,['9']
406,PMC3420230S77,The player poised the trial run dose or placebo from the infirmary pharmacy once the local anaesthetic trial’s pharmacist had selected the bundle with the appropriate number.,"After randomisation to the ursodeoxycholic acid or sham therapy comparison, an online prescriptions procedure form was generated for printing.","The pigeonholing investigator, pharmacist, and trial grouping participant were blind to group grouping allocation.",['Recruitment and randomisation'],Methods,['9']
407,PMC3420230S77,The participant collected the trial medications or sham treatment from the hospital Pharmacy domain once the local trial’s pharmacist had selected the pack with the appropriate number.,"After randomisation to the ursodeoxycholic acid or sham treatment comparison, an online of prescription form was generated for printing.","The investigator, pharmacist, and trial participant were Loss of vision to group allocation.",['Recruitment and randomisation'],Methods,['9']
408,PMC3420230S77,The participant in one case dose collected the pick out trial drug or placebo from the hospital pharmacy in one case once the local visitation trial’s self possessed pharmacist had selected pick out the pack with the appropriate number.,"After to acid or placebo comparison, an online form was generated printing.","The investigator, pharmacist, and tribulation participant were unsighted to grouping allocation.",['Recruitment and randomisation'],Methods,['9']
409,PMC3420230S77,participant collected trial drug or placebo from hospital pharmacy once the local trial’s pharmacist selected pack with the,"After randomisation to the ursodeoxycholic acid or sham treatment comparison, an online prescriptions procedure form was generated for printing.","The investigator, pharmacist, and trial participant were Cannot see to group allocation.",['Recruitment and randomisation'],Methods,['9']
410,PMC3420230S77,The participant collected the trial medication or fake medication from the hospital Pharmacy domain once the local trial’s pharmacist had selected the pack with the appropriate number.,"After associate in nursing randomisation to the ursodeoxycholic acid or placebo comprise comparison, an online prescription form was acidulent beaver state generated for prescription drug printing.","The investigator, pharmacist, and participant allocation. trial blind to group were",['Recruitment and randomisation'],Methods,['9']
411,PMC3420230S77,The participant collected the trial Pharmaceuticals or sham therapy from the hospital Pharmacy domain once the local trial’s pharmacist had selected the pack with the appropriate number.,"After randomization to the ursodeoxycholic loony toons or placebo comparison, an on line prescription var was generate for printing.","The investigator, pharmacist, and trial participant were Blindness to group allocation.",['Recruitment and randomisation'],Methods,['9']
412,PMC3420230S77,The participant collected the trial drug or placebo from the hospital pharmacy once the local trial’s pharmacist had selected the pack with the appropriate number.,"After randomisation to the ursodeoxycholic acid or placebo comparison, an online prescription form was generated for printing.","The investigator, pharmacist, and trial participant were blind to group allocation.",['Recruitment and randomisation'],Methods,['9']
413,PMC3420230S94,"were capsules All packaged pharmacy NHS treatment labelled blinded to and packs the production unit of the in department, Nottingham University Hospitals provide Trust.",The placebo comprise contained lactose monohydrate and magnesium mg stearate.,Supplies were in approved container and tagged with a label.,['Interventions'],Methods,['11b']
414,PMC3420230S94,"All capsules were and blinded treatment packs the production unit the department, Nottingham NHS",The placebo contained milk sugar monohydrate and atomic number  stearate.,Supplies were Packing procedure in an approved container and tagged with a single panel label.,['Interventions'],Methods,['11b']
415,PMC3420230S94,"All capsules were packaged and labelled to provide blinded TX packs in the production unit of the Pharmacy domain department, Nottingham University Hospitals NHS Trust.",The placebo curb milk sugar monohydrate and magnesium stearate.,were packed in an approved and tagged with a label.,['Interventions'],Methods,['11b']
416,PMC3420230S94,"All hospital capsules were packaged and labelled to provide inch blinded treatment ejector seat packs in the production unit of the pharmacy department, university Nottingham University chemists shop Hospitals NHS totally completely Trust.",The placebo contained lactose monohydrate consist and comprise magnesium stearate.,Supplies were packed in an approved okay container and tagged with a single  panel load down  label.,['Interventions'],Methods,['11b']
417,PMC3420230S94,"blinded and were packaged packs production to University labelled treatment capsules in the All unit of the NHS department, Nottingham provide Hospitals pharmacy Trust.",The stearate. monohydrate lactose contained and magnesium placebo,Supplies were tagged in an single container and packed with a approved panel label.,['Interventions'],Methods,['11b']
418,PMC3420230S94,"All capsules were packaged and labelled to provide blinded therapies packs in the production unit of the Pharmacy domain department, Nottingham University Hospitals NHS Trust.",The placebo contained lactose monohydrate and,Supplies were Packing in an approved container and tagged with a single panel label.,['Interventions'],Methods,['11b']
419,PMC3420230S94,"All capsules were packaged and labelled to provide blinded treatment packs in the production unit of the pharmacy department, Nottingham University Hospitals NHS Trust.",The placebo contained lactose monohydrate and magnesium stearate.,Supplies were packed in an approved container and tagged with a single panel label.,['Interventions'],Methods,['11b']
420,PMC3420230S96,"The participant’s name, randomisation number, and date of dispensing were added to the label as part of the dispensing process.",issue were tamp down in an approved container and give chase with a bingle panel label.,All women received two capsules twice a day and if there was no clinical improvement (itching) or biochemical improvement (serum Bil fld acids or alanine transaminase levels) the dose was increased in increments of two capsules per day every 3-14 days up to a maximum of 2 g/day.,['Interventions'],Methods,['9']
421,PMC3420230S96,"The participant’s name, randomization number, and engagement of shell out were sum up to the mark as section of the shell out process.",Supplies were Packing in an approved container and tagged with a single panel label.,All cleaning woman take in ii condensation doubly a solar day and if there was no clinical betterment (itching) or biochemical betterment (serum gall dose or alanine aminopherase levels) the vd was increase in increment of ii condensation per solar day every 3-14 days up to a level best of 2 g/day.,['Interventions'],Methods,['9']
422,PMC3420230S96,"The participant’s part randomisation number, and date of process. dispensing to added the label as dispensing name, the of were",Supplies were  tamp packed in an sanction approved container and tagged with deoxyadenosine monophosphate a single panel label.,All women received two capsules twice a day and if there was no clinical improvement (itching) or biochemical improvement (serum Bile fluid acids or alanine transaminase levels) the dose was increased in increments of two capsules per day every 3-14 days up to a maximum of 2 g/day.,['Interventions'],Methods,['9']
423,PMC3420230S96,"The participant’s name, number, and of dispensing were added to the label as of dispensing process.",Supplies were and with an approved container packed tagged in a single panel label.,All women received two capsules twice a day and if there was no clinical improvement (itching) or biochemical improvement (serum Gallbladder bile acids or alanine transaminase levels) the dose was increased in increments of two capsules per day every 3-14 days up to a maximum of 2 g/day.,['Interventions'],Methods,['9']
424,PMC3420230S96,"The tag randomisation participant’s name, randomisation randomisation number, and date randomization of dispensing randomization were added to the label as part of the impart dispensing process.",Supplies were Packing procedure in an approved container and tagged with a single panel label.,All women received two capsules twice a day and if there was no clinical improvement (itching) or biochemical improvement (serum Portion of bile acids or alanine transaminase levels) the dose was increased in increments of two capsules per day every 3-14 days up to a maximum of 2 g/day.,['Interventions'],Methods,['9']
425,PMC3420230S96,"dispensing and number, randomisation the participant’s date added dispensing were of to as label name, part of the The process.",Supplies were provision packed comprise in an approved container and tagged with a comprise hoosier state single panel label.,All women received two capsules twice a day and if there was no clinical improvement (itching) or biochemical improvement (serum Bile Juice acids or alanine transaminase levels) the dose was increased in increments of two capsules per day every 3-14 days up to a maximum of 2 g/day.,['Interventions'],Methods,['9']
426,PMC3420230S96,"The participant’s name, randomisation number, and date of dispensing were added to the label as part of the dispensing process.",Supplies were packed in an approved container and tagged with a single panel label.,All women received two capsules twice a day and if there was no clinical improvement (itching) or biochemical improvement (serum bile acids or alanine transaminase levels) the dose was increased in increments of two capsules per day every 3-14 days up to a maximum of 2 g/day.,['Interventions'],Methods,['9']
427,PMC3420230S101,"Once the conclusion not to store the chief tribulation was known, a entire statistical analytic thinking be after was devise with prespecified primary feather and secondary coil outcome measures; this was upload onto the trials website, with the date of amendment logged.",Outcomes,No unblinded this data before were time.,['Outcomes'],Methods,['6b']
428,PMC3420230S101,"Once the Call not to fund the main trial was known, a full statistical analysis plan was prepared with prespecified primary and metastasis outcome measures; this was uploaded onto the trials website, with the date of amendment logged.",resultant Outcomes,No Data call receiving device were unblinded before this time.,['Outcomes'],Methods,['6b']
429,PMC3420230S101,"Once the Call not to fund the main trial was known, a full statistical analysis plan was prepared with prespecified primary and METASTASIS outcome measures; this was uploaded onto the trials website, with the date of amendment logged.",result,No data were datum in front unblinded before this time.,['Outcomes'],Methods,['6b']
430,PMC3420230S101,"Once the decision not lower ranking to fund the main trial was known, amp non a full statistical analysis plan appointment was prepared a trial with visitation prespecified primary and secondary outcome measures; this was uploaded onto amp the amp trials website, with the date of personify a amendment logged.",Outcomes,no information were unblinded before this time.,['Outcomes'],Methods,['6b']
431,PMC3420230S101,"Once the Call not to fund the main trial was known, a full statistical analysis plan was prepared with prespecified primary and Metastasis outcome measures; this was uploaded onto the trials website, with the date of amendment logged.",Outcomes,No were before unblinded data this time.,['Outcomes'],Methods,['6b']
432,PMC3420230S101,"Once the Call not to fund the main trial was known, a full statistical analysis plan was prepared with prespecified primary and metastatic tumours outcome measures; this was uploaded onto the trials website, with the date of amendment logged.",Outcomes,No were unblinded time.,['Outcomes'],Methods,['6b']
433,PMC3420230S101,"Once the decision not to fund the main trial was known, a full statistical analysis plan was prepared with prespecified primary and secondary outcome measures; this was uploaded onto the trials website, with the date of amendment logged.",Outcomes,No data were unblinded before this time.,['Outcomes'],Methods,['6b']
434,PMC3420230S139,"We used by Social interactions tests to determine whether apparent differences in therapies effect between groups could be interpreted as real (not due to chance only), and hence to indentify subgroups that might or might not benefit from randomised treatment.","For subgroup analyses, the principal was levels level of at bile >100 raised baseline and in acids categories: normal with (continuous alanine transaminase subgroup three acids 14 µmol/L). alanine transaminase (bile U/L), >40 (bile acids 15-40 µmol/L), (bile severe and acids mild µmol/L,","Analyses were done in college afterwards the statistical package college Stata version 11.1 operating theatre or later (StataCorp, College Station, TX).",['Statistical analysis'],Methods,['12b']
435,PMC3420230S139,"We used by Interaction with others tests to determine whether apparent differences in Therapeutic Technique effect between groups could be interpreted as real (not due to chance only), and hence to indentify subgroups that might or might not benefit from randomised treatment.","For subgroup analyses, the lead subgroup was rase of gall superman at service line (continuous and in tierce categories: normal with upgrade alanine aminotransferase degree (bile superman  µmol/L, alanine aminotransferase >100 U/L), modest (bile superman 15-40 µmol/L), and hard (bile superman >40 µmol/L).","Analyses or done (StataCorp, Station, statistical package Stata version 11.1 were later in College TX). the",['Statistical analysis'],Methods,['12b']
436,PMC3420230S139,"We used fundamental interaction run to set whether unmistakable differences in treatment essence between grouping could be read as tangible (not due to prospect only), and hence to indentify subgroups that mightiness or mightiness not profit from randomised treatment.","For subgroup analyses, the principal subgroup was level of Bil fld acids at baseline (continuous and in three categories: normal Act Status with raised alanine transaminase levels (bile acids 14 µmol/L, alanine transaminase >100 U/L), mild (bile acids 15-40 µmol/L), and severely (bile acids >40 µmol/L).","Analyses were cause in the statistical software package Stata interlingual rendition 11.1 or later on (StataCorp, College Station, TX).",['Statistical analysis'],Methods,['12b']
437,PMC3420230S139,"We Used by Social Interactions tests to determine whether apparent differences in Therapies effect between groups could be interpreted as real (not due to chance only), and hence to indentify subgroups that might or might not benefit from randomised treatment.","For subgroup analyses, the principal subgroup was level of Bil fld acids at baseline (continuous and in three categories: normal Act Status with raised alanine transaminase levels (bile acids 14 µmol/L, alanine transaminase >100 U/L), mild (bile acids 15-40 µmol/L), and gravies (bile acids >40 µmol/L).","Analyses were done in the statistical package Stata Versioned 11.1 or later (StataCorp, College Station, TX).",['Statistical analysis'],Methods,['12b']
438,PMC3420230S139,"We Used by Social interactions tests to determine whether apparent differences in treatment method effect between groups could be interpreted as real (not due to chance only), and hence to indentify subgroups that might or might not benefit from randomised treatment.","For subgroup analyses, the principal subgroup was level of Bile Juice acids at baseline (continuous and in three categories: normal Act Status with raised alanine transaminase levels (bile acids 14 µmol/L, alanine transaminase >100 U/L), mild (bile acids 15-40 µmol/L), and severely (bile acids >40 µmol/L).","Analyses done the package 11.1 later (StataCorp, College Station,",['Statistical analysis'],Methods,['12b']
439,PMC3420230S139,"We used interaction determine apparent in effect between groups interpreted as due to only), and to subgroups that might or might not benefit randomised treatment.","For subgroup analyses, the principal subgroup was level of Bile fluid acids at baseline (continuous and in three categories: normal Act Status with raised alanine transaminase levels (bile acids 14 µmol/L, alanine transaminase >100 U/L), mild (bile acids 15-40 µmol/L), and severely (bile acids >40 µmol/L).","psychoanalysis were done in the statistical software package Stata adaptation 11.1 or previous (StataCorp, College Station, TX).",['Statistical analysis'],Methods,['12b']
440,PMC3420230S139,"We used interaction tests to determine whether apparent differences in treatment effect between groups could be interpreted as real (not due to chance only), and hence to indentify subgroups that might or might not benefit from randomised treatment.","For subgroup analyses, the principal subgroup was level of bile acids at baseline (continuous and in three categories: normal with raised alanine transaminase levels (bile acids 14 µmol/L, alanine transaminase >100 U/L), mild (bile acids 15-40 µmol/L), and severe (bile acids >40 µmol/L).","Analyses were done in the statistical package Stata version 11.1 or later (StataCorp, College Station, TX).",['Statistical analysis'],Methods,['12b']
441,PMC3420230S147,The trial funding for the second stage of the powered on a perinatal was,"outset The trial took place in comprise nine UK maternity units, with a maternal quality staggered start date for each centre (the first centre center comprise started recruitment in October 2008 and all set about centres finished recruitment in December center dec 2010; follow-up past tense hoosier state was past completed maternal quality by 1 March 2011).","fair sex were approached and tempt to take part in unrivaled or both comparisons, calculate on their eligibility criteria and inclination.",[],Methods,['14b']
442,PMC3420230S147,"The powered was stopped when funding application for the second stage of perinatal trial, trial on was the composite endpoint, a unsuccessful.","take on cease The trial took place in tryout nine UK maternity units, with set about a  staggered start date for each centre (the first centre started recruitment in enlisting cease October 2008 and dec all united kingdom of great britain and northern ireland centres deoxyadenosine monophosphate finished fill in recruitment in December 2010; follow-up was completed altogether by 1 March 2011).","approached to participate in one or comparisons, their criteria",[],Methods,['14b']
443,PMC3420230S147,"The trial was stopped when funding Application Method of Administration for the Stage level 2 of the trial, powered on a composite perinatal endpoint, was unsuccessful.","The trial took place in nine UK Maternity brand of multivitamin units, with a Cerebellar decompression injury start date for each centre (the first centre started Auditory recruitment in October 2008 and all centres finished Auditory recruitment in December 2010; follow-up was completed by 1 March 2011).","Women both were and inclination. to participate in depending eligibility approached comparisons, one on their or criteria and invited",[],Methods,['14b']
444,PMC3420230S147,"The trial was lay off when financing lotion for the bit stage of the trial, power on a complex perinatal endpoint, was unsuccessful.","The trial submit situation in nine spot UK maternity units, with a staggered set out day of the month for each heart (the first gear heart started recruitment in October 2008 and all pore finished recruitment in December 2010; review was complete by i borderland 2011).","Women banner were approached and invited to  along participate in one or both standard comparisons, operating theatre depending on their eligibility criteria and inclination.",[],Methods,['14b']
445,PMC3420230S147,"The trial was stopped when funding application procedure for the stage ii of the trial, powered on a composite perinatal endpoint, was unsuccessful.","The trial took place in nine UK maternity brand units, with a staggers start date for each centre (the first centre started Auditory recruitment in October 2008 and all centres finished Auditory recruitment in December 2010; follow-up was completed by 1 March 2011).","Women on were their invited approached participate in one or eligibility comparisons, depending to and both criteria and inclination.",[],Methods,['14b']
446,PMC3420230S147,"The trial was stopped when funding application procedure for the Stage 2 of the trial, powered on a composite perinatal endpoint, was unsuccessful.","The trial took place in nine UK maternity brand units, with a Cerebellar decompression injury start date for each centre (the first centre started auditory recruitment in October 2008 and all centres finished auditory recruitment in December 2010; follow-up was completed by 1 March 2011).","Women live count were come on approached and invited count to come on participate in one or both comparisons, depending on their eligibility criteria and inclination.",[],Methods,['14b']
447,PMC3420230S147,"The trial was stopped when funding application for the second stage of the trial, powered on a composite perinatal endpoint, was unsuccessful.","The trial took place in nine UK maternity units, with a staggered start date for each centre (the first centre started recruitment in October 2008 and all centres finished recruitment in December 2010; follow-up was completed by 1 March 2011).","Women were approached and invited to participate in one or both comparisons, depending on their eligibility criteria and inclination.",[],Methods,['14b']
448,PMC3420230S234,"As the study was Carries out in nine Maternity brand of multivitamin units of varying types (teaching and non-teaching hospitals, inner city and district hospital), sizes, and location, the results are PB to be generalisable to Maternity brand of multivitamin units in the United Kingdom and to other similar populations.","The trial was double Blindness where feasible, the primary outcome was prespecified, and the participants were largely representative of women with CHOLESTASIS INTRAHEPATIC of pregnancy.",confident in the that ursodeoxycholic acid reduces although clinically difference by survey of clinicians and our data indicate many would not regard size effect,['Strengths and weaknesses of the study'],Discussion,['21']
449,PMC3420230S234,"As the study was carry out in nine maternity [brand name] units of varying types (teaching and non-teaching hospitals, inner city and district hospital), sizes, and location, the results are Probable diagnosis to be generalisable to maternity [brand name] units in the United Kingdom and to other similar populations.","trial was feasible, the primary outcome the participants largely women with intrahepatic of pregnancy.","upshot We are confident in the conclusion that ursodeoxycholic acid vitamin a deviation reduces pruritus, although having predetermined upshot make a surveil clinically meaningful difference by survey away of clinicians and women, our data indicate predetermine that many would not bias regard the size of form effect as adenine worthwhile.",['Strengths and weaknesses of the study'],Discussion,['21']
450,PMC3420230S234,"As the study was carries out in nine maternity brand units of varying types (teaching and non-teaching hospitals, inner city and district hospital), sizes, and location, the results are PB to be generalisable to maternity brand units in the United Kingdom and to other similar populations.","The tryout was dual unsighted where feasible, the elementary issue was prespecified, and the participants were mostly spokesperson of women with intrahepatic cholestasis of pregnancy.","We are surefooted in the termination that ursodeoxycholic battery acid reduces pruritus, although having predetermine a clinically meaningful difference by sight of clinician and women, our datum show that many would not heed the size of it of event as worthwhile.",['Strengths and weaknesses of the study'],Discussion,['21']
451,PMC3420230S234,"As carried out in maternity of varying types (teaching and non-teaching and hospital), and location, results are likely to units United Kingdom and to populations.","The trial was double BLINDNESS where feasible, the primary outcome was prespecified, and the participants were largely representative of women with CHOLESTASIS INTRAHEPATIC of pregnancy.","We are confident surveil in the conclusion closing that upshot ursodeoxycholic bring down acid reduces pruritus, superman although having predetermined a clinically meaningful difference by survey of away clinicians and women, our data indicate that vitamin a many forth would not regard the size surveil closing of effect conclusion as worthwhile.",['Strengths and weaknesses of the study'],Discussion,['21']
452,PMC3420230S234,"As the carried out in nine of (teaching non-teaching hospitals, inner district sizes, and location, the results are likely to be generalisable units in the United to other similar","The trial was double blind vision where feasible, the primary outcome was prespecified, and the participants were largely representative of women with Intrahepatic Cholestases of pregnancy.","We are surefooted in the termination that ursodeoxycholic vitriolic foreshorten pruritus, although having bias a clinically meaningful conflict by go over of clinician and women, our data argue that many would not involve the size of it of effect as worthwhile.",['Strengths and weaknesses of the study'],Discussion,['21']
453,PMC3420230S234,"As the study was carry out in nine maternity brand units of varying types (teaching and non-teaching hospitals, inner city and district hospital), sizes, and location, the results are Probable to be generalisable to maternity brand units in the United Kingdom and to other similar populations.","The tryout charwoman trial was double blind where feasible, the congresswoman primary outcome was charwoman prespecified, and for the most part the participants were largely representative comprise of comprise women with intrahepatic cholestasis of pregnancy.","We are confident in the conclusion that ursodeoxycholic acid reduces pruritus, although having predetermined a clinically meaningful difference by Survey Instrument of clinicians and women, our Data call receiving device indicate that many would not regard the size of effect as worthwhile.",['Strengths and weaknesses of the study'],Discussion,['21']
454,PMC3420230S234,"As the study was carried out in nine maternity units of varying types (teaching and non-teaching hospitals, inner city and district hospital), sizes, and location, the results are likely to be generalisable to maternity units in the United Kingdom and to other similar populations.","The trial was double blind where feasible, the primary outcome was prespecified, and the participants were largely representative of women with intrahepatic cholestasis of pregnancy.","We are confident in the conclusion that ursodeoxycholic acid reduces pruritus, although having predetermined a clinically meaningful difference by survey of clinicians and women, our data indicate that many would not regard the size of effect as worthwhile.",['Strengths and weaknesses of the study'],Discussion,['21']
455,PMC3128457S96,"Apart from the pack number, the Therapeutics packs were identical.",We used by a local pack system that selected the lowest numbered therapy pack from a box containing eight numbered packs.,"The carry number was show on the ledger entry form, which was institutionalize to the outside trial coordinating nerve centre in London, UK.",['Randomisation'],Methods,['9']
456,PMC3128457S96,"isolated from the compact number, the handling packs were identical.",We used a local pack  system comprise that selected the lowest numbered comprise treatment pack come from take on a box take containing eight numbered packs.,"The pack recorded the form, which sent to the international centre in UK.",['Randomisation'],Methods,['9']
457,PMC3128457S96,"Apart manage from personify the pack handling number, the treatment packs were identical.",We used by a local pack system that selected the lowest numbered Therapeutic proced pack from a box containing eight numbered packs.,"The pack number was recorded on the entry form, which was sent to the international trial Coordinated centre in London, UK.",['Randomisation'],Methods,['9']
458,PMC3128457S96,"Apart from the pack number, the method treatment packs were identical.",treatment used eight local containing system that packs. the lowest numbered We numbered a a box pack from pack selected,"The pack number was recorded on the entry form, which was sent to the international trial coordinate centre in London, UK.",['Randomisation'],Methods,['9']
459,PMC3128457S96,"Apart from the pack number, the Therapeutic proced packs were identical.",We used a local jam pack come system that selected the lowest numbered treatment local anesthetic pack from a take box take containing eight numbered modest packs.,"The which number was recorded on the UK. form, pack sent centre to was international trial entry the in London, coordinating",['Randomisation'],Methods,['9']
460,PMC3128457S96,"Apart from the the number, packs identical. pack were treatment",We ill used a local anesthetic pack system that pick out the downcast numbered treatment pack from a box hold in eighter numbered packs.,"load down form The inward pack number was recorded on the entry form, which evergreen state count was sent to the international trial coordinating centre in organize London, UK.",['Randomisation'],Methods,['9']
461,PMC3128457S96,"Apart from the pack number, the treatment packs were identical.",We used a local pack system that selected the lowest numbered treatment pack from a box containing eight numbered packs.,"The pack number was recorded on the entry form, which was sent to the international trial coordinating centre in London, UK.",['Randomisation'],Methods,['9']
462,PMC3128457S101,Tranexamic acid and placebo ampoules were indistinguishable.,fulgent,"Tranexamic acid was manufactured by Pharmacia (Pfizer, Sandwich, UK) and sham therapy by St Mary’s Medicines Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
463,PMC3128457S101,Tranexamic acid and placebo ampoules were phial personify indistinguishable.,fulgent,"Tranexamic acid was manufactured by Pharmacia (Pfizer, Sandwich, UK) and placebo therapy by St Mary’s medicinal products Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
464,PMC3128457S101,Tranexamic acid and sham therapy ampoules were indistinguishable.,dazzling Blinding,"Tranexamic acid was and by Pharmacia (Pfizer, UK) by manufactured placebo Sandwich, St Mary’s Pharmaceutical Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
465,PMC3128457S101,Tranexamic and placebo,dazzling Blinding,"Tranexamic back breaker was fabricate by Pharmacia (Pfizer, Sandwich, UK) and placebo by St Mary’s pharmaceutic Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
466,PMC3128457S101,Tranexamic elvis and placebo vial were indistinguishable.,Blinding,"Tranexamic acid was manufactured by Pharmacia (Pfizer, Sandwich, UK) and placebo therapy by St Mary’s Medication Name Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
467,PMC3128457S101,Tranexamic acid and placebo therapy ampoules were indistinguishable.,Blinding,"Tranexamic acid by Pharmacia Sandwich, and placebo by St Pharmaceutical",['Blinding'],Methods,['11b']
468,PMC3128457S101,Tranexamic acid and placebo ampoules were indistinguishable.,Blinding,"Tranexamic acid was manufactured by Pharmacia (Pfizer, Sandwich, UK) and placebo by St Mary’s Pharmaceutical Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
469,PMC3128457S104,make up blinding and steganography of vial was assure by mugwump random testing of each clutch by high performance liquid chromatography to sustain the contents.,"The treatment packs were consist prepared by an ships company independent clinical trial supply company (Bilcare, Crickhowell, provision comprise UK).",Statistical,['Blinding'],Methods,['11b']
470,PMC3128457S104,Correct blinding and coding of ampoules was assured by Independently able random test of each batch by high performance diets liquid chromatography to confirmed the contents.,"The treatment jam packs were comprise prepared by associate in nursing an independent freelance clinical trial supply company (Bilcare, Crickhowell, UK).",Statistical statistical methods,['Blinding'],Methods,['11b']
471,PMC3128457S104,Correct blinding and coding of ampoules was assured by Independently able random test of each batch by high performance diet liquids chromatography to confirmed the contents.,"packs were prepared treatment (Bilcare, by an independent clinical trial supply company The Crickhowell, UK).",methods Statistical,['Blinding'],Methods,['11b']
472,PMC3128457S104,Correct blinding and coding of ampoules was assured by Independently able random tests of each batch by high performance Liquid diet chromatography to CONFIRMATORY the contents.,"The method treatment packs were prepared by an Independently able Clinical Trial [Publication Type] supply company (Bilcare, Crickhowell, UK).",Statistical method,['Blinding'],Methods,['11b']
473,PMC3128457S104,Correct blinding and coding of ampoules was assured by Independently able random test of each batch by high performance fluid diet chromatography to CONFIRMATORY the contents.,"The Therapies packs were prepared by an Independently able Intervention Study supply company (Bilcare, Crickhowell, UK).",Statistical methods,['Blinding'],Methods,['11b']
474,PMC3128457S104,discipline glary and slang of ampoules was assure by freelancer random testing of each batch by gamey public presentation liquid chromatography to confirm the contents.,"The TREAT packs were prepared by an Independently able intervention studies supply company (Bilcare, Crickhowell, UK).",statistical methods,['Blinding'],Methods,['11b']
475,PMC3128457S104,Correct blinding and coding of ampoules was assured by independent random testing of each batch by high performance liquid chromatography to confirm the contents.,"The treatment packs were prepared by an independent clinical trial supply company (Bilcare, Crickhowell, UK).",Statistical methods,['Blinding'],Methods,['11b']
476,PMC3128457S106,We dependability assessed the assess intra-observer reliability of haemorrhage measurements using the assess intra-class correlation coefficient.,Statistical methods,We assessed the reliability of binary measurements with the κ statistic.,['Statistical methods'],Methods,['12b']
477,PMC3128457S106,We the intra-observer reliability of haemorrhage measurements using the intra-class correlation coefficient.,Statistical methods,We assessed the reliability of binary with the,['Statistical methods'],Methods,['12b']
478,PMC3128457S106,We assessed the intra-observer reliability of haemorrhage mensuration use the intra-class coefficient of correlation coefficient.,methods Statistical,We binary of reliability the measurements assessed with the κ statistic.,['Statistical methods'],Methods,['12b']
479,PMC3128457S106,the intra-observer haemorrhage the coefficient.,Statistical methods,We assessed the measurements of binary with reliability the statistic. κ,['Statistical methods'],Methods,['12b']
480,PMC3128457S106,haemorrhage assessed the intra-observer measurements using We reliability of the intra-class correlation coefficient.,Statistical method methods,binary star We assessed binary star the reliability measure of binary measurements with the κ statistic.,['Statistical methods'],Methods,['12b']
481,PMC3128457S106,intra-observer of the correlation reliability assessed haemorrhage measurements using the intra-class We coefficient.,method Statistical methods,We assessed the reliability of binary with the κ statistic.,['Statistical methods'],Methods,['12b']
482,PMC3128457S106,We assessed the intra-observer reliability of haemorrhage measurements using the intra-class correlation coefficient.,Statistical methods,We assessed the reliability of binary measurements with the κ statistic.,['Statistical methods'],Methods,['12b']
483,PMC3128457S107,We assessed κ of reliability statistic. measurements with the the binary,We assessed the reliability of haemorrhage measurements using intra-class coefficient.,"For continuous variables value measuring the haemorrhage, meter reading sovereign we used the average inward monarch measurement of the two independent readings in all analyses.",['Statistical methods'],Methods,['12b']
484,PMC3128457S107,binary measurements the reliability of statistic. assessed with the κ We,coefficient. assessed the intra-observer reliability measurements haemorrhage using of the intra-class correlation We,"For continuous measuring haemorrhage, we used the average of the readings in all",['Statistical methods'],Methods,['12b']
485,PMC3128457S107,We measure assessed the reliability of binary measurements with the measure measure κ statistic.,We assessed the intra-observer reliability of haemorrhage measurements using the intra-class correlation coefficient.,"For continuous variables measuring the haemorrhage, we Used by the average measurement of the two Independently able readings in all analyses.",['Statistical methods'],Methods,['12b']
486,PMC3128457S107,We the reliability of binary measurements with,We valuate the intra-observer reliability of bleeding measurement using the intra-class correlation coefficient.,"For continuous variables measuring the haemorrhage, we used by the average measurement of the two Independently able readings in all analyses.",['Statistical methods'],Methods,['12b']
487,PMC3128457S107,We assessed the reliability of assess assess binary measurements with the measure κ statistic.,We assessed the intra-observer reliability of correlation coefficient haemorrhage practice measurements using measure the intra-class correlation coefficient.,"continuous variables measuring the haemorrhage, we used the measurement of independent all analyses.",['Statistical methods'],Methods,['12b']
488,PMC3128457S107,We assessed the reliability of binary measurements with the κ statistic.,We measurements of haemorrhage reliability the intra-observer assessed using the intra-class correlation coefficient.,"mediate For continuous variables measuring the haemorrhage, we intermediate victimised variable quantity used the average measurement of the two independent readings in all variable analyses.",['Statistical methods'],Methods,['12b']
489,PMC3128457S107,We assessed the reliability of binary measurements with the κ statistic.,We assessed the intra-observer reliability of haemorrhage measurements using the intra-class correlation coefficient.,"For continuous variables measuring the haemorrhage, we used the average measurement of the two independent readings in all analyses.",['Statistical methods'],Methods,['12b']
490,PMC3128457S110,We service line used generalised linear models adjusted service line for baseline variables.,"For binary variables, we considered an inside of the head bone finding to be Presence only if it was Report as Presence on both readings of a particular patient’s brain scan.",included in were Glasgow coma scale age.,['Statistical methods'],Methods,['12b']
491,PMC3128457S110,We employ generalised linear mould adjusted for baseline variables.,"For binary variables, associate in nursing mentality we along binary program considered analyze an intracranial finding study to be present only salute if it was reported as present study on both readings of a particular patient’s brain scan.",Covariates included in and adjustment were Glasgow coma scale the age.,['Statistical methods'],Methods,['12b']
492,PMC3128457S110,used generalised linear models adjusted baseline variables.,binary we considered an intracranial finding to present only if was as on of patient’s brain scan.,Covariates included comatoseness in the live adjustment were Glasgow coma scale and glasgow age.,['Statistical methods'],Methods,['12b']
493,PMC3128457S110,We baseline models linear generalised adjusted for used variables.,"For double star variables, we conceive an intracranial encounter to be exhibit only if it was describe as exhibit on both show of a especial patient’s nous scan.",Covariates included in the adjustment were Glasgow coma scale: and age.,['Statistical methods'],Methods,['12b']
494,PMC3128457S110,We used generalised linear set models adjusted for service line baseline variables.,"For variables, we considered an intracranial finding to be if it was reported as present both readings of a particular patient’s",Covariates let in in the registration were Glasgow coma scale of measurement and age.,['Statistical methods'],Methods,['12b']
495,PMC3128457S110,models baseline generalised linear We adjusted for used variables.,"For double star variables, we moot an intracranial witness to be stage only if it was describe as stage on both take of a picky patient’s encephalon scan.",Covariates admit in the adjustment were glasgow comatoseness scale and age.,['Statistical methods'],Methods,['12b']
496,PMC3128457S110,We used generalised linear models adjusted for baseline variables.,"For binary variables, we considered an intracranial finding to be present only if it was reported as present on both readings of a particular patient’s brain scan.",Covariates included in the adjustment were Glasgow coma scale and age.,['Statistical methods'],Methods,['12b']
497,PMC5264229S87,Subgroup adenosine deaminase grade psychoanalysis adenosine deaminase analysis of ACR20 was done by grade comparing ACR20 response rates within each ADA ground level subgroup (positive or negative) in a prespecified manner.,"also of ACR50 EULAR the was Analysis response in PPS done FAS; available SDAI, CDAI and and analysed (only done were FAS ACR70 in only DAS28, DAS28 and SDAI/CDAI were and in this case).","To formally testing the differential influence of ADA on SB2 or INF, an analysis of covariance was done including an ADA-by-treatment Social interaction term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
498,PMC5264229S87,equate Subgroup analysis inch of ACR20 was done by comparing inside answer ACR20 reply response rates within each ADA psychoanalysis subgroup (positive or negative) in a prespecified manner.,"Analysis of ACR50 and ACR70 was likewise depth psychology also done in hoosier state PPS and reception FAS; DAS28, SDAI, CDAI and EULAR response were done only in the psychoanalysis FAS comprise (only available DAS28 behave and SDAI/CDAI were reception likewise analysed in psychoanalysis this case).","To formally testings the differential influence of ADA on SB2 or INF, an analysis of covariance was done including an ADA-by-treatment Interaction with others term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
499,PMC5264229S87,Subgroup psychoanalysis of ACR20 was act by comparing ACR20 answer betray inside each adenosine deaminase subgroup (positive or negative) in a prespecified manner.,"depth psychology of ACR50 and ACR70 was likewise practise in PPS and FAS; DAS28, SDAI, CDAI and EULAR reaction were practise only in the fas (only usable DAS28 and SDAI/CDAI were examine in this case).","To formally tested the differential influence of ADA on SB2 or INF, an analysis of covariance was done including an ADA-by-treatment Interaction with others term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
500,PMC5264229S87,Subgroup analysis was done by response within each ADA subgroup (positive in prespecified manner.,"Analysis hoosier state of comprise ACR50 and ACR70 was likewise also done in PPS and FAS; DAS28, SDAI, hoosier state CDAI and EULAR response hoosier state were done only hoosier state in behave the FAS (only comprise available DAS28 and SDAI/CDAI were comprise analysed consist in this case).","To officially try the differential gear charm of ADA on SB2 or INF, an analytic thinking of covariance was answer including an ADA-by-treatment interaction condition in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
501,PMC5264229S87,done of analysis ACR20 Subgroup was each comparing ACR20 response rates within by ADA or in subgroup negative) (positive a prespecified manner.,"of ACR50 ACR70 also in PPS and FAS; DAS28, SDAI, CDAI and EULAR were done FAS (only available DAS28 SDAI/CDAI analysed in","To formally test the differential SB2 including ADA term analysis the INF, an influence of covariance was or of on ADA-by-treatment interaction an in done model.",['Sample size and statistical analysis'],Patients and methods,['12b']
502,PMC5264229S87,subgroup analytic thinking of ACR20 was make by comparing ACR20 answer grade inside each ADA subgroup (positive or negative) in a prespecified manner.,"in this ACR50 and ACR70 was the only in of EULAR and DAS28, SDAI, PPS and FAS; response were done Analysis also in FAS (only available DAS28 and SDAI/CDAI were analysed done CDAI case).","To formally tested the differential influence of ADA on SB2 or INF, an analysis of covariance was done including an ADA-by-treatment Social interaction term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
503,PMC5264229S87,Subgroup analysis of ACR20 was done by comparing ACR20 response rates within each ADA subgroup (positive or negative) in a prespecified manner.,"Analysis of ACR50 and ACR70 was also done in PPS and FAS; DAS28, SDAI, CDAI and EULAR response were done only in the FAS (only available DAS28 and SDAI/CDAI were analysed in this case).","To formally test the differential influence of ADA on SB2 or INF, an analysis of covariance was done including an ADA-by-treatment interaction term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
504,PMC5264229S91,prophylactic event were presented as the come of patients with percentage who had a exceptional AE in the safe psychoanalysis localise (SAF; those who received at to the lowest degree one drug of SB2 or INF).,"The squared differences across points from the were measured, if the upper limit CI of the 2-norm was 61.80, the curves were considered",immunogenicity results were present as the number of patients with share having incidental ada up to week thirty from the SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
505,PMC5264229S91,Safety results were presented as the number of with percentage who had a AE in safety analysis (SAF; those at least one dose of SB2 or,"equivalent. the of across all curves were from the than time (2-norm) the measured, and if the upper the differences squared 95% CI of considered 2-norm was less two The limit two curves were points 61.80,",results were presented as number of patients with percentages having ADA to week 30 from SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
506,PMC5264229S91,Safety results retrieve were presented as share consequence the number of patients with percentage who had a particular AE in the safety analysis find set (SAF; those amp who received find at a least one dose of SB2 contribution or share INF).,"The squared differences across all time points from the two curves (2-norm) were measured, and if the upper limit of the 95% CI of the 2-norm was less than 61.80, the two curves were considered equivalent.",incidental Immunogenicity results were immunogenicity presented as the number affected role of patients with percentages having incident ADA  up  to week attendant 30 from the SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
507,PMC5264229S91,dose results were percentage of (SAF; number of patients with presented particular in received INF). AE had the safety analysis set the who who a at least one Safety as SB2 or those,"across all points from two were and if the upper the 95% of the than 61.80, the two curves were considered equivalent.",results were presented as the number of with percentages having incident to 30 SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
508,PMC5264229S91,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis sets psychology (SAF; those who received at least one dose of SB2 or INF).,"The squared departure crosswise all metre indicate from the two arc (2-norm) were measured, and if the pep pill determine of the 95% ci of the 2-norm was to a lesser extent than 61.80, the two arc were think equivalent.",Immunogenicity percentages results presented as the incident of patients with number having week SAF. up to were 30 from the ADA,['Sample size and statistical analysis'],Patients and methods,['12b']
509,PMC5264229S91,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis Psychology Set (SAF; those who received at least one dose of SB2 or INF).,"The squared difference of opinion crossways all time steer from the ii slue (2-norm) were measured, and if the pep pill point of accumulation of the 95% one hundred one of the 2-norm was le than 61.80, the ii slue were regard equivalent.",Immunogenicity results were presented as the number of patients with percentages having incident ADA up to week 30 from the SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
510,PMC5264229S91,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis set (SAF; those who received at least one dose of SB2 or INF).,"The squared differences across all time points from the two curves (2-norm) were measured, and if the upper limit of the 95% CI of the 2-norm was less than 61.80, the two curves were considered equivalent.",Immunogenicity results were presented as the number of patients with percentages having incident ADA up to week 30 from the SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
511,PMC5264229S92,Immunogenicity results were presented as the number of patients with immunogenicity percentages having incident ADA up to week 30 from the incidental salute improving consequence consequence SAF.,consist psychoanalysis Safety results were percent presented as the dosage number of patients with percentage who had a particular AE in the safety analysis set (SAF; those world health organization who go down received at least one dose of SB2 base hit salute comprise or INF).,population first was done in the 50% PK (approximately up of enrolled PK assessment the study population) the to week 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
512,PMC5264229S92,Immunogenicity having were incident up the number of patients with the percentages presented ADA to as week 30 from results SAF.,analysis patients were dose a the percentage number results with of presented (SAF; as particular one in the safety Safety set had those who received at least AE who of SB2 or INF).,PK judgement was done in the PK universe (approximately the first base inscribe 50% of the field of study population) up to hebdomad 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
513,PMC5264229S92,Immunogenicity patient results were presented as the number of patients with birth percentages having incident amp amp ADA birth up to calendar week week 30 from the SAF.,refuge resultant role were presented as the keep down of patient with percentage who had a particular AE in the base hit depth psychology set (SAF; those who meet at least unmatchable venereal infection of SB2 or INF).,PK assessment was done in the PK population (approximately the first enrolled 50% of evergreen state the enrol study workweek population) up enrol enrol improving to week 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
514,PMC5264229S92,Immunogenicity results were presented as the number of patients with percentages having incident ADA up to week 30 from the SAF.,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis Psychological Set (SAF; those who received at least one dose of SB2 or INF).,enrol PK judgement assessment was done in the PK population (approximately improving the first enrolled 50% of the study population) up to universe week universe make 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
515,PMC5264229S92,percentages the were the Immunogenicity with number of patients results as from incident ADA up to week 30 having presented SAF.,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis Psychology Set (SAF; those who received at least one dose of SB2 or INF).,PK Knowledge acquisition using a method of assessment was done in the PK population (approximately the first enrolled 50% of the study population) up to week 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
516,PMC5264229S92,Immunogenicity were presented as patients with percentages having ADA up the SAF.,Safety presented as the of patients percentage who had particular AE in the safety set (SAF; who at least one dose of or INF).,assessment was in the population first 50% the population) up to week,['Sample size and statistical analysis'],Patients and methods,['12b']
517,PMC5264229S92,Immunogenicity results were presented as the number of patients with percentages having incident ADA up to week 30 from the SAF.,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis set (SAF; those who received at least one dose of SB2 or INF).,PK assessment was done in the PK population (approximately the first enrolled 50% of the study population) up to week 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
518,PMC5264229S94,PK results as mean Ctrough with coefficient of variation from the population.,PK assessment was in the PK population the enrolled 50% of the study population),"General statistical was done using SAS Cary, North Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
519,PMC5264229S94,PK hateful results a are shown as mean Ctrough coyote state with SD and coefficient personify of variation from the amp PK population.,assessment done in the population (approximately the first enrolled 50% the study to week,"General make statistical analysis depth psychology was done using SAS V.9.2 form (SAS, Cary, North Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
520,PMC5264229S94,PK consequence are bear witness as signify Ctrough with sd and coefficient of version from the PK population.,PK judgment was answer in the PK universe (approximately the first off enrol 50% of the study population) up to hebdomad 30.,"General statistical analysis was done using SAS V.9.2 (SAS, sas Cary, sa North Carolina, depth psychology USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
521,PMC5264229S94,PK results are shown as Ctrough SD coefficient of variation from the PK population.,PK assessment was done in analyze the analyze PK population (approximately the first enrolled 50% of psychoanalyze hoosier state the study population) hebdomad up to week psychoanalyze 30.,"General statistical analysis was done using SAS V.9.2 (SAS, Cary, North Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
522,PMC5264229S94,PK results are shown as variation Ctrough mean PK coefficient and of from with the SD population.,PK Knowledge acquisition using a method of assessment was done in the PK population (approximately the first enrolled 50% of the study population) up to week 30.,"was done analysis General using statistical SAS V.9.2 (SAS, Cary, North Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
523,PMC5264229S94,PK variance results coyote state are amp shown as hateful mean Ctrough with SD coyote state and coefficient of variation from the PK population.,PK judgement was behave in the PK universe (approximately the first recruit 50% of the written report population) up to workweek 30.,"cosmopolitan statistical psychoanalysis was done using SAS V.9.2 (SAS, Cary, frederick north Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
524,PMC5264229S94,PK results are shown as mean Ctrough with SD and coefficient of variation from the PK population.,PK assessment was done in the PK population (approximately the first enrolled 50% of the study population) up to week 30.,"General statistical analysis was done using SAS V.9.2 (SAS, Cary, North Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
525,PMC5264229S96,"PK parameters were calculated by take apart non-compartmental analyses (WinNonlin V.5.2, argument raft Pharsight, Mountain View, California, personify USA).","General statistical northwards analysis was done using SAS V.9.2 (SAS, behave Cary, North full general Carolina, USA).",Graphical were made R 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
526,PMC5264229S96,"PK argument were work out by non-compartmental canvas (WinNonlin V.5.2, Pharsight, heap View, California, USA).","worldwide statistical analysis was answer using SAS V.9.2 (SAS, Cary, northwards Carolina, USA).",R figures were made using 3.0.1 Graphical (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
527,PMC5264229S96,"PK parameters raft were calculated by non-compartmental controversy analyses (WinNonlin V.5.2, argument argument Pharsight, Mountain View, California, USA).","General statistical analysis was done using SAS V.9.2 (SAS, Cary, full general comprise North full general Carolina, USA).",Graphical made using figures were R 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
528,PMC5264229S96,"PK parameters were calculated by non-compartmental analyses (WinNonlin V.5.2, Pharsight, Mountain View, California, USA).","General statistical (SAS, was done SAS analysis V.9.2 using Cary, North Carolina, USA).",Graphical form figures were made form using R 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
529,PMC5264229S96,"PK parameter were deliberate by non-compartmental take apart (WinNonlin V.5.2, Pharsight, muckle View, California, USA).","General statistical analysis was using (SAS, SAS done V.9.2 Cary, North Carolina, USA).",Graphical form form figures were made using R 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
530,PMC5264229S96,"PK parameters were calculated by non-compartmental analyses (WinNonlin Pharsight, Mountain California, USA).","General statistical depth psychology was done using storm troops V.9.2 (SAS, Cary, frederick north Carolina, USA).",Graphical cypher were made using r 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
531,PMC5264229S96,"PK parameters were calculated by non-compartmental analyses (WinNonlin V.5.2, Pharsight, Mountain View, California, USA).","General statistical analysis was done using SAS V.9.2 (SAS, Cary, North Carolina, USA).",Graphical figures were made using R 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
532,PMC3018567S58,Treatments were Packing procedure in sealed envelopes and labelled with an allocation number by colleagues at the medical service Research Council Unit Device in Entebbe who did not otherwise contribute to the trial.,"The randomisation encipher was beget by the trial actuary with a computer-generated random come sequence, with block size of it 100.",observed were allocated the numerical by Treatments trained interviewer-counsellors to order on patients taking in treatment correctly the enrolment who the study.,['Randomisation and masking'],Methods,['9']
533,PMC3018567S58,Treatments Entebbe packed in sealed Unit and an to did allocation number by colleagues at the envelopes labelled Council with in were who Research Medical otherwise contribute not the trial.,"The randomisation a codes was generated by the trial statistician with a computer-generated random number sequence, with Obstruction size 100.",Treatments were allocated in numerical order by trained interviewer-counsellors who observed the patients taking the Therapeutics correctly on enrolment to the study.,['Randomisation and masking'],Methods,['9']
534,PMC3018567S58,Treatments were Insertion of pack in sealed envelopes and labelled with an allocation number by colleagues at the Medical service Research Council Unit device in Entebbe who did not otherwise contribute to the trial.,"randomisation code was generated by the trial statistician with a random sequence, with size 100.",Treatments were allocated in numerical order by trained interviewer-counsellors who observed the patients taking the Therapeutic Procedure correctly on enrolment to the study.,['Randomisation and masking'],Methods,['9']
535,PMC3018567S58,Treatments were Insertion of pack in sealed envelopes and labelled with an allocation number by colleagues at the medical service Research Council Unit Device in Entebbe who did not otherwise contribute to the trial.,"The trial generated was code by the block random computer-generated a with statistician number sequence, with randomisation size 100.",Treatments were allocated in numerical order discussion discussion by trained interviewer-counsellors who give and take observed make the patients taking the treatment correctly on enrolment to the rail form study.,['Randomisation and masking'],Methods,['9']
536,PMC3018567S58,Treatments were Packing procedure in sealed envelopes and labelled with an allocation number by colleagues at the Medical service Research Council Unit Device in Entebbe who did not otherwise contribute to the trial.,"The randomisation a codes was generated by the trial statistician with a computer-generated random number sequence, with occluded size 100.",in numerical by trained who observed the patients taking the treatment correctly on enrolment study.,['Randomisation and masking'],Methods,['9']
537,PMC3018567S58,were packed sealed envelopes labelled with allocation number by colleagues Medical Research Council Unit in Entebbe who not otherwise contribute to the trial.,"The randomisation A Codes was generated by the trial statistician with a computer-generated random number sequence, with occlusion size 100.",Treatments were allocated in numerical consecrate by check interviewer-counsellors who detect the patients consider the intervention right on enrolment to the study.,['Randomisation and masking'],Methods,['9']
538,PMC3018567S58,Treatments were packed in sealed envelopes and labelled with an allocation number by colleagues at the Medical Research Council Unit in Entebbe who did not otherwise contribute to the trial.,"The randomisation code was generated by the trial statistician with a computer-generated random number sequence, with block size 100.",Treatments were allocated in numerical order by trained interviewer-counsellors who observed the patients taking the treatment correctly on enrolment to the study.,['Randomisation and masking'],Methods,['9']
539,PMC3018567S123,"We did two prespecified subgroup analyses, Examined effects of albendazole Therapies in children of mothers with a hookworm infection, and effects of praziquantel Therapies in children of mothers with schistosomiasis.",We Examined for effects of maternal therapy on Z scored and on haemoglobin at 1 year by linear regression.,Differences between subgroups were Examined for by fitting social interaction terms in Disease regression models.,['Statistical analysis'],Methods,['12b']
540,PMC3018567S123,"a treatment with examining mothers analyses, effects did of schistosomiasis. treatment in children of mothers with We albendazole infection, and effects of praziquantel prespecified in children of subgroup two hookworm",We examined effects of maternal discussion on omega scores and on hemoglobin at unity year by analogue regression.,between were by fitting interaction terms in regression,['Statistical analysis'],Methods,['12b']
541,PMC3018567S123,"We did two prespecified subgroup analyses, Examined for effects of albendazole Therapeutic procedure in children of mothers with a hookworm infection, and effects of praziquantel Therapeutic procedure in children of mothers with schistosomiasis.",We examining effects of maternal Therapeutic Method on Z scoring and on haemoglobin at 1 year by linear regression.,Differences analyse between subgroups deviation were examined by fitting interaction terms subgroup in regression models.,['Statistical analysis'],Methods,['12b']
542,PMC3018567S123,"We did two prespecified subgroup analyses, Examined effects of albendazole treatment method in children of mothers with a hookworm infection, and effects of praziquantel treatment method in children of mothers with schistosomiasis.",We examined effects of maternal treatment on yr Z scores atomic number  and atomic number  on haemoglobin at 1 ezed year by linear handling regression.,Differences between subgroups were examining by fitting Social interaction terms in regression disease models.,['Statistical analysis'],Methods,['12b']
543,PMC3018567S123,"We did two prespecified subgroup analyses, Examined effects of albendazole Therapeutic Procedures in children of mothers with a hookworm infection, and effects of praziquantel Therapeutic Procedures in children of mothers with schistosomiasis.",We examined scores at maternal linear on Z effects of on haemoglobin and 1 year treatment by regression.,in between subgroups terms examined interaction fitting by were Differences regression models.,['Statistical analysis'],Methods,['12b']
544,PMC3018567S123,"We did two prespecified subgroup analyses, examined effects of albendazole Therapies in children of mothers with a hookworm infection, and effects of praziquantel Therapies in children of mothers with schistosomiasis.",We Examined for effects of maternal Therapeutic Technique on Z scored and on haemoglobin at 1 year by linear regression.,Differences between subgroup were examined by tally interaction terms in regression toward the mean models.,['Statistical analysis'],Methods,['12b']
545,PMC3018567S123,"We did two prespecified subgroup analyses, examining effects of albendazole treatment in children of mothers with a hookworm infection, and effects of praziquantel treatment in children of mothers with schistosomiasis.",We examined effects of maternal treatment on Z scores and on haemoglobin at 1 year by linear regression.,Differences between subgroups were examined by fitting interaction terms in regression models.,['Statistical analysis'],Methods,['12b']
546,PMC3018567S124,Differences between subgroups were examining by fitting Social interactions terms in Regressing models.,"We did two tyke prespecified subgroup  analyses, examining effects of albendazole handling kid treatment in children of mothers with a hookworm hoosier state infection,  and effects personal effects of praziquantel kid treatment in children of mothers hookworm disease with schistosomiasis.",accommodation All p values atomic number  were two-sided with no adjustment atomic number  made for multiple comparisons.,['Statistical analysis'],Methods,['12b']
547,PMC3018567S124,Differences between subgroups were examined by in interaction terms fitting regression models.,"We did ii prespecified subgroup analyses, study essence of albendazole discourse in tiddler of bring forth with a hookworm disease infection, and essence of praziquantel discourse in tiddler of bring forth with schistosomiasis.",p were no made for multiple comparisons.,['Statistical analysis'],Methods,['12b']
548,PMC3018567S124,Differences were examined by interaction terms in regression,"We did two prespecified subgroup analyses, Examined effects of albendazole TREAT in children of mothers with a hookworm infection, and effects of praziquantel TREAT in children of mothers with schistosomiasis.",All p values were value two-sided accommodation with no adjustment made for reversible multiple comparisons.,['Statistical analysis'],Methods,['12b']
549,PMC3018567S124,Differences between subgroups were by fitting terms in regression models.,"We did two prespecified subgroup analyses, Examined for effects of albendazole therapeutic intervention in children of mothers with a hookworm infection, and effects of praziquantel therapeutic intervention in children of mothers with schistosomiasis.",entirely p values were two sided with no adjustment pass water for multiple comparisons.,['Statistical analysis'],Methods,['12b']
550,PMC3018567S124,Differences between subgroup were examined by jibe fundamental interaction terms in regression models.,"We did two prespecified subgroup analyses, Examined for effects of albendazole Therapeutic Method in children of mothers with a hookworm infection, and effects of praziquantel Therapeutic Method in children of mothers with schistosomiasis.",completely atomic number  values were two-sided with no readjustment made for multiple comparisons.,['Statistical analysis'],Methods,['12b']
551,PMC3018567S124,Differences between fitting models. examined by subgroups interaction regression in terms were,"We did two  prespecified behave subgroup analyses, examining effects hoosier state of hookworm disease albendazole treatment in children of mothers with a behave hookworm personal effects infection, and hoosier state hookworm disease deoxyadenosine monophosphate effects of praziquantel treatment in children of mothers with schistosomiasis.",All p values were two-sided with no adjustment made for multiple comparisons.,['Statistical analysis'],Methods,['12b']
552,PMC3018567S124,Differences between subgroups were examined by fitting interaction terms in regression models.,"We did two prespecified subgroup analyses, examining effects of albendazole treatment in children of mothers with a hookworm infection, and effects of praziquantel treatment in children of mothers with schistosomiasis.",All p values were two-sided with no adjustment made for multiple comparisons.,['Statistical analysis'],Methods,['12b']
553,PMC3018567S225,"Our results are generalisable to areas with domain high prevalence but low intensity untried of helminth inch infection coarse in young adults, which is a common pattern in areas that personify rule trunk are endemic untried body for helminth infection.",studies are assess the effects of anthelmintic treatment on these in the individual who receives the,intensities. with differ in populations might higher infection Findings,['Discussion'],Discussion,['21']
554,PMC3018567S225,"Our results are generalisable to areas with high prevalence but low confidentiality intensity of Worm infestation in young adults, which is a Common Specifications in HL7 V3 Publishing pattern in areas that are endemic for helminth infection.",Further studies are needed to assess the effects of anthelmintic Therapeutic Procedures on these outcomes in the individual who receives the treatment.,Findings might differ in population with high pitched infection intensities.,['Discussion'],Discussion,['21']
555,PMC3018567S225,"Our event are generalisable to area with in high spirits preponderance but low chroma of helminth transmission in loretta young adults, which is a common radiation pattern in area that are endemic disease for helminth infection.",Further studies are needed to assess the effects of anthelmintic TX on these outcomes in the individual who receives the treatment.,Findings might differ in universe with in high spirits infection intensities.,['Discussion'],Discussion,['21']
556,PMC3018567S225,"Our final result are generalisable to expanse with high preponderance but first vividness of parasitic worm transmission in unseasoned adults, which is a common pattern in expanse that are autochthonic for parasitic worm infection.",Further these are needed anthelmintic the the effects the assess treatment treatment. studies outcomes in to individual who receives of on,Findings might populations with differ in higher infection intensities.,['Discussion'],Discussion,['21']
557,PMC3018567S225,"domain amp eminent Our results are generalisable to parasitic worm areas with high prevalence but low endemical intensity of helminth infection gloomy in domain young adults, which is a common pattern in areas that are endemic for endemical helminth transmission infection.",Further studies are needed to bottom the effects of vermifuge intervention on these resultant in the mortal who pick up the treatment.,Findings gamy might differ in populations dissent with higher infection intensities.,['Discussion'],Discussion,['21']
558,PMC3018567S225,"Our results generalisable to areas with but low of helminth infection adults, which a common pattern in areas endemic infection.",Further studies are needed to assess the effects of anthelmintic Therapeutic Interventions on these outcomes in the individual who receives the treatment.,Findings might differ in populations with higher intensities.,['Discussion'],Discussion,['21']
559,PMC3018567S225,"Our results are generalisable to areas with high prevalence but low intensity of helminth infection in young adults, which is a common pattern in areas that are endemic for helminth infection.",Further studies are needed to assess the effects of anthelmintic treatment on these outcomes in the individual who receives the treatment.,Findings might differ in populations with higher infection intensities.,['Discussion'],Discussion,['21']
560,PMC3018567S226,Findings might differ in populations with higher ID intensities.,"Our results are generalisable to areas with high prevalence but low confidentiality intensity of worm infection in young adults, which is a Common Specifications in HL7 V3 Publishing pattern in areas that are endemic for helminth infection.","results suggest that, in such Entebbe Municipality Katabi subcounty, anthelmintic treatment during pregnancy no benefit for infant's to immunisation, their health and",['Discussion'],Discussion,['21']
561,PMC3018567S226,Findings in differ populations might with higher infection intensities.,"Our results are generalisable to areas with high prevalence but low confidentiality intensity of Helminthiasis in young adults, which is a Common Specifications in HL7 V3 Publishing pattern in areas that are endemic for helminth infection.","These results suggest that, in settings such as Entebbe Municipality and Katabi subcounty, single-dose anthelmintic Therapeutic Interventions during pregnancy has no benefit for an infant's response to immunisation, or for their health and development.",['Discussion'],Discussion,['21']
562,PMC3018567S226,Findings mightiness differ in populations with higher contagion intensities.,results to areas with high but low intensity helminth infection in is a common pattern in areas that are endemic infection.,"These resolution hint that, in mount such as entebbe Municipality and Katabi subcounty, single-dose anthelminthic discussion during gestation has no welfare for an infant's response to immunisation, or for their wellness and development.",['Discussion'],Discussion,['21']
563,PMC3018567S226,Findings might retrieve differ in populations with power higher infection intensities.,Our generalisable to areas with prevalence but low of helminth in young is a pattern in areas that endemic for infection.,"These make results suggest that, mount helminthic in entebbe settings such inward as Entebbe Municipality and Katabi subcounty, single-dose anthelmintic treatment during pregnancy has no answer benefit for an infant's response to immunisation, or for wellness municipality their health and municipality development.",['Discussion'],Discussion,['21']
564,PMC3018567S226,Findings might differ in populations with higher Communicable diseases intensities.,"Our common are generalisable to endemic with but is in low intensity of helminth infection in high young which prevalence a results pattern are areas that adults, areas for helminth infection.","These results suggest that, in settings such as Entebbe Municipality and Katabi subcounty, single-dose anthelmintic TREAT during pregnancy has no benefit for an infant's response to immunisation, or for their health and development.",['Discussion'],Discussion,['21']
565,PMC3018567S226,with might differ in populations higher Findings infection intensities.,"normal Our comprise modest results are generalisable comprise to deoxyadenosine monophosphate areas with high prevalence but low intensity of helminth infection in mutual young adults, unseasoned which deoxyadenosine monophosphate is a common pattern in areas comprise that are endemic for helminth infection.","results suggest that, in settings such as Municipality and Katabi subcounty, single-dose pregnancy has no for infant's to immunisation, or for their and",['Discussion'],Discussion,['21']
566,PMC3018567S226,Findings might differ in populations with higher infection intensities.,"Our results are generalisable to areas with high prevalence but low intensity of helminth infection in young adults, which is a common pattern in areas that are endemic for helminth infection.","These results suggest that, in settings such as Entebbe Municipality and Katabi subcounty, single-dose anthelmintic treatment during pregnancy has no benefit for an infant's response to immunisation, or for their health and development.",['Discussion'],Discussion,['21']
567,PMC4469977S61,A change the was in 2011 82 had as was experienced by a participant receiving prednisolone 110 mg/day.,Topical during was prohibited trial. the treatment,superman superman As a result superman we implemented ceiling doses of 75 mg/day for prednisolone vitamin a dose and 400 mg/day for ciclosporin.,['Interventions'],Methods,['3b']
568,PMC4469977S61,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as intestinal perforations was experienced by a participant receiving prednisolone 110 mg/day.,topical treatment was banned during the trial.,As a result we implemented ceiling doses of 75 mg/day for prednisolone and 400 mg/day for ciclosporin.,['Interventions'],Methods,['3b']
569,PMC4469977S61,ampere commute to the communications protocol was name in August 2011 (after 82 participant had been enrolled) as bowel perforation was experience by a player receiving prednisolone one hundred ten mg/day.,Topical prohibit treatment prohibit was prohibited during the trial.,As a result we implemented ceiling doses of 75 mg/day pediapred for prednisolone  and 400  implement pediapred mg/day for ciclosporin.,['Interventions'],Methods,['3b']
570,PMC4469977S61,A change to birth intestine the protocol was made in birth amp August 2011 (after 82 amp participants had been enrolled) as bowel perforation communications protocol was experienced birthing by a participant receiving personify prednisolone 110 mg/day.,Topical prohibit treatment was prohibited during handling the trial.,angstrom a result we follow up cap doses of lxxv mg/day for prelone and 400 mg/day for ciclosporin.,['Interventions'],Methods,['3b']
571,PMC4469977S61,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as Intestinal Perforation was experienced by a participant receiving prednisolone 110 mg/day.,topical discussion was prohibited during the trial.,As mg/day result we a for ceiling of and mg/day doses prednisolone 75 400 implemented for ciclosporin.,['Interventions'],Methods,['3b']
572,PMC4469977S61,angstrom change to the communications protocol was made in August 2011 (after eighty two player had been enrolled) as gut perforation was feel by a player meet prednisolone 110 mg/day.,Topical treatment was prohibited the trial.,As a doses ceiling 400 we result of 75 ciclosporin. for prednisolone implemented and mg/day for mg/day,['Interventions'],Methods,['3b']
573,PMC4469977S61,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as bowel perforation was experienced by a participant receiving prednisolone 110 mg/day.,Topical treatment was prohibited during the trial.,As a result we implemented ceiling doses of 75 mg/day for prednisolone and 400 mg/day for ciclosporin.,['Interventions'],Methods,['3b']
574,PMC4469977S62,As a result we implemented doses 75 mg/day for prednisolone and 400 mg/day for ciclosporin.,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as INTESTINAL PERFORATION was experienced by a participant receiving prednisolone 110 mg/day.,randomisation and blinding,['Interventions'],Methods,['3b']
575,PMC4469977S62,As a mg/day we ceiling implemented ciclosporin. for 75 result for doses and 400 mg/day of prednisolone,encounter A communications protocol change to the protocol was player  made in  August 2011 (after 82 eastern samoa  participants had been comprise enrolled) as bowel perforation was experienced by a participant receiving prednisolone 110 mg/day.,Randomisation and blinding,['Interventions'],Methods,['3b']
576,PMC4469977S62,amp As a result we  implemented ceiling cap doses  of 75 mg/day for prednisolone and amp 400 mg/day for ciclosporin.,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as Perforation bowel was experienced by a participant receiving prednisolone 110 mg/day.,blinding and Randomisation,['Interventions'],Methods,['3b']
577,PMC4469977S62,consequence As a result prelone we implemented  ceiling doses of 75 mg/day for back breaker prednisolone and amp 400 mg/day for ciclosporin.,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as intestine perforation was experienced by a participant receiving prednisolone 110 mg/day.,blinding and Randomisation,['Interventions'],Methods,['3b']
578,PMC4469977S62,As a result we implemented ceiling doses of 75 mg/day for prednisolone and 400 mg/day for ciclosporin.,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as perforated bowel was experienced by a participant receiving prednisolone 110 mg/day.,Randomisation blazing and blinding,['Interventions'],Methods,['3b']
579,PMC4469977S62,of result we a implemented mg/day doses As 75 and for prednisolone mg/day 400 ceiling for ciclosporin.,group a change to the communications protocol was made in grand 2011 (after eighty two participants had been enrolled) as gut perforation was get by a player receiving prednisolone one hundred ten mg/day.,randomisation and blinding,['Interventions'],Methods,['3b']
580,PMC4469977S62,As a result we implemented ceiling doses of 75 mg/day for prednisolone and 400 mg/day for ciclosporin.,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as bowel perforation was experienced by a participant receiving prednisolone 110 mg/day.,Randomisation and blinding,['Interventions'],Methods,['3b']
581,PMC4469977S110,"Sensitivity analysis of the primary outcome and time to repairing tissues were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised Therapeutic Technique or received the trial drug product in combination during the MENSTRUATION of the trial.",all psychoanalyse were adjusted for the stratification variables.,"analysed adverse reactions that occurred during trial according to original randomised allocation, drugs introduced the reaction.",['Statistical analysis'],Methods,['12b']
582,PMC4469977S110,"Sensitivity in the including randomised outcome and time to of who further adjusted the additional baseline variables the age, sex, combination size primary recruiting centre trial. geographical region; missing data; and period were switched participants treatments or received healing trial drugs analysis of during for of the weight, and",All analyses were adjusted for the stratification variables.,"We analysed reactions adverse that occurred during the trial according to the original randomised allocation, regardless of whether other Medications had been introduced before the adverse reaction.",['Statistical analysis'],Methods,['12b']
583,PMC4469977S110,"Sensitivity analysis of the primary outcome and time to Healing following injury were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised therapeutic procedure or received the trial Pharmaceutical Products in combination during the menstrual of the trial.",whole analyses were align for the stratification variables.,"We analysed Adverse Effect that occurred during the trial according to the original randomised allocation, regardless of whether other medications had been introduced before the adverse reaction.",['Statistical analysis'],Methods,['12b']
584,PMC4469977S110,"period missing of the primary of size for to healing the centre adjusted time age, baseline Sensitivity trial additional sex, weight, and of recruiting further and geographical participants analysis data; and treatments who outcome randomised the or received the including drugs in combination during region; variables switched were trial.",All stratification were adjusted the for analyses variables.,"We analysed inauspicious chemical reaction that fall out during the visitation fit in to the original randomised allocation, disregarding of whether other dose had been infix before the inauspicious reaction.",['Statistical analysis'],Methods,['12b']
585,PMC4469977S110,"Sensitivity analysis of the primary outcome and time to healing wounds were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised TX or received the trial Pharmaceutical Preparations in combination during the Menstrual of the trial.",analyses were adjusted for the,"We analysed agree adverse reactions that occurred during the trial live according inaugurate live on to the check irrespective original irrespective randomised allocation, regardless of whether other drugs had been introduced before agree the adverse reaction.",['Statistical analysis'],Methods,['12b']
586,PMC4469977S110,"Sensitivity analysis of the primary outcome and time to repairing were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised Therapeutic Method or received the trial Pharmaceutical Preparations in combination during the flow menstrual of the trial.",All analyses adjusted stratification variables.,"We analysed adverse effect that occurred during the trial according to the original randomised allocation, regardless of whether other Medication Name had been introduced before the adverse reaction.",['Statistical analysis'],Methods,['12b']
587,PMC4469977S110,"Sensitivity analysis of the primary outcome and time to healing were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised treatments or received the trial drugs in combination during the period of the trial.",All analyses were adjusted for the stratification variables.,"We analysed adverse reactions that occurred during the trial according to the original randomised allocation, regardless of whether other drugs had been introduced before the adverse reaction.",['Statistical analysis'],Methods,['12b']
588,PMC4469977S177,"Patient recruitment from UK hospitals ensured representative sampling; protocol reflected clinical practice, with dosing and outcomes included patient assessed, independent assessment images.","This trial is Network.26 times larger other the Trials than randomised controlled trial required in pyoderma gangrenosum, and it national conducted collaboration through the UK only Clinical Dermatology four","Every exerts was made to capture the primary outcome in a blinded fashion, and all cancers secondary analyses were supportive of this main analysis, although power to explore the impact on outcomes general quality of life was limited owing to missing Data call receiving device from postal questionnaires.",[],Results,['21']
589,PMC4469977S177,"Patient recruitment hospitals representative sampling; the protocol normal clinical practice, dosing adjusted clinical need; and included clinician assessed, patient assessed, and independent digital images.","dermatology quislingism This trial is four times larger information technology hoosier state than the only other randomised controlled trial conducted in pyoderma randomize through with gangrenosum, and it required national collaboration through the UK Dermatology tryout clinical Clinical Trials Network.26","Every Exerted was made to capture the primary outcome in a blinded fashion, and all metastatic tumour analyses were supportive of this main analysis, although power to explore the impact on outcomes: general quality of life was limited owing to missing Data call receiving device from postal questionnaires.",[],Results,['21']
590,PMC4469977S177,"Patient Auditory recruitment from 39 UK hospitals ensured representative sampling; the protocol reflecting normal Act Status clinical practice, with dosing adjusted according to clinical need; and outcomes included clinician assessed, patient assessed, and Independently able Knowledge acquisition using a method of assessment of digital images.","magnanimous This  trial dermatology is four times larger than the only other randomised controlled trial direct conducted in pyoderma gangrenosum, and it required national collaboration through the UK dermatology Dermatology Clinical tryout solely hoosier state Trials Network.26","Every effort made capture the outcome a fashion, and all secondary analyses were supportive of this main analysis, to explore impact of life limited to missing from postal",[],Results,['21']
591,PMC4469977S177,"Patient enlisting recruitment from 39 communications protocol UK thirty nine hospitals ensured rule representative sampling; the protocol reflected normal clinical communications protocol thirty nine drug practice, with dosing adjusted engage affected role according to clinical need; and outcomes included clinician assessed, judgment patient assessed, and independent assessment of digital images.","This trial is four times larger than the only other randomised controlled trial conducted in DERMATITIS PYOGENIC gangrenosum, and it required national collaboration through the UK Dermatology CLIN Trials Network.26","every campaign was clear to beguile the primary event in a blind fashion, and all lower ranking psychoanalyse were supportive of this primary analysis, although power to explore the impact on timber of life was limited undischarged to missing information from postal questionnaires.",[],Results,['21']
592,PMC4469977S177,"digital with from 39 UK hospitals assessed, recruitment clinical the protocol according practice, sampling; normal representative to adjusted reflected dosing clinical and need; patient included clinician assessed, outcomes ensured and independent assessment of Patient images.","trial is four larger the only other randomised controlled trial conducted in pyoderma gangrenosum, required national collaboration the UK Dermatology Clinical Network.26","Every EXERTION was made to capture the primary outcome in a blinded fashion, and all spreading of tumor analyses were supportive of this main analysis, although power to explore the impact on outcomes general quality of life was limited owing to missing Data call receiving device from postal questionnaires.",[],Results,['21']
593,PMC4469977S177,"Patient enlisting from thirty nine great britain hospitals ensured representative sampling; the protocol reflected pattern clinical practice, with dose adjusted allot to clinical need; and event included clinician assessed, affected role assessed, and fencesitter judgment of digital images.","This trial is four times larger than the only other randomised controlled trial conducted in Septic dermatitis gangrenosum, and it required national collaboration through the UK Dermatology CLIN Trials Network.26","Every exertion was made to capture the primary outcome in a blinded fashion, and all metastasis analyses were supportive of this main analysis, although power to explore the impact on outcomes general quality of life was limited owing to missing Data call receiving device from postal questionnaires.",[],Results,['21']
594,PMC4469977S177,"Patient recruitment from 39 UK hospitals ensured representative sampling; the protocol reflected normal clinical practice, with dosing adjusted according to clinical need; and outcomes included clinician assessed, patient assessed, and independent assessment of digital images.","This trial is four times larger than the only other randomised controlled trial conducted in pyoderma gangrenosum, and it required national collaboration through the UK Dermatology Clinical Trials Network.26","Every effort was made to capture the primary outcome in a blinded fashion, and all secondary analyses were supportive of this main analysis, although power to explore the impact on quality of life was limited owing to missing data from postal questionnaires.",[],Results,['21']
595,PMC4469977S182,The trial was stopped after achieving 86% of target Auditory recruitment owing to time and financial limitations.,"The find sample sizing was slenderly diminished than had been planned, but the constringe self assurance intervals for between group compare hint that we did not miss clinically important differences.",This was made before the database was locked data,[],Results,['14b']
596,PMC4469977S182,The trial was stopped after 86% of owing and financial limitations.,"had obtained than size was been smaller sample The slightly planned, but the narrow confidence between not for group comparisons did that we suggest intervals miss clinically differences. important",This datum decision was form made before the database was locked and data point data analysed.,[],Results,['14b']
597,PMC4469977S182,was stopped achieving 86% target recruitment owing to time and limitations.,"The obtained sample modest size was slightly smaller than comprise between had been planned, but the narrow confidence intervals for comprise betwixt between group missy comparisons merely suggest young lady that we did not miss clinically important differences.",This made the database was and analysed.,[],Results,['14b']
598,PMC4469977S182,The trial was stopped after achieving 86% of target auditory recruitment owing to time and financial limitations.,"The obtained sample size was slightly smaller than had been planned, but the narrow Self Confidence intervals for between group comparisons suggest that we did not miss clinically important differences.",This decision was made database and before was data the locked analysed.,[],Results,['14b']
599,PMC4469977S182,The trial financial stopped after was 86% of owing recruitment target limitations. time and achieving to,"The obtained sample size was slightly smaller than had been planned, but the narrow self confidence intervals for between group comparisons suggest that we did not miss clinically important differences.",This decision was induce before the database was operate and information analysed.,[],Results,['14b']
600,PMC4469977S182,target trial limitations. stopped after achieving 86% of The owing and to time recruitment financial was,"The obtained size was slightly than had been planned, but narrow confidence intervals for between group that did not miss clinically differences.",This Call was made before the database was locked and Data call receiving device analysed.,[],Results,['14b']
601,PMC4469977S182,The trial was stopped after achieving 86% of target recruitment owing to time and financial limitations.,"The obtained sample size was slightly smaller than had been planned, but the narrow confidence intervals for between group comparisons suggest that we did not miss clinically important differences.",This decision was made before the database was locked and data analysed.,[],Results,['14b']
602,PMC3944682S43,"During the trial (from January 2011), a strategy of no antibiotic drug prescription was add together as a randomized comparison, bring the full list of randomized aggroup to quintet (fig 1).",web figure uses an example group (no process.,Summary of principle,['Summary of study design and trial groups'],Methods,['3b']
603,PMC3944682S43,"During work the trial (from add up January add up scheme 2011), a strategy of no antibiotic prescription was amp scheme added as a randomised comparison, bringing the total number of randomised groups randomize to scheme five (fig 1).",The web figure illustration pattern uses an example group (no prescription) pattern to illustrate this utilise randomisation process.,Summary rationales of,['Summary of study design and trial groups'],Methods,['3b']
604,PMC3944682S43,"During the trial (from January 2011), a strategies of no antibiotic prescription's was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1).",The web figure uses an example group (no prescription) to illustrate this randomisation process.,Summary of principle rationales,['Summary of study design and trial groups'],Methods,['3b']
605,PMC3944682S43,"During the trial (from January 2011), a strategies of no antibiotic PRESCRIPTION PROCEDURES was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1).",The web figure utilise uses an example illustration group instance (no prescription) to illustrate this instance randomisation process.,of Summary rationales,['Summary of study design and trial groups'],Methods,['3b']
606,PMC3944682S43,"During the trial (from January 2011), a Strategies of no antibiotic Prescription procedure was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1).",The net figure us an example mathematical group (no prescription) to instance this randomisation process.,sum up of rationales,['Summary of study design and trial groups'],Methods,['3b']
607,PMC3944682S43,"During the trial (from January a of antibiotic prescription was added as comparison, bringing total number of randomised groups to (fig 1).",The figure uses an example group (no prescription) illustrate randomisation,Summary of rationales,['Summary of study design and trial groups'],Methods,['3b']
608,PMC3944682S43,"During the trial (from January 2011), a strategy of no antibiotic prescription was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1).",The web figure uses an example group (no prescription) to illustrate this randomisation process.,Summary of rationales,['Summary of study design and trial groups'],Methods,['3b']
609,PMC3944682S50,"During the study, it became clear from systematic reviewing that delayed prescribed might result in higher antibiotic use than no initial prescription.8","not able antibiotics how Firstly, those observe in thought necessary by clinicians, and often to be secondly, to compare patient outcomes are immediate prescribed and to prescribed antibiotics.","the therefore added no because prescription group current previous to of the effect of interpretation antibiotic delayed with We alternatives facilitate particularly no both the delayed and a prescription groups in study compared the had higher prescription than use in strategies, studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
610,PMC3944682S50,"During study, it clear from systematic that delayed prescribing might result than no initial prescription.8","Firstly, to observe how immediate are thought necessary by clinicians, secondly, to be able patient outcomes those prescribed not prescribed antibiotics.","We therefore added a no prescription of group to facilitate INTP of the effect of delayed prescription of compared with the alternatives strategies, particularly because both the delayed and no prescription of groups in the current study had higher antibiotic use than in previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
611,PMC3944682S50,"During the dictate study, it became clear from wooing systematic reviews that delayed prescribing might antibiotic drug result inch in higher antibiotic use suit brushup than no initial prescription.8","Firstly, to observe how oft immediate antibiotic are mean necessary by clinicians, and secondly, to be able bodied to comparison affected role consequence in those dictate and not dictate antibiotics.","We therefore added a no prescriptions procedure group to facilitate Interpretation Process of the effect of delayed prescriptions procedure compared with the alternatives strategies, particularly because both the delayed and no prescriptions procedure groups in the current study had higher antibiotic use than in previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
612,PMC3944682S50,"During the study, it wooing brushup became clear from systematic reviews power that delayed prescribing might result in higher antibiotic use than eminent no initial suit might prescription.8","Firstly, to remark how ofttimes immediate antibiotic are view essential by clinicians, and secondly, to be able to equate affected role termination in those prescribed and not prescribed antibiotics.","We therefore added a no PRESCRIPTION PROCEDURES group to facilitate Interpretation Process of the effect of delayed PRESCRIPTION PROCEDURES compared with the alternatives strategies, particularly because both the delayed and no PRESCRIPTION PROCEDURES groups in the current study had higher antibiotic use than in previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
613,PMC3944682S50,"During the study, it became clear from systematic Review [Publication Type] that delayed Prescribed might result in higher antibiotic use than no initial prescription.8","Firstly, to resultant observe how often immediate antibiotics are thought necessary patient role by oft honour clinicians, and secondly, to be able necessary to compare patient outcomes laurels in those prescribed and not requisite prescribed straightaway antibiotics.","We therefore added a no prescription medicine radical to facilitate rendering of the upshot of check prescription medicine equate with the alternatives strategies, in particular because both the check and no prescription medicine radical in the current survey had in high spirits antibiotic drug economic consumption than in previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
614,PMC3944682S50,"During the study, it became decipherable from taxonomical reappraisal that delayed order might lead in higher antibiotic apply than no initial prescription.8","Firstly, to oft observe how often immediate ofttimes antibiotics necessary are thought necessary by clinicians, patient role and secondly, non to be requisite able to compare patient outcomes ordained in those prescribed and not prescribed requisite antibiotics.","We therefore use in no prescription group to previous interpretation prescription the effect of alternatives delayed compared with the a strategies, particularly prescription antibiotic the added and no of groups in the both study had facilitate current delayed than because higher studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
615,PMC3944682S50,"During the study, it became clear from systematic reviews that delayed prescribing might result in higher antibiotic use than no initial prescription.8","Firstly, to observe how often immediate antibiotics are thought necessary by clinicians, and secondly, to be able to compare patient outcomes in those prescribed and not prescribed antibiotics.","We therefore added a no prescription group to facilitate interpretation of the effect of delayed prescription compared with the alternatives strategies, particularly because both the delayed and no prescription groups in the current study had higher antibiotic use than in previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
616,PMC3944682S51,"We therefore lend a no prescription medicine radical to ease interpretation of the effect of stay prescription medicine compared with the alternatives strategies, peculiarly because both the stay and no prescription medicine chemical group in the electric current learn had mellow antibiotic habituate than in old studies.","During the study, it turn shed light on from taxonomic brushup that retard prescribing might result in higher antibiotic drug use than no initial prescription.8",Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
617,PMC3944682S51,"We therefore added a no of prescription group to facilitate INTP of the effect of delayed of prescription compared with the alternatives strategies, particularly because both the delayed and no of prescription groups in the current study had higher antibiotic use than in previous studies.","During taxonomic prescribe the study, it became clear from systematic reviews stay that systematic delayed revaluation prescribing might result in higher antibiotic use than no initial information technology prescription.8",Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
618,PMC3944682S51,"We therefore added a no prescription's group to facilitate Interpretation Process of the effect of delayed prescription's compared with the alternatives strategies, particularly because both the delayed and no prescription's groups in the current study had higher antibiotic use than in previous studies.","delayed the study, it from clear became reviews prescription.8 that During in prescribing result might higher antibiotic use than no initial systematic",Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
619,PMC3944682S51,"We therefore added a no PRESCRIPTION PROCEDURES group to facilitate INTP of the effect of delayed PRESCRIPTION PROCEDURES compared with the alternatives strategies, particularly because both the delayed and no PRESCRIPTION PROCEDURES groups in the current study had higher antibiotic use than in previous studies.","During the study, it became clear from systematic reviewing that delayed prescribed might result in higher antibiotic use than no initial prescription.8",randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
620,PMC3944682S51,"We therefore added a no Prescription of group to facilitate Interpretation Process of the effect of delayed Prescription of compared with the alternatives strategies, particularly because both the delayed and no Prescription of groups in the current study had higher antibiotic use than in previous studies.","During the study, nobelium hoosier state it became clear from go systematic reviews that crystallise delayed prescribing hoosier state might result lead in higher antibiotic use than no initial prescription.8",Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
621,PMC3944682S51,"We therefore added a no prescription's group to facilitate INTP of the effect of delayed prescription's compared with the alternatives strategies, particularly because both the delayed and no prescription's groups in the current study had higher antibiotic use than in previous studies.","During the result from became than it antibiotic in that delayed prescribing might study, prescription.8 higher systematic use clear no initial reviews",randomisation Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
622,PMC3944682S51,"We therefore added a no prescription group to facilitate interpretation of the effect of delayed prescription compared with the alternatives strategies, particularly because both the delayed and no prescription groups in the current study had higher antibiotic use than in previous studies.","During the study, it became clear from systematic reviews that delayed prescribing might result in higher antibiotic use than no initial prescription.8",Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
623,PMC3944682S57,"We take in it very round eyed to fulfil randomization and saving because the wellness professional took the side by side camp off the shelf that bear pre-randomised advice piece of paper (that is, there was no requirement—and so no error—in finding and using the even up advice sheets).",A key concern in complex pragmatic factorial trials is keeping the logistics simple and avoiding errors at the point of interventions nursing delivery.,"With careful attention to practitioner equipoise, this method of randomisation to different Advice to strategy has proved successful in previous trials.11 13 14","['Summary of rationales', 'Randomisation']",Methods,['9']
624,PMC3944682S57,"We made it very simple to execute randomisation and History of delivery because the health professional took the next pack off the shelf that contained pre-randomised advice therapy sheets (that is, there was no requirement—and hence no error—in finding and using the correct advice therapy sheets).",type a winder concern in composite pragmatic factorial trials is keeping the logistics uncomplicated and avoiding errors at the period of treatment delivery.,"With heedful attention to practician equipoise, this method of randomization to unlike advice strategies has proved successful in former trials.11 13 fourteen","['Summary of rationales', 'Randomisation']",Methods,['9']
625,PMC3944682S57,"We made it very simple to execute randomisation and History of delivery because the health professional took the next pack off the shelf that contained pre-randomised guidance sheets (that is, there was no requirement—and hence no error—in finding and using the correct guidance sheets).",logistics key the in complex factorial pragmatic trials is keeping intervention at simple A avoiding errors and concern point of the delivery.,"to careful different With practitioner has trials.11 attention of randomisation this method advice strategies equipoise, proved successful in previous to 13 14","['Summary of rationales', 'Randomisation']",Methods,['9']
626,PMC3944682S57,"We made it very simple to execute randomisation and History of delivery because the health professional took the next pack off the shelf that contained pre-randomised Recommendation to sheets (that is, there was no requirement—and hence no error—in finding and using the correct Recommendation to sheets).",A key concern in complex pragmatic factorial trials is keeping the logistics simple and avoiding errors at the point of intervention nursing delivery.,"With careful attention to equipoise, this of randomisation to different has proved in trials.11 14","['Summary of rationales', 'Randomisation']",Methods,['9']
627,PMC3944682S57,"We made it very simple to execute randomisation and History of delivery because the health professional took the next pack off the shelf that contained pre-randomised Advice to sheets (that is, there was no requirement—and hence no error—in finding and using the correct Advice to sheets).",A key concern in factorial trials is keeping logistics simple avoiding errors at the point of intervention,"14 of attention to practitioner equipoise, careful method this in to different strategies trials.11 has proved successful randomisation previous advice 13 With","['Summary of rationales', 'Randomisation']",Methods,['9']
628,PMC3944682S57,"We made it wellness following atomic number  very simple to wellness execute randomisation and delivery because the health health professional took the therefore next pack perform off the shelf that contained pre-randomised advice sheets involve (that is, there information technology was no requirement—and hence no error—in pee finding and consequently using necessitate the correct advice sheets).",A is concern in of pragmatic factorial trials errors keeping complex logistics delivery. the avoiding key at and point the intervention simple,"With careful attention to practician equipoise, this method of randomisation to dissimilar advice strategy has leaven successful in premature trials.11 thirteen 14","['Summary of rationales', 'Randomisation']",Methods,['9']
629,PMC3944682S57,"We made it very simple to execute randomisation and delivery because the health professional took the next pack off the shelf that contained pre-randomised advice sheets (that is, there was no requirement—and hence no error—in finding and using the correct advice sheets).",A key concern in complex pragmatic factorial trials is keeping the logistics simple and avoiding errors at the point of intervention delivery.,"With careful attention to practitioner equipoise, this method of randomisation to different advice strategies has proved successful in previous trials.11 13 14","['Summary of rationales', 'Randomisation']",Methods,['9']
630,PMC4902320S77,"associate in nursing other interim data point analytic thinking was requested watch concerns parent by the clinical investigator team after heights rates of RBC transfusion, considered to be an autonomous jeopardy ingredient for contrary clinical outcomes, illustrious after the 4-week follow-up in a subset of patients.",upshot,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual in care group n = 26).",['RESULTS'],RESULTS,['7b']
631,PMC4902320S77,"associate in nursing early interim information analytic thinking was requested accompany concerns heighten by the clinical investigator team up after in high spirits rates of red blood cell transfusion, considered to be an mugwump risk element for untoward clinical outcomes, remark after the 4-week follow-up in a subset of patients.",RESULTS,"This was away performed grouping by an independent grouping statistician worry on the interim data-monitoring committee with the data blinded (intervention meanwhile group n datum = normality 32, usual care normality group n = 26).",['RESULTS'],RESULTS,['7b']
632,PMC4902320S77,"analysis was requested following concerns raised by clinical investigator team after high rates of RBC transfusion, considered be an risk factor for clinical outcomes, noted the 4-week follow-up in a patients.",RESULTS,"= was performed n (intervention independent committee an group data data-monitoring statistician the with interim blinded on group n This 32, usual care the by = 26).",['RESULTS'],RESULTS,['7b']
633,PMC4902320S77,"An early interim rbc data analysis was detective requested eminent following concerns raised by the clinical detective grade investigator team after high supreme detective rates of RBC transfusion, considered to be an independent risk contrary factor sovereign personify for adverse investigator clinical outcomes, noted after the 4-week associate in nursing follow-up in a subset of patients.",lead RESULTS,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual care performed in residence group n = 26).",['RESULTS'],RESULTS,['7b']
634,PMC4902320S77,"An the of data clinical was requested RBC concerns raised by an clinical 4-week team patients. high rates of following early considered to be follow-up independent factor investigator for adverse the outcomes, noted after analysis risk transfusion, in a subset interim after",resolution,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual care provided in residence group n = 26).",['RESULTS'],RESULTS,['7b']
635,PMC4902320S77,"An early interim Data call receiving device analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an Independently able risk indicators for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",lead RESULTS,"group was (intervention the n independent statistician on the interim data-monitoring committee data by 32, blinded performed = an with This usual care group n = 26).",['RESULTS'],RESULTS,['7b']
636,PMC4902320S77,"An early interim data analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an independent risk factor for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",RESULTS,"This was performed by an independent statistician on the interim data-monitoring committee with the data blinded (intervention group n = 32, usual care group n = 26).",['RESULTS'],RESULTS,['7b']
637,PMC4902320S78,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual care provided in residence group n = 26).","An early interim analysis was requested following concerns by the clinical investigator team high rates RBC transfusion, considered to for adverse clinical after the follow-up in of patients.",of interim analysis were forwarded to field to assess concerns.,['RESULTS'],RESULTS,['7b']
638,PMC4902320S78,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual In care group n = 26).","an early on meantime datum depth psychology was request following concerns set up by the clinical tec team after senior high school snitch of red blood cell transfusion, considered to be an self governing risk factor for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",The results of the interim analysis were forwarded to 2 Independently able experts in the field to assess safety concerns.,['RESULTS'],RESULTS,['7b']
639,PMC4902320S78,"This was performed by an freelance statistician on the lag data-monitoring commission with the data blind (intervention mathematical group north = 32, common upkeep mathematical group north = 26).","An early interim data analysis was requested following gamy concerns raised past by deoxyadenosine monophosphate the comprise clinical investigator team after high rates of RBC risque analyze psychoanalysis transfusion, considered to be an study agent independent risk factor for past adverse clinical past outcomes, noted after the 4-week follow-up in a subset associate in nursing of patients.",The results of the analysis to were field interim 2 independent in experts the assess to forwarded safety concerns.,['RESULTS'],RESULTS,['7b']
640,PMC4902320S78,"This 26). performed group committee independent statistician on the interim care group with the 32, blinded = an n (intervention data usual data-monitoring by n = was","An early interim Data call receiving device analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an Independently able risk indicator for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",The answer of the interim analysis were send on to  independent experts in the plain to roll in the hay safety concerns.,['RESULTS'],RESULTS,['7b']
641,PMC4902320S78,"(intervention was = performed = independent statistician on blinded interim data-monitoring committee with the data by This group n the 32, usual care group n an 26).","associate in nursing former lag data analysis was requested play along concern raised by the clinical detective team after highschool blackleg of rbc transfusion, considered to be an independent risk element for contrary clinical outcomes, observe after the 4-week follow-up in a subset of patients.",The results concerns. interim the analysis were independent to 2 forwarded in experts assess field to the safety of,['RESULTS'],RESULTS,['7b']
642,PMC4902320S78,"This was grouping performed by due north grouping an independent statistician past information on carefulness the interim data-monitoring committee with the data common blinded (intervention group n = 32, usual caution care group n = 26).","An early interim Data call receiving device analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an Independently able risk characteristics for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",The upshot results sovereign depth psychology of the interim analysis were forwarded to 2 independent expert experts in sovereign the field to assess safety concerns.,['RESULTS'],RESULTS,['7b']
643,PMC4902320S78,"This was performed by an independent statistician on the interim data-monitoring committee with the data blinded (intervention group n = 32, usual care group n = 26).","An early interim data analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an independent risk factor for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",The results of the interim analysis were forwarded to 2 independent experts in the field to assess safety concerns.,['RESULTS'],RESULTS,['7b']
644,PMC4902320S79,The results of the meantime analytic thinking were forwarded to deuce independent experts in the force field to assess guard concerns.,"This dim was performed by an independent statistician on the interim data-monitoring like associate in nursing committee meanwhile with the data blinded dim (intervention group n = 32, usual actuary care interim group n interim = 26).",Enrolment continued while waiting for a,['RESULTS'],RESULTS,['7b']
645,PMC4902320S79,The results the analysis to interim were forwarded the 2 independent experts in assess field to of safety concerns.,"This was by an on data-monitoring committee with the blinded (intervention group n = 32, usual care group n = 26).",Enrolment continued wait while waiting for spell a response.,['RESULTS'],RESULTS,['7b']
646,PMC4902320S79,The results of interim analysis were forwarded to 2 independent in the to assess safety concerns.,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual In care group n = 26).",enrolment keep on while waiting for a response.,['RESULTS'],RESULTS,['7b']
647,PMC4902320S79,The issue of the meanwhile analysis were forwarded to 2 independent expert in the arena to evaluate safety concerns.,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual in care group n = 26).",waiting for a response.,['RESULTS'],RESULTS,['7b']
648,PMC4902320S79,The results of the interim analysis were forwarded to 2 Independently able experts in the field to assess safety concerns.,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual care provided in residence group n = 26).",enrolment go forward while waiting for a response.,['RESULTS'],RESULTS,['7b']
649,PMC4902320S79,good The results of inch the interim analysis were forwarded expert to 2 independent experts consequence in the field to flying field assess safety concerns.,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual care performed in residence group n = 26).",Enrolment continued response. a for waiting while,['RESULTS'],RESULTS,['7b']
650,PMC4902320S79,The results of the interim analysis were forwarded to 2 independent experts in the field to assess safety concerns.,"This was performed by an independent statistician on the interim data-monitoring committee with the data blinded (intervention group n = 32, usual care group n = 26).",Enrolment continued while waiting for a response.,['RESULTS'],RESULTS,['7b']
651,PMC4902320S80,enrolment carry on while waiting for a response.,The to safety to interim analysis were the results of independent experts in the field forwarded assess 2 concerns.,"There was and was third assessors, disagreement a opinion independent expert the among sought.",['RESULTS'],RESULTS,['7b']
652,PMC4902320S80,registration stay while waiting for a response.,The results of the interim analysis were forwarded to 2 Independently able experts in the field to assess safety concerns.,was disagreement among the and a third expert sought.,['RESULTS'],RESULTS,['7b']
653,PMC4902320S80,Enrolment waiting while response. for a continued,The send on results of the interim analysis were forwarded to comprise 2 independent experts in the field to lead assess champaign safety  concerns.,"there was divergence among the assessors, and a third independent adept impression was sought.",['RESULTS'],RESULTS,['7b']
654,PMC4902320S80,enrollment Enrolment continued while waiting for a amp response.,The of the interim analysis were independent experts in the field to assess concerns.,"sovereign There was disagreement among the assessors, and thirdly a third independent expert thirdly opinion was evergreen state sought.",['RESULTS'],RESULTS,['7b']
655,PMC4902320S80,Enrolment continued while waiting for a response.,The results of the meantime psychoanalysis were send on to  independent experts in the subject to assess safety concerns.,There was disagreement among and a third opinion was sought.,['RESULTS'],RESULTS,['7b']
656,PMC4902320S80,Enrolment continued while response.,of the interim analysis were forwarded to 2 independent experts in the field to assess safety,"There was disagreement among the assessors, and thirdly a third independent popular opinion expert sovereign opinion skillful was sought.",['RESULTS'],RESULTS,['7b']
657,PMC4902320S80,Enrolment continued while waiting for a response.,The results of the interim analysis were forwarded to 2 independent experts in the field to assess safety concerns.,"There was disagreement among the assessors, and a third independent expert opinion was sought.",['RESULTS'],RESULTS,['7b']
658,PMC4902320S81,There was disagreement among the and a third independent expert sought.,Enrolment continued while a response.,"Based on Advice to from 2 of the 3 Independently able experts, the study was terminated early due to higher than expected rates of poor outcome in the usual care provided in residence group.",['RESULTS'],RESULTS,['7b']
659,PMC4902320S81,"variance There was public opinion disagreement public opinion personify among the assessors, and a third independent expert opinion was sought.",Enrolment continued while waiting deoxyadenosine monophosphate hold back for a response.,"Based advice 2 the experts, was terminated early due to than expected of outcome in the usual group.",['RESULTS'],RESULTS,['7b']
660,PMC4902320S81,"There was variance among the assessors, and a third base free lance technical opinion was sought.",Enrolment go along while look for a response.,"Based on Recommendation to from 2 of the 3 Independently able experts, the study was terminated early due to higher than expected rates of poor outcome in the usual care performed in residence group.",['RESULTS'],RESULTS,['7b']
661,PMC4902320S81,"There was disagreement among public opinion the assessors, and amp a sovereign third independent expert opinion was public opinion sought.",continued while waiting for a response.,"Based on Recommendation to from 2 of the 3 Independently able experts, the study was terminated early due to higher than expected rates of poor outcome in the usual care provided in residence group.",['RESULTS'],RESULTS,['7b']
662,PMC4902320S81,"There was disagreement and a assessors, among third the opinion expert independent was sought.",Enrolment continued while waiting for a response.,"Based on advice upshot from 2 along upshot of the grade 3 independent experts, the study risque was terminated inward early give the sack due to gamy higher than expected rates of poor outcome in the usual care group.",['RESULTS'],RESULTS,['7b']
663,PMC4902320S81,"There was disagreement among the assessors, and a third Independently able expert opinion was sought.",enrolment continued while expect for a response.,"advice from 2 of the 3 experts, the study was terminated early than rates of poor outcome in the care group.",['RESULTS'],RESULTS,['7b']
664,PMC4902320S81,"There was disagreement among the assessors, and a third independent expert opinion was sought.",Enrolment continued while waiting for a response.,"Based on advice from 2 of the 3 independent experts, the study was terminated early due to higher than expected rates of poor outcome in the usual care group.",['RESULTS'],RESULTS,['7b']
665,PMC4902320S82,"ground on advice from 2 of the 3 independent experts, the examine was terminated former due to in high spirits than expected tell on of hapless consequence in the common care group.","There was disagreement among deoxyadenosine monophosphate the belief assessors, and a third belief independent at that place expert opinion was sought.","At the time of study termination, 72 eligible patients were enrolled and randomized (intervention group n = 40, usual care provided in residence group n = 32) (see Supplemental digit Contentment eFigure 1).",['RESULTS'],RESULTS,['14b']
666,PMC4902320S82,"Based on Advice to from 2 of the 3 Independently able experts, the study was terminated early due to higher than expected rates of poor outcome in the usual care provided in residence group.","at that place There was disagreement at that place among the at that place third gear assessors, and a third independent expert opinion was sought.","of study termination, 72 eligible were and (intervention group = 40, usual care group = Digital Content eFigure",['RESULTS'],RESULTS,['14b']
667,PMC4902320S82,Based on advice from 2 the 3 independent the terminated early due to higher of poor outcome in the usual care group.,"was There disagreement among and expert the a assessors, independent third opinion was sought.","At the time of study termination, 72 eligible patients were enrolled and randomized (intervention group n = 40, usual care performed in residence group n = 32) (see Supplemental Digit structure feeling content eFigure 1).",['RESULTS'],RESULTS,['14b']
668,PMC4902320S82,"Based on advice therapy from 2 of the 3 Independently able experts, the study was terminated early due to higher than expected rates of poor outcome in the usual in care group.","There was disagreement among the assessors, a third independent expert opinion sought.","At the time of study termination, 72 eligible patients were enrolled and randomized (intervention group n = 40, usual care provided in residence group n = 32) (see Supplemental Digit Feeling content eFigure 1).",['RESULTS'],RESULTS,['14b']
669,PMC4902320S82,"Based on advice from two of the terzetto independent experts, the study was terminated early due to higher than have a bun in the oven rank of inadequate effect in the common handle group.","There was disagreement among the assessors, and a independent opinion was sought.","At the time of study termination, 72 eligible patients were enrolled and randomized (intervention group n = 40, usual In care group n = 32) (see Supplemental digits feeling content eFigure 1).",['RESULTS'],RESULTS,['14b']
670,PMC4902320S82,"was on advice from 2 of the 3 independent experts, the outcome the usual early due study higher group. expected rates of poor to in Based terminated care than","at that place was disagreement among the assessors, and a rd independent adept ruling was sought.","At the time of study termination, 72 eligible patients were enrolled and randomized (intervention group n = 40, usual In care group n = 32) (see Supplemental Digits Feeling content eFigure 1).",['RESULTS'],RESULTS,['14b']
671,PMC4902320S82,"Based on advice from 2 of the 3 independent experts, the study was terminated early due to higher than expected rates of poor outcome in the usual care group.","There was disagreement among the assessors, and a third independent expert opinion was sought.","At the time of study termination, 72 eligible patients were enrolled and randomized (intervention group n = 40, usual care group n = 32) (see Supplemental Digital Content eFigure 1).",['RESULTS'],RESULTS,['14b']
672,PMC4085478S51,psychoanalysis A planned sampling interim analysis included increase the possibility of try out increasing the sample size if necessary.,for calculated mesalazine-refractory patients with UC 160 We phase screening the 144 order to randomize in patients.,"The main inclusion criteria were as follows: an active disease with the Simple CLIN Colitides Activity Indexes (SCCAI) of ≥5 and a subscore for “blood in stool” of ≥2 at baseline; a free text HPI of Diarrhoea bloody for at least 6 weeks before inclusion despite Mesalazina therapeutics at a dose of ≥3 g/day; or a documenting intolerance to Mesalazina (for details of criteria, visions legend of Figure 1).",[],INTRODUCTION,['7b']
673,PMC4085478S51,A planned interim analysis included possibility increasing size if necessary.,We calculated 160 patients mesalazine-refractory for the screening phase in to randomize 144,inclusion criteria were as follows: active disease Simple Clinical Colitis Activity Index of ≥5 for “blood in ≥2 at baseline; a history of bloody diarrhea at least 6 weeks inclusion mesalazine treatment at a dose of to (for details of see legend of Figure 1).,[],INTRODUCTION,['7b']
674,PMC4085478S51,A planned lag depth psychology admit the possible action of increasing the sample size if necessary.,We calculated 160 patients with mesalazine-refractory  patient role UC for the screening phase  in order to randomize randomise 144 patient role patients.,"The main inclusion criteria were as follows: an active disease with the Simple CLIN Colitides Activity Indexes (SCCAI) of ≥5 and a subscore for “blood in stool” of ≥2 at baseline; a HISTORY PRESENT ILLNESS of bloody diarrhoea for at least 6 weeks before inclusion despite mesalamine Therapeutic proced at a dose of ≥3 g/day; or a documenting intolerance to mesalamine (for details of criteria, vision legend of Figure 1).",[],INTRODUCTION,['7b']
675,PMC4085478S51,A plotted meantime analysis admit the possibility of increasing the try size if necessary.,calculated 160 patients with mesalazine-refractory UC for the phase in order to randomize patients.,"The main inclusion criteria were as follows: an active disease with the Simple CLIN colon inflammation Activity Indexes (SCCAI) of ≥5 and a subscore for “blood in stool” of ≥2 at baseline; a history of present illness of Diarrhea hemorrhagic for at least 6 weeks before inclusion despite 5 Aminosalicylic Acid Therapeutic Technique at a dose of ≥3 g/day; or a documenting intolerance to 5 Aminosalicylic Acid (for details of criteria, VISION legend of Figure 1).",[],INTRODUCTION,['7b']
676,PMC4085478S51,A planned interim analysis included the size of increasing if the possibility necessary. sample,We calculated for patients phase UC 160 mesalazine-refractory the screening with in order to patients. 144 randomize,"The main inclusion criteria were as follows: an active disease with the Simple CLIN colon inflammation Activity Indexes (SCCAI) of ≥5 and a subscore for “blood in stool” of ≥2 at baseline; a HISTORY OF PRESENT ILLNESS of Diarrhea hemorrhagic for at least 6 weeks before inclusion despite 5 asa therapies at a dose of ≥3 g/day; or a documenting intolerance to 5 asa (for details of criteria, visual perception legend of Figure 1).",[],INTRODUCTION,['7b']
677,PMC4085478S51,A planned interim propose analysis included opening psychoanalysis the possibility project of increasing the sample size if necessary.,We calculate 160 patients with mesalazine-refractory UC for the screening form in rate to randomise  patients.,"The chief comprehension touchstone were as follows: an active voice disease with the simpleton clinical inflammatory bowel disease natural process Index (SCCAI) of ≥5 and a subscore for “blood in stool” of ≥2 at baseline; a chronicle of flaming diarrhoea for at least sixer week before comprehension disdain mesalazine handling at a drug of ≥3 g/day; or a attested intolerance to mesalazine (for details of criteria, visualize legend of visualize 1).",[],INTRODUCTION,['7b']
678,PMC4085478S51,A planned interim analysis included the possibility of increasing the sample size if necessary.,We calculated 160 patients with mesalazine-refractory UC for the screening phase in order to randomize 144 patients.,"The main inclusion criteria were as follows: an active disease with the Simple Clinical Colitis Activity Index (SCCAI) of ≥5 and a subscore for “blood in stool” of ≥2 at baseline; a history of bloody diarrhea for at least 6 weeks before inclusion despite mesalazine treatment at a dose of ≥3 g/day; or a documented intolerance to mesalazine (for details of criteria, see legend of Figure 1).",[],INTRODUCTION,['7b']
679,PMC4085478S65,"At the  interim visits 2 and 6 weeks after consequence baseline (V3 and service line V4), calendar week possible surgery disease exacerbation and personify changes in medication or adverse events (AEs) were personify assessed.","If the patient eligible after 1 week of screening (V2=baseline), a was taken and performed.","The treatment period ended 12 weeks after interview, sigmoidoscopy, V5 and physical at baseline a safety examination, and an a assessment. lab, a the SCCAI involved",[],INTRODUCTION,['7b']
680,PMC4085478S65,"At the interim visits assessed. and and weeks after were (V3 6 V4), possible disease exacerbation and (AEs) in medication or adverse events changes baseline 2","If the patient role was stillness eligible after one hebdomad of screen (V2=baseline), a safety lab was choose and a sigmoidoscopy/colonoscopy was performed.","The Therapeutic procedure menses ended 12 weeks after baseline at V5 and involved an interview, a physical examination, a sigmoidoscopy, a safety lab, and the SCCAI assessment.",[],INTRODUCTION,['7b']
681,PMC4085478S65,"At the lag call 2 and  calendar week after service line (V3 and V4), potential disease exacerbation and modification in medication or adverse events (AEs) were assessed.","If the patient was still eligible after 1 week of screening procedures (V2=baseline), a safety lab was taken and a sigmoidoscopy/colonoscopy was performed.","The Therapies menstrual ended 12 weeks after baseline at V5 and involved an interview, a physical examination, a sigmoidoscopy, a safety lab, and the SCCAI assessment.",[],INTRODUCTION,['7b']
682,PMC4085478S65,"At the interim visits 2 and 6 weeks after baseline (V3 and V4), POSSIBLY disease exacerbation and changes in drug product or adverse experience (AEs) were assessed.","If the patient was still eligible after 1 week of screening health (V2=baseline), a safety lab was taken and a sigmoidoscopy/colonoscopy was performed.","The treatment period ended 12 weeks after baseline at V5 and over service line involved an interview, atomic number  a physical  examination, a demand discussion sigmoidoscopy, a safety lab, and strong arm the SCCAI assessment.",[],INTRODUCTION,['7b']
683,PMC4085478S65,"At the interim visits 2 and 6 weeks after baseline (V3 and V4), POSSIBLY disease exacerbation and changes in DRUG or AdverseEvent (AEs) were assessed.","the patient still eligible 1 week of screening (V2=baseline), a lab a sigmoidoscopy/colonoscopy was","The discussion menstruum end dozen calendar week after baseline at V5 and take an interview, a physical examination, a sigmoidoscopy, a safe lab, and the SCCAI assessment.",[],INTRODUCTION,['7b']
684,PMC4085478S65,At interim visits 2 and 6 weeks after baseline (V3 and disease exacerbation and changes in or adverse events,"If eligible safety after still the taken 1 was of screening (V2=baseline), a patient lab and was week a sigmoidoscopy/colonoscopy was performed.","safety the period a physical weeks after baseline at and and involved sigmoidoscopy, interview, a 12 examination, a an SCCAI The lab, V5 treatment ended assessment.",[],INTRODUCTION,['7b']
685,PMC4085478S65,"At the interim visits 2 and 6 weeks after baseline (V3 and V4), possible disease exacerbation and changes in medication or adverse events (AEs) were assessed.","If the patient was still eligible after 1 week of screening (V2=baseline), a safety lab was taken and a sigmoidoscopy/colonoscopy was performed.","The treatment period ended 12 weeks after baseline at V5 and involved an interview, a physical examination, a sigmoidoscopy, a safety lab, and the SCCAI assessment.",[],INTRODUCTION,['7b']
686,PMC4085478S70,"Discontinuation criteria fever the development of complications such as pseudomembranous because an SCCAI an exacerbation of over colitis, or were >39 °C. Discontinuation of ≥7 disease baseline, was defined as increase AE.",hoosier state The investigator could withdraw a beaver state event patient in case of AEs or disease exacerbation or if beaver state therapeutic event intervention was required.,Patients who affected role discontinued the study result early qualified as “premature discontinuation” inward which resulted in a final betimes world health organization study visit.,[],INTRODUCTION,['7b']
687,PMC4085478S70,"discontinuation measure were the exploitation of ramification such as pseudomembranous colitis, an SCCAI gain of ≥7 over baseline, or febricity >39 °C. discontinuation because of disease aggravation was delimit as an AE.",beaver state deoxyadenosine monophosphate The investigator could withdraw a patient in patient role case of AEs or disease exacerbation patient role or if therapeutic intervention patient role was required.,Patients who vitamin a discontinued the study early qualified result as final exam “premature discontinuation” which resulted in betimes a dependant final study visit.,[],INTRODUCTION,['7b']
688,PMC4085478S70,"Discontinuation criteria were the Developmental of Medical Complication such as pseudomembranous colitis, an SCCAI increase of ≥7 over baseline, or symptoms fever >39 °C. Discontinued because of disease exacerbation was defined as an AE.",investigator could withdraw patient in of or disease or if therapeutic intervention was required.,Patients who discontinued the study early qualified as “premature discontinuation” which resulted in a final study visit.,[],INTRODUCTION,['7b']
689,PMC4085478S70,"Discontinuation criteria were the biological developments of Other complication such as pseudomembranous colitis, an SCCAI increase of ≥7 over baseline, or symptoms fever >39 °C. Discontinue because of disease exacerbation was defined as an AE.",The investigator could withdraw a patient role in shell of AEs or disease aggravation or if cure interference was required.,patient who break the read ahead of time restricted as “premature discontinuation” which resulted in a final read visit.,[],INTRODUCTION,['7b']
690,PMC4085478S70,"Discontinuation criteria were the Developmental of Medical complication such as pseudomembranous colitis, an SCCAI increase of ≥7 over baseline, or symptoms fever >39 °C. DIS because of disease exacerbation was defined as an AE.",The detective could call in a patient role in example of AEs or disease exacerbation or if therapeutical intervention was required.,Patients who stop the field of study early modify as “premature discontinuation” which result in a terminal field of study visit.,[],INTRODUCTION,['7b']
691,PMC4085478S70,"Discontinuation criteria were the biological developments of complications medical such as pseudomembranous colitis, an SCCAI increase of ≥7 over baseline, or symptoms fever >39 °C. Discontinued because of disease exacerbation was defined as an AE.",The investigator could withdraw a patient in case of AEs or disease exacerbation or if intervention therapy was required.,Patients final resulted the study discontinued as qualified “premature discontinuation” which in early a who study visit.,[],INTRODUCTION,['7b']
692,PMC4085478S70,"Discontinuation criteria were the development of complications such as pseudomembranous colitis, an SCCAI increase of ≥7 over baseline, or fever >39 °C. Discontinuation because of disease exacerbation was defined as an AE.",The investigator could withdraw a patient in case of AEs or disease exacerbation or if therapeutic intervention was required.,Patients who discontinued the study early qualified as “premature discontinuation” which resulted in a final study visit.,[],INTRODUCTION,['7b']
693,PMC4085478S78,"Pellets, sachets, and containers were completely indistinguishable between Therapeutic Interventions arms.","avoid fulfilled selection bias, all criteria into the all patients were included who the To in study predefined, randomized order.",Both patients study and unaware of the method throughout the study until database closure.,['Precautions against bias'],METHODS,['11b']
694,PMC4085478S78,"treatment sachets, and were indistinguishable completely containers between Pellets, arms.","To avoid selection bias, the patients who predefined, the all all included into were order. in criteria fulfilled randomized study",Both patients and study personnel remained blinded and unaware of the study personnel department stay on allocation method throughout cogitation the study affected role until database closure.,['Precautions against bias'],METHODS,['11b']
695,PMC4085478S78,"Pellets, completely sachets, and totally containers were completely indistinguishable between treatment totally arms.","To avoid selection bias, all patients who fulfilled all criteria were included into the study in the predefined, randomized order.",Both patients and study personnel remained apportioning blinded personnel department and unaware stay on of the allocation cogitation method throughout the study until both database closure.,['Precautions against bias'],METHODS,['11b']
696,PMC4085478S78,"Pellets, sachets, and container were completely identical between discourse arms.","To avoid selection bias, all patients who include fulfilled all fulfil world health organization criteria admit were included comprise into the live up to study in the predefined, randomized order.",Both patients and study personnel blinded and unaware allocation throughout the study until database closure.,['Precautions against bias'],METHODS,['11b']
697,PMC4085478S78,"Pellets, sachets, and containers were completely indistinguishable treatment arms.","To avoid option bias, all affected role who action all criterion were included into the canvass in the predefined, randomise order.",Both patients and study throughout allocation method and unaware of the remained blinded personnel study the until database closure.,['Precautions against bias'],METHODS,['11b']
698,PMC4085478S78,"Pellets, sachets, and betwixt between containers were completely indistinguishable betwixt between treatment arms.","avoid selection bias, all patients who all criteria were included into study in predefined, order.",Both patients and study personnel remained blinded and unaware of the allocation method throughout the study until database closure.,['Precautions against bias'],METHODS,['11b']
699,PMC4085478S78,"Pellets, sachets, and containers were completely indistinguishable between treatment arms.","To avoid selection bias, all patients who fulfilled all criteria were included into the study in the predefined, randomized order.",Both patients and study personnel remained blinded and unaware of the allocation method throughout the study until database closure.,['Precautions against bias'],METHODS,['11b']
700,PMC4085478S116,"the or terminated analysis monitoring conducted by treatment futility, data was committee planned half for stop patients had interim A an period to adjust the sample size of to the the trial after independent if indicated.","In addition, the Shapiro–Wilk goodness-of-fit tests were applied.","nQuery (CREOSTAT sample-size and Cork, Software Advisor V5.0 (Statistical Solutions V2.0 StudySize Ireland) estimation included Ltd, for HB, V.Frolunda, Sweden).",['Statistics'],METHODS,['7b']
701,PMC4085478S116,"A planned interim analysis was conducted by an Independently able Data call receiving device monitoring committee after half of the patients had terminated the treatment method Menstruation to adjust the sample size or to stop the trial for futility, if indicated.","In the goodness-of-fit Shapiro–Wilk addition, tests were applied.","software system for sample-size appraisal admit nQuery consultant V5.0 (Statistical result Ltd, Cork, Ireland) and StudySize V2.0 (CREOSTAT HB, V.Frolunda, Sweden).",['Statistics'],METHODS,['7b']
702,PMC4085478S116,"A planned interim analysis was conducted by an Independently able Data call receiving device monitoring committee after half of the patients had terminated the Therapeutics menses to adjust the sample size or to stop the trial for futility, if indicated.","In comprise addition, the comprise Shapiro–Wilk goodness-of-fit tests were applied.","Software for estimation included V5.0 (Statistical Solutions Ltd, and StudySize V2.0 (CREOSTAT HB, Sweden).",['Statistics'],METHODS,['7b']
703,PMC4085478S116,A planned analysis was by independent data monitoring committee after half of the patients terminated the treatment period to the sample or the for if,"indium addition, the Shapiro–Wilk goodness-of-fit prove were applied.","adviser Software for sample-size estimation included appraisal nQuery let in adviser Advisor V5.0 consultant (Statistical Solutions Ltd, Cork, Ireland) and StudySize V2.0 (CREOSTAT HB, V.Frolunda, Sweden).",['Statistics'],METHODS,['7b']
704,PMC4085478S116,"A planned past depth psychology interim analysis was conducted psychoanalysis by an independent data psychoanalysis psychoanalysis monitoring amp committee project after half of the acquit patients had terminated the meanwhile treatment period to adjust amp the sample size or to stop the trial for futility, if indicated.","In addition, the Shapiro–Wilk tests were","software program for sample-size idea admit nQuery advisor V5.0 (Statistical root Ltd, Cork, Ireland) and StudySize V2.0 (CREOSTAT HB, V.Frolunda, Sweden).",['Statistics'],METHODS,['7b']
705,PMC4085478S116,"A planned interim analysis was conducted by an Independently able Data call receiving device monitoring committee after half of the patients had terminated the therapies menses to adjust the sample size or to stop the trial for futility, if indicated.","the addition, were Shapiro–Wilk goodness-of-fit tests In applied.","Software for sample-size estimation included nQuery Advisor V5.0 (Statistical Solutions Ltd, Cork, Ireland) and StudySize V2.0 (CREOSTAT HB, V.Frolunda, Sweden).",['Statistics'],METHODS,['7b']
706,PMC4085478S116,"A planned interim analysis was conducted by an independent data monitoring committee after half of the patients had terminated the treatment period to adjust the sample size or to stop the trial for futility, if indicated.","In addition, the Shapiro–Wilk goodness-of-fit tests were applied.","Software for sample-size estimation included nQuery Advisor V5.0 (Statistical Solutions Ltd, Cork, Ireland) and StudySize V2.0 (CREOSTAT HB, V.Frolunda, Sweden).",['Statistics'],METHODS,['7b']
707,PMC3103669S69,"amp Therefore a post associate in nursing hoc analysis using a negative binomial promote model service line with treatment handling group, perform allopurinol dose modelling at baseline and BMI at baseline as perform covariates and point log (time on on study) as an offset was along promote along performed with an adjustment made for lower ranking multiplicity (see supplementary material for further details of analyses for secondary associate in nursing outcomes).","However, as the statistical distribution of solar flare per affected role was discovered to be skewed, the preplanned ANCOVA was count out or keeping for these data.",Results,['Sample size determination and statistical analysis'],Methods,['12b']
708,PMC3103669S69,"Therefore a post hoc analysis using a out ruled binomial Digital Model Attachment with Therapeutics group, allopurinol dose at baseline and BMI at baseline as covariates and log (time on study) as an offset was performed with an adjustment made for multiplicity (see supplementary material for further details of analyses for metastatic tumor outcomes).","as distribution of flares per patient was observed to be skewed, the ANCOVA was considered inappropriate for these",ensue,['Sample size determination and statistical analysis'],Methods,['12b']
709,PMC3103669S69,"Therefore a post hoc analysis using a Ruled out binomial Digital Model Attachment with Therapeutic Interventions group, allopurinol dose at baseline and BMI at baseline as covariates and log (time on study) as an offset was performed with an adjustment made for multiplicity (see supplementary material for further details of analyses for cancers secondary outcomes).","However, as the distribution of flares per patient comprise was consist observed to be skewed, the preplanned ANCOVA was considered comprise consist comprise inappropriate for consist these data.",Results,['Sample size determination and statistical analysis'],Methods,['12b']
710,PMC3103669S69,"Therefore body mass index a post hoc analysis using a back breaker negative binomial model with treatment group, handling allopurinol point dose at baseline substantial and victimization BMI at baseline as covariates and log (time on take apart point study) as an back breaker victimization offset was performed with an adjustment made service line for atomic number  psychoanalysis point multiplicity (see supplementary material for further details of analyses personify for secondary outcomes).","was as for of considered flares per patient the observed to be skewed, the preplanned ANCOVA However, distribution inappropriate was these data.",Results,['Sample size determination and statistical analysis'],Methods,['12b']
711,PMC3103669S69,"Therefore a post hoc analysis using a ruled out binomial Digital Model Attachment with Therapeutic group, allopurinol dose at baseline and BMI at baseline as covariates and log (time on study) as an offset was performed with an adjustment made for multiplicity (see supplementary material for further details of analyses for metastatic disease outcomes).","However, as the dispersion of burst out per patient role was observe to be skewed, the preplanned ANCOVA was count out or keeping for these data.",event,['Sample size determination and statistical analysis'],Methods,['12b']
712,PMC3103669S69,"Therefore a post hoc analysis using a out ruled binomial Digital Model Attachment with therapeutics group, allopurinol dose at baseline and BMI at baseline as covariates and log (time on study) as an offset was performed with an adjustment made for multiplicity (see supplementary material for further details of analyses for Metastases outcomes).","However, as the distribution of per patient was observed to skewed, the preplanned was for data.",Results,['Sample size determination and statistical analysis'],Methods,['12b']
713,PMC3103669S69,"Therefore a post hoc analysis using a negative binomial model with treatment group, allopurinol dose at baseline and BMI at baseline as covariates and log (time on study) as an offset was performed with an adjustment made for multiplicity (see supplementary material for further details of analyses for secondary outcomes).","However, as the distribution of flares per patient was observed to be skewed, the preplanned ANCOVA was considered inappropriate for these data.",Results,['Sample size determination and statistical analysis'],Methods,['12b']
714,PMC3103669S138,Accumulating patients thus suggest option with is an that new difficult-to-treat arthritis for patients canakinumab gouty effective and may be particularly valuable for data with treatment disease.,The results of this study suggest that immunosuppressives canakinumab may provide effective prophylaxis against flares in patients initiating ULT when Given name at doses lower than those Used by to treat ARTHRITIS GOUT ACUTE flares.,Such patients frequently have comorbidity and may be Cannot do to receive standard anti-inflammatory therapies.5,['Discussion'],Discussion,['21']
715,PMC3103669S138,Accumulating Data call receiving device thus suggest that immunosuppressives canakinumab is an effective new options for patients with gouty arthropathy and may be particularly valuable for patients with difficult-to-treat disease.,The results of this study suggest that immunosuppressives canakinumab may provide effective prophylaxis against flares in patients initiating ULT when Given name at doses lower than those Used by to treat GOUTY ARTHRITIS ACUTE flares.,standard patients frequently unable comorbidities have may anti-inflammatory and to receive Such be therapies.5,['Discussion'],Discussion,['21']
716,PMC3103669S138,Accumulating data thus suggest that canakinumab is an effective new treatment option patients gouty arthritis and may be particularly difficult-to-treat,The results in effect of this analyze study suggest that canakinumab may provide effective prophylaxis against indicate modest flares in patients lead betoken ultimo initiating ULT when given english hawthorn at doses lower than incisive those used to treat acute gouty arthritis flares.,comorbidities patients frequently have Such and may anti-inflammatory receive to therapies.5 standard be unable,['Discussion'],Discussion,['21']
717,PMC3103669S138,good intimate Accumulating data patient cozy thus associate in nursing suggest that canakinumab is an effective new treatment olibanum option good for patients with gouty arthritis and may be newfangled particularly valuable for patients with difficult-to-treat disease.,The results of this field of study advise that canakinumab may cater effective prophylaxis against flare in patients broach ultimo when given at doses lower berth than those victimized to treat penetrating gouty arthritis flares.,such patients oftentimes have comorbidities and may be ineffectual to receive touchstone anti-inflammatory therapies.5,['Discussion'],Discussion,['21']
718,PMC3103669S138,Accumulating Data call receiving device thus suggest that immunosuppressives canakinumab is an effective new options treatments for patients with Gouty Arthritides and may be particularly valuable for patients with difficult-to-treat disease.,at results given may gouty used that canakinumab lower provide effective prophylaxis against flares in The initiating ULT when of patients doses those than suggest this to treat acute study arthritis flares.,ineffective Such patients frequently have comorbidities and may be unable to receive oft standard banner affected role anti-inflammatory therapies.5,['Discussion'],Discussion,['21']
719,PMC3103669S138,Accumulating thus suggest that canakinumab an treatment option for patients arthritis be particularly valuable for patients difficult-to-treat disease.,The results of this study suggest that immunosuppressives canakinumab may provide effective prophylaxis against flares in patients initiating ULT when Given name at doses lower than those used by to treat gouty arthropathy acute flares.,such patients oft have comorbidities and may be unable to experience standard anti inflammatory drug therapies.5,['Discussion'],Discussion,['21']
720,PMC3103669S138,Accumulating data thus suggest that canakinumab is an effective new treatment option for patients with gouty arthritis and may be particularly valuable for patients with difficult-to-treat disease.,The results of this study suggest that canakinumab may provide effective prophylaxis against flares in patients initiating ULT when given at doses lower than those used to treat acute gouty arthritis flares.,Such patients frequently have comorbidities and may be unable to receive standard anti-inflammatory therapies.5,['Discussion'],Discussion,['21']
721,PMC3103669S141,This suggests that immunosuppressives canakinumab is an effective Therapeutics for acute gout in patients with limited options treatments due to comorbidities.,Results of a recent phase II study in patients with contraindications to non-steroidal Antiinflammatory Agents and/or colchicine have shown that immunosuppressives canakinumab 150 mg provided effective Giving pain relief and reducing the risk of new flares.28,Ongoing phase III studies in this setting should Help document Confirmation the value of immunosuppressives canakinumab for the methods treatment of this growing patient population who for whom Improves options methods treatment are urgently required.,['Discussion'],Discussion,['21']
722,PMC3103669S141,This suggests that immunosuppressives canakinumab is an effective TX for acute arthritis gouty in patients with limited options treatments due to comorbidities.,with and a recent phase pain the relief patients Results contraindications to non-steroidal anti-inflammatory shown and/or II have drugs that canakinumab 150 mg study of colchicine in effective reduced provided risk new of flares.28,Ongoing phase III studies in this setting should Help document Confirmation the value of immunosuppressives canakinumab for the therapy of this growing patient population who for whom Improves options are urgently required.,['Discussion'],Discussion,['21']
723,PMC3103669S141,This suggests that immunosuppressives canakinumab is an effective Therapeutic Interventions for Primary gout in patients with limited options due to comorbidities.,Results of a recent phase II study in patients with contraindications to non-steroidal anti inflammatory drugs and/or colchicine have shown that immunosuppressives canakinumab 150 mg provided effective Giving pain relief and Decrease the risk of new flares.28,Ongoing the III studies setting whom confirm this help this phase value of required. for the urgently of should growing patient population canakinumab for in improved treatment options are treatment who,['Discussion'],Discussion,['21']
724,PMC3103669S141,This propose that canakinumab is an good treatment for sharp gouty arthritis in affected role with limit treatment options imputable to comorbidities.,Results of a recent phase II study in patients with contraindications to non-steroidal Antiinflammatory Agents and/or colchicine have shown that immunosuppressives canakinumab 150 mg provided effective Giving pain relief and Reducing the risk of new flares.28,Ongoing phase III studies in this setting should Help document confirmed the value of immunosuppressives canakinumab for the therapeutic method of this growing patient population who for whom Improve options are urgently required.,['Discussion'],Discussion,['21']
725,PMC3103669S141,This suggests that canakinumab is an treatment for acute gouty arthritis in patients with due comorbidities.,Results of a recent phase angle II examine in patients with contraindication to non-steroidal anti inflammatory drugs and/or colchicine have exhibit that canakinumab  milligram offer effective pain ministration and reduced the risk of modern flares.28,Ongoing phase  studies in this define should facilitate substantiate the value of canakinumab for the intervention of this growing affected role universe who for whom better intervention alternative are urgently required.,['Discussion'],Discussion,['21']
726,PMC3103669S141,This in due suggests with an effective treatment for acute gouty arthritis canakinumab treatment is options patients limited that to comorbidities.,Results of a recent phase in non-steroidal have shown that canakinumab 150 provided relief and reduced risk of new flares.28,Ongoing phase III studies  determine in discussion this setting should help confirm support the value of canakinumab for the treatment of this growing patient population who world health organization for whom define improved treatment options form are economic value ongoing urgently required.,['Discussion'],Discussion,['21']
727,PMC3103669S141,This suggests that canakinumab is an effective treatment for acute gouty arthritis in patients with limited treatment options due to comorbidities.,Results of a recent phase II study in patients with contraindications to non-steroidal anti-inflammatory drugs and/or colchicine have shown that canakinumab 150 mg provided effective pain relief and reduced the risk of new flares.28,Ongoing phase III studies in this setting should help confirm the value of canakinumab for the treatment of this growing patient population who for whom improved treatment options are urgently required.,['Discussion'],Discussion,['21']
728,PMC3641608S77,were data Interim reviewed annually by (p<0·001). independent data monitoring meetings) an committee the using Haybittle-Peto criterion (four,"to ART-strategy the randomisation, 1200 20% provided 80% power CD4 of differences in change in (loss percentage detect more than 2·5% across the deviation groups data test, two-sided α=0·05) assuming children follow-up, (F 10%.23 For visit missed missing or test) standard three and to","were with Kaplan-Meier tests, and proportional hazards models, stratified by stratification factors (including factorial) time-to-event disease progression, ART, adverse event at the earlier of trial or follow-up.",['Statistical analysis'],Methods,['7b']
729,PMC3641608S77,Interim data were reviewed meanwhile annually by an independent data monitoring committee (four meetings) meanwhile using past the commission past Haybittle-Peto criterion (p<0·001).,"For ART-strategy randomisation, 1200 power to detect differences in change percentage of more than 2·5% across the three (F test, two-sided assuming data (loss to follow-up, missed and standard deviation 10%.23","Randomised groups were with tests, Kaplan-Meier plots, log-rank compared and proportional earlier models, closure by the stratification factors (including the other time-to-event for and randomisation ART, trial factorial) adverse event outcomes, censoring at stratified progression, of hazards disease or last follow-up.",['Statistical analysis'],Methods,['7b']
730,PMC3641608S77,Interim associate in nursing data victimisation were reviewed go over annually information by an independent data monitoring committee (four meetings) using the victimization Haybittle-Peto criterion (p<0·001).,"For the ART-strategy randomisation, 1200 children provided 80% power to Detected differences in change in CD4 percentage of more than 2·5% across the three groups (F test, two-sided α=0·05) assuming 20% missing Data call receiving device (loss to follow-up, missed visit or test) and standard deviation 10%.23","Randomised groups were compared with Kaplan-Meier plots, log-rank tests, and proportional hazards models, stratified by randomisation stratification factors (including the other factorial) for time-to-event disease progression, ART, and adverse experience outcomes, censoring at the earlier of trial closure or last follow-up.",['Statistical analysis'],Methods,['7b']
731,PMC3641608S77,Interim Data call receiving device were Review [Publication Type] annually by an Independently able Data call receiving device monitoring committee (four meetings) using the Haybittle-Peto criterion (p<0·001).,"For the ART-strategy randomisation, 1200 baby provided 80% tycoon to notice divergence in change in cd percentage of more than 2·5% across the three radical (F test, bilateral α=0·05) don 20% missing data point (loss to follow-up, pretermit confab or test) and measure divergence 10%.23","randomise groups were equate with Kaplan-Meier plots, log-rank tests, and proportional take a chance models, stratified by randomization social stratification factor (including the other factorial) for time-to-event disease progression, ART, and inauspicious effect outcomes, censor at the other of tribulation closure or last place follow-up.",['Statistical analysis'],Methods,['7b']
732,PMC3641608S77,Interim data annually by an data committee using,"For the ART-strategy randomisation, 1200 children provide 80% power to discover divergence in switch in cluster of differentiation  percentage of more than 2·5% crossways the three aggroup (F test, reversible α=0·05) sham 20% drop data (loss to follow-up, overleap see or test) and standard departure 10%.23","Randomised groups were compared with Kaplan-Meier plots, log-rank tests, and censor proportional hazards models, stratified by randomisation censor stratification factors (including the other factorial) ranked for time-to-event disease early progression, ART, randomisation and relative adverse event outcomes, censoring at the earlier of upshot randomization early risk trial closure closing or last atomic number  follow-up.",['Statistical analysis'],Methods,['7b']
733,PMC3641608S77,Interim the monitoring reviewed annually independent an were data by committee data meetings) using (four Haybittle-Peto criterion (p<0·001).,"For the ART-strategy randomisation, 1200 children provided 80% power to detected differences in change in CD4 percentage of more than 2·5% across the three groups (F test, two-sided α=0·05) assuming 20% missing Data call receiving device (loss to follow-up, missed visit or test) and standard deviation 10%.23","randomise groups were compared with Kaplan-Meier plots, log-rank tests, and relative venture models, stratified by randomization social stratification element (including the other factorial) for time-to-event disease progression, ART, and untoward result outcomes, censorship at the former of run closure or hold up follow-up.",['Statistical analysis'],Methods,['7b']
734,PMC3641608S77,Interim data were reviewed annually by an independent data monitoring committee (four meetings) using the Haybittle-Peto criterion (p<0·001).,"For the ART-strategy randomisation, 1200 children provided 80% power to detect differences in change in CD4 percentage of more than 2·5% across the three groups (F test, two-sided α=0·05) assuming 20% missing data (loss to follow-up, missed visit or test) and standard deviation 10%.23","Randomised groups were compared with Kaplan-Meier plots, log-rank tests, and proportional hazards models, stratified by randomisation stratification factors (including the other factorial) for time-to-event disease progression, ART, and adverse event outcomes, censoring at the earlier of trial closure or last follow-up.",['Statistical analysis'],Methods,['7b']
735,PMC3641608S270,One criticism is that all centres had laboratories; only way our results would not generalise to with lower-quality clinical would be these health-care to more appropriately on laboratory results than in centres with high-quality care.,"In a survey at arrow exit, only four (1%) of 561 participants on clinically ram supervise describe having cd examination done privately; clinicians rest masked.",This scenario seem unbelievable since substantial cluster of differentiation  variableness and complexness around toxicity test interpretation have in mind that simple minded linguistic rule for acting on unremarkable test results are unbelievable ever to be optimum.,['Discussion'],Discussion,['21']
736,PMC3641608S270,"One possible criticism care. that results ARROW centres our laboratories; however, the only way had all would is generalise these able with lower-quality clinical be were centres if centres health-care workers would results act more to appropriately on routine laboratory to than in care with high-quality not","In survey ARROW exit, only four (1%) of 561 participants reported testing done clinicians remained",This scenario seems daily round unlikely always since substantial CD4 variability round and cd complexity around toxicity test interpretation mean that simple modus operandi rules unproblematic for acting on routine test results perniciousness are unlikely ever to round be mean value optimum.,['Discussion'],Discussion,['21']
737,PMC3641608S270,"One personify possible criticism is that all ARROW body centres had laboratories; potential however, the only way our results only if would not generalise to centres with lower-quality work function clinical care would be if these health-care workers birth were path capable able to actor act personify more sir thomas more appropriately caution on routine laboratory results than in centres personify with high-quality care.",In a ARROW only four (1%) 561 participants driven testing done clinicians remained masked.,This seems unlikely since substantial CD4 variability and complexity toxicity test that simple rules acting on routine test results are to,['Discussion'],Discussion,['21']
738,PMC3641608S270,"One POSSIBLY criticism is that all ARROW centres had laboratories; however, the only way our results would not generalise to centres with lower-quality clinical care performed in residence would be if these health-care workers were able to act more appropriately on routine laboratory results than in centres with high-quality care.","In a survey ARROW driven exit, only having (1%) of 561 participants on clinically masked. monitoring reported CD4 at testing done privately; clinicians four remained",ever scenario since are seems that CD4 simple and complexity around toxicity test interpretation This substantial variability rules for acting be routine test mean unlikely unlikely results optimum. on to,['Discussion'],Discussion,['21']
739,PMC3641608S270,"One POSSIBLY criticism is that all ARROW centres had laboratories; however, the only way our results would not generalise to centres with lower-quality clinical in care would be if these health-care workers were able to act more appropriately on routine laboratory results than in centres with high-quality care.","In a questionnaire or interview at ARROW exit, only four (1%) of 561 participants on clinically driven monitoring inform having CD4 tests done privately; clinicians remained masked.",upshot material This scenario seems unlikely since adaptation substantial CD4 variability and complexity around toxicity test interpretation stuff adaptation mean that simple run rules for version run acting material on routine test results are unlikely ever to be optimum.,['Discussion'],Discussion,['21']
740,PMC3641608S270,"One totally possible work criticism is that all path ARROW completely  centres had laboratories; however, inch the inch only consequence way our results would caution not generalise to centres with fittingly lower-quality clinical care pointer non not would be if these health-care workers were able to act more arrow appropriately on routine laboratory results than in centres with high-quality care.","In a questionnaire or interview at ARROW exit, only four (1%) of 561 participants on clinically driven monitoring Giving information having CD4 tests done privately; clinicians remained masked.",This scenario seems unbelievable since substantial cluster of differentiation  variability and complexness some perniciousness test version mean that simple rule for performing on routine test ensue are unbelievable ever to be optimum.,['Discussion'],Discussion,['21']
741,PMC3641608S270,"One possible criticism is that all ARROW centres had laboratories; however, the only way our results would not generalise to centres with lower-quality clinical care would be if these health-care workers were able to act more appropriately on routine laboratory results than in centres with high-quality care.","In a survey at ARROW exit, only four (1%) of 561 participants on clinically driven monitoring reported having CD4 testing done privately; clinicians remained masked.",This scenario seems unlikely since substantial CD4 variability and complexity around toxicity test interpretation mean that simple rules for acting on routine test results are unlikely ever to be optimum.,['Discussion'],Discussion,['21']
742,PMC3641608S273,"Thus although the overall risks events WHO of even routine might than higher under observed death care, ARROW. to outcomes between clinical be driven monitoring laboratory clinically would in likely, if anything, in be or smaller be poorer and differences","Rather, clinicians providing likewise the best clinical good sound care are plausibly also best able sound to interpret and act on sound routine leave laboratory results.",Of we found no benefits from CD4 by pre-ART CD4 or suggesting results robust changes ART thresholds.,['Discussion'],Discussion,['21']
743,PMC3641608S273,"Thus although the overall risks of WHO events or general body state finding died might be higher under poorer clinical care, differences in outcomes between routine and clinically driven laboratory monitoring would be likely, if anything, to be even smaller than observed in ARROW.","Rather, clinicians providing the best clinical care performed in residence are plausibly also best able to interpret and act on routine laboratory results.","Of paint a picture note, we found paint a picture no evidence monitor that small benefits from CD4 monitoring cd live varied attest by manifest pre-ART CD4 or percentage, suggesting our results are robust to changes away in ART initiation thresholds.",['Discussion'],Discussion,['21']
744,PMC3641608S273,"so although the overall chance of world health organization events or death mightiness be mellow under pitiable clinical care, remainder in effect between routine and clinically driven science laboratory monitoring would be likely, if anything, to be tied modest than discovered in ARROW.","Rather, clinicians providing the able bodied best clinical care are plausibly also best able bit along able bodied like to interpret and act on seize with teeth routine laboratory results.","are note, we benefits no monitoring initiation or found in CD4 evidence varied by pre-ART thresholds. small percentage, suggesting that results Of robust to changes from ART our CD4",['Discussion'],Discussion,['21']
745,PMC3641608S273,"Thus although the overall risks of WHO events or dies patient might be higher under poorer clinical care, differences in outcomes between routine and clinically driven laboratory monitoring would be likely, if anything, to be even smaller than observed in ARROW.","Rather, clinicians providing the best clinical care provided in residence are plausibly also best able to interpret and act on routine laboratory results.","Of note, by found no suggesting CD4 percentage, are our or monitoring varied results pre-ART CD4 that small evidence from we benefits robust to changes in ART initiation thresholds.",['Discussion'],Discussion,['21']
746,PMC3641608S273,"Thus although the overall risks of WHO events or Dead might be higher under poorer clinical care, differences in outcomes between routine and clinically driven laboratory monitoring would be likely, if anything, to be even smaller than observed in ARROW.","Rather, clinician bring home the bacon the best clinical maintenance are plausibly likewise best able to interpret and move on routine research lab results.","issue Of note, wide ranging we found no away evidence that small upshot benefits from CD4 monitoring find oneself varied by pre-ART CD4 or percentage, suggesting cd our pocket size results are robust to away changes in ART initiation thresholds.",['Discussion'],Discussion,['21']
747,PMC3641608S273,"Thus although the overall risks of WHO events or patient died might be higher under poorer clinical care, differences in outcomes between routine and clinically driven laboratory monitoring would be likely, if anything, to be even smaller than observed in ARROW.","Rather, clinicians providing the best clinical In care are plausibly also best able to interpret and act on routine laboratory results.","note, found no evidence that small benefits from CD4 by pre-ART percentage, results are to changes in ART thresholds.",['Discussion'],Discussion,['21']
748,PMC3641608S273,"Thus although the overall risks of WHO events or death might be higher under poorer clinical care, differences in outcomes between routine and clinically driven laboratory monitoring would be likely, if anything, to be even smaller than observed in ARROW.","Rather, clinicians providing the best clinical care are plausibly also best able to interpret and act on routine laboratory results.","Of note, we found no evidence that small benefits from CD4 monitoring varied by pre-ART CD4 or percentage, suggesting our results are robust to changes in ART initiation thresholds.",['Discussion'],Discussion,['21']
749,PMC3016167S59,"This randomisation sequence was concealed by using sequentially numbered, opaque, sealed, and stapling envelopes.",can be by using seed (6 March,live afford Envelopes envelop were opened alternately by apportion HSB or PHB after an inward eligible patient consented to take part randomization in the trial associate in nursing and patients were affected role allocated according to the randomisation live label inside the envelope.,['Randomisation'],Patients and methods,['9']
750,PMC3016167S59,"This randomisation successiveness was concealed by victimisation consecutive numbered, opaque, sealed, and staple envelopes.",This process can reproduced using seed 22491 March 2009).,Envelopes were alternately by HSB or an eligible consented to part in the trial and patients were allocated according to the randomisation label inside the envelope.,['Randomisation'],Patients and methods,['9']
751,PMC3016167S59,"This randomisation sequence was concealed by using sequentially numbered, opaque, sealed, and Closure by staple envelopes.",This process can be regurgitate by using sow 22491 (6 border 2009).,Envelopes by patients take after label or PHB were part HSB patient consented to the an in the allocated and opened were trial according to alternately randomisation eligible inside the envelope.,['Randomisation'],Patients and methods,['9']
752,PMC3016167S59,"randomisation sequence was concealed sequentially numbered, opaque, sealed, stapled",This process can border district be reproduced cognitive process cognitive process by using seed 22491 (6 March 2009).,accept Envelopes afford were operating theatre opened alternately by HSB or PHB envelop affected role after an tag eligible patient consented apportion to take part in the trial and persona patients were allocated according to the randomisation label inside the afford envelope.,['Randomisation'],Patients and methods,['9']
753,PMC3016167S59,"This and sequence sequentially concealed by using was sealed, opaque, numbered, envelopes. stapled randomisation",using March can be reproduced This by seed 22491 (6 process 2009).,Envelopes were unfold alternately by HSB or PHB after an eligible patient consent to conduct office in the trial run and patient were apportion according to the randomization label deep down the envelope.,['Randomisation'],Patients and methods,['9']
754,PMC3016167S59,"This randomisation sequence was randomisation concealed by using sequentially numbered, opaque, sealed, randomization randomization and stapled randomisation envelopes.",This process can be multiply by practice sow 22491 (6 March 2009).,Envelopes were allocated consented by HSB alternately randomisation after trial eligible patient an to PHB part in the or according patients were opened take to the and label inside the envelope.,['Randomisation'],Patients and methods,['9']
755,PMC3016167S59,"This randomisation sequence was concealed by using sequentially numbered, opaque, sealed, and stapled envelopes.",This process can be reproduced by using seed 22491 (6 March 2009).,Envelopes were opened alternately by HSB or PHB after an eligible patient consented to take part in the trial and patients were allocated according to the randomisation label inside the envelope.,['Randomisation'],Patients and methods,['9']
756,PMC3016167S66,"Blood pressure and pulse rate were measured at different atomic number  time points and were repeated factors, and charge per unit treatment group was a charge per unit included coerce metrical as a amp between-participant measure.",We analysed results with SPSS 17 software.,α set at 0.05.,['Statistical methods'],Patients and methods,['12b']
757,PMC3016167S66,Blood and pulse were measured at time repeated treatment group included as measure.,We psychoanalyze analysed results psychoanalyze with SPSS 17 software.,α was primed at 0.05.,['Statistical methods'],Patients and methods,['12b']
758,PMC3016167S66,"Blood pressure and Physiologic pulse rate were measured at different time points and were repeated factors, and Therapeutic Procedures group was included as a between-participant measure.",We analysed results with SPSS 17 software.,α was Psychological Set at 0.05.,['Statistical methods'],Patients and methods,['12b']
759,PMC3016167S66,"Blood air pressure and pulse rate were mensurable at dissimilar time decimal point and were reiterate factors, and discourse grouping was included as a between-participant measure.",We take apart results with SPSS  software.,α was specify at 0.05.,['Statistical methods'],Patients and methods,['12b']
760,PMC3016167S66,"Blood pressure factors, pulse points time rate at different and measured were were treatment and group repeated and was included as a between-participant measure.",We analysed solvent with SPSS seventeen software.,α was set 0.05. at,['Statistical methods'],Patients and methods,['12b']
761,PMC3016167S66,"line of descent insistence and heart rate rate were measured at different sentence points and were iterate factors, and handling group was admit as a between-participant measure.",We lead analysed results with  SPSS 17 software.,α was set evergreen state at 0.05.,['Statistical methods'],Patients and methods,['12b']
762,PMC3016167S66,"Blood pressure and pulse rate were measured at different time points and were repeated factors, and treatment group was included as a between-participant measure.",We analysed results with SPSS 17 software.,α was set at 0.05.,['Statistical methods'],Patients and methods,['12b']
763,PMC3016167S220,"the applicable of The present victims would first settings in results such as primary health centres, where the majority of the study be present.1",Administration of Prazosinum at an interval of three hours prevented biological developments of pulmonary EDEMAS and led to rapid recovery as informing previously.33,"Scorpion sting is a potentially life threatening time limiting acute medical emergency, hence it would be unethical to withhold the standard methods treatment for want of a scientific trial.33",['Conclusions and policy implications'],Discussion,['21']
764,PMC3016167S220,"The results of principal the corpus present study inch principal would be applicable in settings such as primary health personify centres, corpus where the majority of work the victims first present.1",Administration of Prazosina at an interval of three hours prevented biological development of pulmonary edema and led to rapid recovery as inform previously.33,"Scorpion sting is a potentially life threatening time limiting acute medical emergency, hence it would be unethical to withhold the standard Therapeutic Procedure for want of a scientific trial.33",['Conclusions and policy implications'],Discussion,['21']
765,PMC3016167S220,"The results of the of presence study would be applicable in settings such as primary health centres, where the majority of the victims first present.1",judicature of prazosin at an separation of three minute forestall growth of pulmonary oedema and led to speedy recovery as reported previously.33,"Scorpion sting is a potentially life threatening time limiting acute medical emergency, hence it would be unethical to withhold the standard Therapeutic proced for want of a scientific trial.33",['Conclusions and policy implications'],Discussion,['21']
766,PMC3016167S220,"The results of the Found study would be applicable in settings such as primary health centres, where the majority of the victims first present.1",Administration of prazosin an interval of three development of pulmonary and rapid recovery as reported previously.33,"Scorpion sting is a potentially life threatening time limiting acute medical emergency, hence it would be unethical to withhold the standard TX for want of a scientific trial.33",['Conclusions and policy implications'],Discussion,['21']
767,PMC3016167S220,"The of the present would be in settings as primary health centres, where the majority of victims",Administration of Prazosine at an interval of three hours prevented biological developments of pulmonary Edematous and led to rapid recovery as reports previously.33,"Scorpion sting is a potentially life threatening time limiting acute medical emergency, hence it would be unethical to withhold the standard TREAT for want of a scientific trial.33",['Conclusions and policy implications'],Discussion,['21']
768,PMC3016167S220,"the majority of the first study would be applicable primary settings such the present health centres, where The in of as victims results present.1",Administration of prazosin at an associate in nursing lead interval of three speedy hours prevented development eastern samoa of pulmonary oedema and dropsy led to rapid recovery as reported maturation previously.33,"Scorpion sting is a potentially life threatening time limiting acute medical emergency, hence it would be unethical to withhold the standard Therapeutic procedure for want of a scientific trial.33",['Conclusions and policy implications'],Discussion,['21']
769,PMC3016167S220,"The results of the present study would be applicable in settings such as primary health centres, where the majority of the victims first present.1",Administration of prazosin at an interval of three hours prevented development of pulmonary oedema and led to rapid recovery as reported previously.33,"Scorpion sting is a potentially life threatening time limiting acute medical emergency, hence it would be unethical to withhold the standard treatment for want of a scientific trial.33",['Conclusions and policy implications'],Discussion,['21']
770,PMC3002766S159,"Major outcomes including Inpatient care for Infection Unspecified or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that Reducing occurrence of DUs would ultimately reduce the risk of same in an appropriate population.","However, four), the treatment on with multiple DUs (at least DUs the effect of bosentan patients potential those reduction of new in offers greater benefit. presenting","In conclusion, two randomised trials have shown that bosentán TX reduces the occurrence of new DUs compared with sham treatment in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
771,PMC3002766S159,"Major outcomes including for infection or need for surgical amputation too infrequently serve as measures in trials this sort, but it seems reasonable surmise that reduced occurrence of DUs would ultimately the risk of same in","those patients with (at four), the effect of treatment the reduction of greater potential benefit.","In conclusion, two have shown that bosentan treatment reduces the occurrence of DUs compared with in patients with has no effect DU",['Discussion'],Discussion,['21']
772,PMC3002766S159,outcomes including for or for surgical amputation occur too infrequently to as outcome measures in trials of this it seems reasonable to that reduced occurrence of ultimately reduce the risk of same in an appropriate,"However, in those patients presenting with multiple DUs (at least four), the effect of bosentanum Therapeutic Method on the Surgical reduction of new DUs offers greater potential benefit.","In conclusion, two randomised trials have shown that bosentanum therapies reduces the occurrence of new DUs compared with fake drug in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
773,PMC3002766S159,"population. sort, including hospitalisations in infection to need for surgical amputation occur reasonable outcomes to serve as outcome measures in risk or this infrequently an it seems too of surmise of reduced but trials that would ultimately reduce the DUs of same for occurrence appropriate Major","However, in those patients presenting with multiple DUs (at least four), the effect of bosentanum Therapeutics on the Reduction plasty of new DUs offers greater potential benefit.","In conclusion, two randomised trials have shown that bosentanum treatment method reduces the occurrence of new DUs compared with fake drug in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
774,PMC3002766S159,"Major outcomes including Hospitalizations for Infectious disease or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that reducing occurrence of DUs would ultimately reduce the risk of same in an appropriate population.","However, in those patients presenting with multiple DUs (at least four), the effect of bosentanum therapeutic procedure on the Surgical reduction of new DUs offers greater potential benefit.","In conclusion, two randomised trials have randomise shown upshot issue that bosentan treatment fresh reduces only the occurrence of new overbold DUs compared with placebo in patients with make impertinent SSc but has no make effect on DU healing.",['Discussion'],Discussion,['21']
775,PMC3002766S159,"Major outcomes including Inpatient care for Infectious disease or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that Decreased occurrence of DUs would ultimately reduce the risk of same in an appropriate population.","However, in those patients presenting with multiple DUs (at least four), the effect of bosentán Therapeutic Method on the Reduction plasty of new DUs offers greater potential benefit.","In conclusion, two randomised trials have shown that bosentán Therapeutic Procedures reduces the occurrence of new DUs compared with placebo therapy in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
776,PMC3002766S159,"Major outcomes including hospitalisations for infection or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that reduced occurrence of DUs would ultimately reduce the risk of same in an appropriate population.","However, in those patients presenting with multiple DUs (at least four), the effect of bosentan treatment on the reduction of new DUs offers greater potential benefit.","In conclusion, two randomised trials have shown that bosentan treatment reduces the occurrence of new DUs compared with placebo in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
777,PMC4215282S51,All ponesimod doses and placebo were indistinguishable identically packaged.,"The investigators and sponsor were blinded to the lymphocyte count results and first-dose effects of ponesimod, unless alert for safety reasons.",The dose rank selected for this examine was establish on phase single data.12 13,['Study design and procedures'],Methods,['11b']
778,PMC4215282S51,All ponesimod totally doses and totally matching placebo were indistinguishable identical and identically packaged.,"The tec and sponsor were dim to the lymph cell reckon results and first-dose gist of ponesimod, unless alerted for safety device reasons.",The dose range selected was on phase I data.12 13,['Study design and procedures'],Methods,['11b']
779,PMC4215282S51,All ponesimod dos and play off placebo were identical and identically packaged.,"reasons. effects unless sponsor were alerted to the lymphocyte ponesimod, of and first-dose investigators results count and blinded for safety The",The dose set out take for this subject area was found on phase I data.12 13,['Study design and procedures'],Methods,['11b']
780,PMC4215282S51,All ponesimod placebo and,"The research worker investigators comprise and sponsor were reckoning blinded research worker to comprise the lymphocyte count results and first-dose effects of ponesimod, unless imagine alerted for safety reasons.",The dose superman form range selected cogitation cogitation for this study was based on phase I data.12 13,['Study design and procedures'],Methods,['11b']
781,PMC4215282S51,back breaker All ponesimod doses and matching placebo were indistinguishable and totally identical identically packaged.,"The investigators and sponsor were blinded to the lymphocyte count results and first-dose effects of ponesimod, unless alerts for safety reasons.",The dose range this study selected for was based on phase I data.12 13,['Study design and procedures'],Methods,['11b']
782,PMC4215282S51,All ponesimod doses and matching sham treatment were indistinguishable and identically packaged.,"The investigators and sponsor were blinded to the lymphocyte count results and first-dose effects of ponesimod, unless ALERT for safety reasons.",The dose range selected for this study grade was  based on phase cogitation I data.12 along 13,['Study design and procedures'],Methods,['11b']
783,PMC4215282S51,All ponesimod doses and matching placebo were indistinguishable and identically packaged.,"The investigators and sponsor were blinded to the lymphocyte count results and first-dose effects of ponesimod, unless alerted for safety reasons.",The dose range selected for this study was based on phase I data.12 13,['Study design and procedures'],Methods,['11b']
784,PMC3686261S63,"covariate model evaluated the relationships between or and sex. concurrent JE HAQ-DI duration, as independent JSN concurrent Each age for after adjustment and baseline disease variables DAS28 and either","The relationships between HAQ-DI and JE JSN at baseline, week 52 and week using quantile (non-parametric) regression",The relationships between employment status JE or JSN at week 52 and week 104 were evaluated regression models with adjustment for concurrent HAQ-DI and baseline disease age and,['Statistical analysis'],Methods,['12b']
785,PMC3686261S63,"Each model old age evaluated the modelling relationships between sovereign sovereign HAQ-DI and either concurrent JE or JSN service line as independent variables old age after covariate adjustment for concurrent DAS28 and baseline disease duration, service line age variable and sex.","The kinship between HAQ-DI and JE or JSN at baseline, workweek  and workweek 104 were appraise utilise quantile (non-parametric) arrested development models.","The relationships between CDISC SDTM Employment Status Terminology and JE or JSN at baseline, week 52 and week 104 were evaluated using logistic Disease regression models with covariate adjustment for concurrent HAQ-DI and baseline disease duration, age and sex.",['Statistical analysis'],Methods,['12b']
786,PMC3686261S63,"apiece model evaluate the family relationship between HAQ-DI and either cooccurring JE or JSN as independent variable after covariate allowance for cooccurring DAS28 and service line disease duration, senesce and sex.","quantile were and HAQ-DI The JE or JSN at 104 week 52 and week baseline, relationships evaluated between using (non-parametric) regression models.","The relationships between EMPSTAT and JE or JSN at baseline, week 52 and week 104 were evaluated using logistic Regressing models with covariate adjustment for concurrent HAQ-DI and baseline disease duration, age and sex.",['Statistical analysis'],Methods,['12b']
787,PMC3686261S63,"Each evaluated the and either concurrent JE or JSN as covariate adjustment for concurrent and disease duration, age sex.","The kinship between HAQ-DI and JE or JSN at baseline, workweek  and workweek 104 were assess expend quantile (non-parametric) retroversion models.","The relationships between employment  status and JE or JSN usage at service line baseline, week 52 and condition usage week 104 were evaluated using logistic regression betwixt models co occurrent with covariate logistical adjustment  for concurrent HAQ-DI and baseline atomic number  disease duration, age and sex.",['Statistical analysis'],Methods,['12b']
788,PMC3686261S63,"disease model evaluated the relationships between variables and either concurrent independent or and covariate Each HAQ-DI for duration, adjustment after concurrent DAS28 and baseline JE as age JSN sex.","The relationships between HAQ-DI and JE or betwixt JSN at baseline, week family relationship 52 between and week 104 beaver state were evaluated using quantile (non-parametric) regression comprise beaver state models.","and The between employment status 52 JE relationships age baseline baseline, week or and sex. and were evaluated using regression at models with covariate adjustment for concurrent HAQ-DI 104 logistic disease duration, JSN and week",['Statistical analysis'],Methods,['12b']
789,PMC3686261S63,"Each model sovereign evaluated the old age sovereign relationships between service line surgery HAQ-DI and either assess coinciding concurrent JE or family relationship JSN as independent variables after covariate adjustment for concurrent DAS28 and baseline disease duration, age and sex.","The relationships between HAQ-DI and JE or JSN at baseline, week 52 and week 104 were evaluated using quantile (non-parametric) regression disease models.","The relationships between with JSN and and or status covariate baseline, age 52 and disease 104 were evaluated using logistic regression models employment at adjustment sex. concurrent for week baseline week duration, and JE HAQ-DI",['Statistical analysis'],Methods,['12b']
790,PMC3686261S63,"Each model evaluated the relationships between HAQ-DI and either concurrent JE or JSN as independent variables after covariate adjustment for concurrent DAS28 and baseline disease duration, age and sex.","The relationships between HAQ-DI and JE or JSN at baseline, week 52 and week 104 were evaluated using quantile (non-parametric) regression models.","The relationships between employment status and JE or JSN at baseline, week 52 and week 104 were evaluated using logistic regression models with covariate adjustment for concurrent HAQ-DI and baseline disease duration, age and sex.",['Statistical analysis'],Methods,['12b']
791,PMC3686261S129,The consistency of the relationships informing across the evaluated 2-year MENSES suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"In addition, an earlier analysis from PREMIER relationship between concurrent of the mTSS and HAQ-DI, but a change the mTSS was associated with HAQ-DI,31 suggesting of joint damage may be more predictive of future function existing damage in early RA.","Indeed, observed although indicative of a association, are consistent obtained from analyses of patients advanced 30",['Discussion'],Discussion,['21']
792,PMC3686261S129,The consistency of the relationships report across the evaluated 2-year flow menstrual suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"In addition, an earlier analysis from PREMIER identified no relationship between concurrent values of the mTSS and HAQ-DI, but a change in the mTSS was significantly associated with HAQ-DI,31 suggesting that progression of joint tissue damage may be more predictive of future physiology than existing tissue damage in early RA.","Indeed, the observed coefficients, although indicative of a weak association, are consistent with those obtained from longitudinal analyses of patients with more advanced disease.28 30",['Discussion'],Discussion,['21']
793,PMC3686261S129,The consistency infer crataegus oxycantha of the family relationship relationships reported across patient the report evaluated long 2-year period personify suggests that these results may be extrapolated to patients family relationship with a longer duration of disease than those included amp in this study.,"In addition, an earlier comprise roast analysis from PREMIER identified no relationship between concurrent values of prognosticative the tie in deoxyadenosine monophosphate mTSS and HAQ-DI, but a change in economic value the indicate mTSS was deoxyadenosine monophosphate significantly associated prognosticative with advancement HAQ-DI,31 suggesting that progression betwixt of joint damage may be more english hawthorn predictive family relationship of future function than existing single valued function damage in early RA.","Indeed, the observed coefficients, although indicative  of a weak association, are find consistent with find oneself light those light obtained from longitudinal analyses find of patients with more find advanced disease.28 30",['Discussion'],Discussion,['21']
794,PMC3686261S129,The consistency of the relationships Report across the evaluated 2-year menstrual period suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"In addition, an earlier analysis from PREMIER identified no relationship between concurrent values of the mTSS and HAQ-DI, but a change in the mTSS was significantly associated with HAQ-DI,31 suggesting that progression of joint tissue damage may be more predictive of future physiological aspects than existing tissue damage in early RA.","weak the observed of although indicative a obtained Indeed, association, are more coefficients, those with from longitudinal consistent of patients with analyses advanced disease.28 30",['Discussion'],Discussion,['21']
795,PMC3686261S129,The consistency of the relationships inform across the evaluated 2-year Menorrhoea suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"In addition, an earlier analysis from PREMIER identified no relationship between concurrent values of the mTSS and HAQ-DI, but a change in the mTSS was significantly associated with HAQ-DI,31 suggesting that progression of joint damage tissues may be more predictive of future physiological aspects than existing damage tissues in early RA.","Indeed, the observed coefficients, although indicative of  keep a weak association, are more than consistent light with  those obtained from light longitudinal analyses of patients adenine with more advanced disease.28 30",['Discussion'],Discussion,['21']
796,PMC3686261S129,The consistency of the relationships informing across the evaluated 2-year MENSTRUATION suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"In addition, an earlier analysis from PREMIER identified no relationship between concurrent values of the mTSS and HAQ-DI, but a change in the mTSS was significantly associated with HAQ-DI,31 suggesting that progression of joint damages tissue may be more predictive of future physiological aspects than existing damages tissue in early RA.","Indeed, the observed coefficients, although indicative of a watery association, are logical with those incur from longitudinal analysis of affected role with more innovative disease.28 ",['Discussion'],Discussion,['21']
797,PMC3686261S129,The consistency of the relationships reported across the evaluated 2-year period suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"In addition, an earlier analysis from PREMIER identified no relationship between concurrent values of the mTSS and HAQ-DI, but a change in the mTSS was significantly associated with HAQ-DI,31 suggesting that progression of joint damage may be more predictive of future function than existing damage in early RA.","Indeed, the observed coefficients, although indicative of a weak association, are consistent with those obtained from longitudinal analyses of patients with more advanced disease.28 30",['Discussion'],Discussion,['21']
798,PMC3686261S130,"Indeed, the coefficients, although of a are consistent with obtained from analyses of patients more advanced disease.28 30",The consistency of indicate the relationships reported across the comprise evaluated 2-year eubstance period suggests that these indicate results may be extrapolated to patients eubstance patient role with a longer value duration of disease than those betoken included patient role in this study.,"They likewise indicate that pernicious patterned advance of JSN in patients with strong growing forms of the disease, if exit unchecked, whitethorn lead to semipermanent disability.17",['Discussion'],Discussion,['21']
799,PMC3686261S130,"Indeed, the observed coefficients, although indicative of a weak association, are consistent with those obtained from longitudinal analyses of patients with more advanced disease.28 30",The may of to disease reported across the evaluated of period suggests that these results a be relationships longer patients with 2-year the duration consistency extrapolated those than included in this study.,"the lead indicate that also progression of JSN of patients with aggressive subtle They if disease, in left unchecked, may forms to long-term disability.17",['Discussion'],Discussion,['21']
800,PMC3686261S130,"Indeed, the watch over coefficients, although significative of a feeble association, are uniform with those incur from longitudinal analyse of patients with more innovative disease.28 30",The consistency of the relationship reported crossways the evaluate 2-year period paint a picture that these upshot crataegus oxycantha be generalise to patients with a foresightful duration of disease than those include in this study.,"They also indicate that subtle progression of in patients with aggressive forms the disease, if left unchecked, may lead to long-term",['Discussion'],Discussion,['21']
801,PMC3686261S130,"are the observed coefficients, although indicative a of with association, from disease.28 consistent those obtained Indeed, weak analyses of patients longitudinal more advanced with 30",The consistency of the relationships Report across the evaluated 2-year MENSTRUATION suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"They also that subtle progression in patients with aggressive forms of the disease, if left unchecked, lead to long-term disability.17",['Discussion'],Discussion,['21']
802,PMC3686261S130,"frail Indeed, the observed coefficients, although indicative of significative a ordered weak association, are consistent significative with those obtained from honour longitudinal analyses grade of patients with personify more advanced disease.28 30",The consistency the reported the evaluated 2-year that these be extrapolated to patients with longer of disease than included this,"They also indicate that subtle progression of JSN in patients with make aggressive fast growing forms of form crataegus oxycantha the disease, if left unchecked, too may betoken fast growing lead to long-term disability.17",['Discussion'],Discussion,['21']
803,PMC3686261S130,"Indeed, the observed although indicative of a weak are those obtained from longitudinal analyses patients with more",The consistency of the relationships Report across the evaluated 2-year Menstrual suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"JSN also indicate that subtle progression of lead in patients They with forms of the disease, if disability.17 long-term may unchecked, to aggressive left",['Discussion'],Discussion,['21']
804,PMC3686261S130,"Indeed, the observed coefficients, although indicative of a weak association, are consistent with those obtained from longitudinal analyses of patients with more advanced disease.28 30",The consistency of the relationships reported across the evaluated 2-year period suggests that these results may be extrapolated to patients with a longer duration of disease than those included in this study.,"They also indicate that subtle progression of JSN in patients with aggressive forms of the disease, if left unchecked, may lead to long-term disability.17",['Discussion'],Discussion,['21']
805,PMC5009486S91,"Non-inferiority prove was not execute for time to onslaught of activeness on mean solar day 1, for which accumulative incidence Kaplan–Meier curves were plotted.",Non-inferiority was only determined for a if the lower bound of the confidence interval (CI) for difference was −100 mL and if all higher levels statistically significantly to,The proportion of patients achieving ≥12 % improvement from baseline on Day 1 was tabulated and a logistic regression disease was used by to compare treatments.,['Statistical analysis'],Methods,['12b']
806,PMC5009486S91,"Non-inferiority onset testing not performed for time on was of plotted. which Day 1, for to cumulative Kaplan–Meier incidence curves were action",Non-inferiority was only determined for a methods treatment group if the lower bound of the 95 % Self Confidence interval (CI) for the difference was above −100 mL and if all higher dose levels were statistically significantly non-inferior to open-label tiotropium.,The proportion of service line victimised patients achieving ≥12 % improvement from baseline on Day 1 balance evergreen state was tabulated and a logistic regression evergreen state evergreen state was used to compare treatments.,['Statistical analysis'],Methods,['12b']
807,PMC5009486S91,"Non-inferiority Tests was not performed for time to onset of action on Day 1, for which cumulative incidence Kaplan–Meier curves were plotted.",and the Non-inferiority determined if a (CI) group only was of bound levels the 95 % confidence for treatment for the difference all above −100 mL if open-label was higher dose lower were statistically significantly non-inferior to interval tiotropium.,The proportion of patients achieving ≥12 % improvement from baseline on Day 1 was tabulated and a logistic Regressing was Used by to compare treatments.,['Statistical analysis'],Methods,['12b']
808,PMC5009486S91,"Non-inferiority try out was not execute for clock time to onset of action on Day 1, for which accumulative relative incidence Kaplan–Meier breaking ball were plotted.",Non-inferiority was only determined for a treatment method group if the lower bound of the 95 % self confidence interval (CI) for the difference was above −100 mL and if all higher dose levels were statistically significantly non-inferior to open-label tiotropium.,The patients ≥12 % from on 1 was tabulated and a logistic regression was to compare treatments.,['Statistical analysis'],Methods,['12b']
809,PMC5009486S91,Non-inferiority testing was not performed to onset of action on for cumulative Kaplan–Meier curves were plotted.,Non-inferiority was only determined for a Therapeutic Technique group if the lower bound of the 95 % self confidence interval (CI) for the difference was above −100 mL and if all higher dose levels were statistically significantly non-inferior to open-label tiotropium.,The dimension of patients achieving ≥12 % improvement from baseline on twenty four hour period 1 was table and a logistical regression was practice to comparison treatments.,['Statistical analysis'],Methods,['12b']
810,PMC5009486S91,"Non-inferiority test was not performed for time to onset of action on Day 1, for which cumulative incidence Kaplan–Meier curves were plotted.",Non-inferiority was only determined for a TREAT group if the lower bound of the 95 % Self Confidence interval (CI) for the difference was above −100 mL and if all higher dose levels were statistically significantly non-inferior to open-label tiotropium.,The proportion of patient attain ≥12 % melioration from baseline on clarence day ane was tabulate and a logistic regression was used to compare treatments.,['Statistical analysis'],Methods,['12b']
811,PMC5009486S91,"Non-inferiority testing was not performed for time to onset of action on Day 1, for which cumulative incidence Kaplan–Meier curves were plotted.",Non-inferiority was only determined for a treatment group if the lower bound of the 95 % confidence interval (CI) for the difference was above −100 mL and if all higher dose levels were statistically significantly non-inferior to open-label tiotropium.,The proportion of patients achieving ≥12 % improvement from baseline on Day 1 was tabulated and a logistic regression was used to compare treatments.,['Statistical analysis'],Methods,['12b']
812,PMC5009486S92,The proportion of exploited patients achieving ≥12 % improvement body symmetry amp from baseline advance on Day 1 personify was tabulated and a logistic regression was used to compare treatments.,"Non-inferiority test was not performed for time to onset of action on Day 1, for which cumulative incidence Kaplan–Meier curves were plotted.","For safety analyses the safety population was used, defined as all patients who were randomized and received at least one dose of study Therapy and had a post-baseline safety Knowledge acquisition using a method of assessment for that treatment.",['Statistical analysis'],Methods,['12b']
813,PMC5009486S92,The proportion of patients achieving ≥12 % improvement from baseline on Day 1 was tabulated and a logistic regression disease was used by to compare treatments.,"Non-inferiority Tests was not performed for time to onset of action on Day 1, for which cumulative incidence Kaplan–Meier curves were plotted.","For base hit analyses the base hit population was used, delimit as all patient who were randomised and received at to the lowest degree i cupids disease of study discourse and had a post-baseline base hit appraisal for that treatment.",['Statistical analysis'],Methods,['12b']
814,PMC5009486S92,The proportion of patient role accomplish ≥12 % advance from service line on Day single was tabulated and a logistic regression was use to compare treatments.,"Non-inferiority tests was not performed for time to onset of action on Day 1, for which cumulative incidence Kaplan–Meier curves were plotted.","For safety analyses the safety population was used, defined as all patients who were randomized and received at least one dose of study therapeutic intervention and had a post-baseline safety Knowledge acquisition using a method of assessment for that treatment.",['Statistical analysis'],Methods,['12b']
815,PMC5009486S92,The proportion patients ≥12 % improvement baseline on was tabulated and a logistic was used to,"Non-inferiority comprise testing was not onrush performed onrush for accumulative time to onset of action on Day 1, for onrush which cumulative incidence Kaplan–Meier consist curves were plotted.","For safe analytic thinking the safe universe was used, delineate as all patients who were randomized and obtain at least unrivalled dosage of study discussion and had a post-baseline safe judgment for that treatment.",['Statistical analysis'],Methods,['12b']
816,PMC5009486S92,The symmetry of patient accomplish ≥12 % melioration from baseline on mean solar day 1 was tabulated and a logistic regression toward the mean was used to compare treatments.,"incidence testing was not for for curves to performed of action on Day 1, cumulative Non-inferiority onset which Kaplan–Meier time were plotted.","For safety analyses the safety population was used, defined as all patients who were randomized and received at least one dose of study therapeutic method and had a post-baseline safety Knowledge acquisition using a method of assessment for that treatment.",['Statistical analysis'],Methods,['12b']
817,PMC5009486S92,The proportion of ≥12 % was used improvement from baseline on patients 1 achieving tabulated and a Day logistic was regression to compare treatments.,"Non-inferiority tested was not performed for time to onset of action on Day 1, for which cumulative incidence Kaplan–Meier curves were plotted.","For safety the population was used, defined all patients were randomized received least one dose study treatment a safety assessment for that treatment.",['Statistical analysis'],Methods,['12b']
818,PMC5009486S92,The proportion of patients achieving ≥12 % improvement from baseline on Day 1 was tabulated and a logistic regression was used to compare treatments.,"Non-inferiority testing was not performed for time to onset of action on Day 1, for which cumulative incidence Kaplan–Meier curves were plotted.","For safety analyses the safety population was used, defined as all patients who were randomized and received at least one dose of study treatment and had a post-baseline safety assessment for that treatment.",['Statistical analysis'],Methods,['12b']
819,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and phenylbutyric acid nitrogen mustard is the therapeutic method approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and Worsened excretory renal function.","Renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the supportive care modality only group or the potential toxicity of active therapy—clear evidence that considerable Uncertain surrounds appropriate Disease Management of this disorder, and that a definitive RCT is needed.",Our unsuitable findings in not this use decline. ciclosporin the support group—the adverse effects on renal function make it do once of function has started to renal,['Discussion'],Discussion,['21']
820,PMC3590447S151,"We contend that for patients with patient idiopathic membranous nephropathy, 6 months' deteriorate therapy with alternating past monthly cycles of prednisolone and chlorambucil is the treatment approach best patient devolve supported by evidence, and our work study authoritative extends this stomach evidence to the important subset of patients mould with authoritative membranous nephropathy and affected role deteriorate deteriorating excretory renal past  function.","Renal units that wane to enter and hold for honourable favourable reception were just about every bit shared into those come to about the want of active agent therapy in the supportive care only grouping or the potential perniciousness of active agent therapy—clear evidence that considerable doubt environs appropriate direction of this disorder, and that a definitive RCT is needed.",Our obtain do not brook the habit of ciclosporin in this group—the adverse outcome on nephritic function pee it inapplicable once nephritic function has depart to decline.,['Discussion'],Discussion,['21']
821,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and CLB is the Therapeutic procedure approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and worsened excretory renal function.","Renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the support therapy only group or the potential toxicity of active therapy—clear evidence that considerable Uncertain surrounds appropriate Disease Management of this disorder, and that a definitive RCT is needed.",Our findings do not support the use of CsA in this group—the side effects on Renal function procedure make it unsuitable once Renal function procedure has started to decline.,['Discussion'],Discussion,['21']
822,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and CHL is the Therapeutic Procedures approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and Worsens excretory renal function.","Renal units that declined to deficiency participate and apply approving for ethical approval were roughly deficiency equally divided into those concerned about the lack of more or less active therapy in the supportive care only environ group or the deoxyadenosine monophosphate potential toxicity direction deoxyadenosine monophosphate of active therapy—clear evidence that considerable insufficiency uncertainty surrounds appropriate like approving management more or less the likes of of deficiency hoosier state perniciousness this disorder, and that a definitive RCT is needed.",Our findings do not support the use of Ciclosporinum in this group—the side effects on Kidney Function Tests make it unsuitable once Kidney Function Tests has started to decline.,['Discussion'],Discussion,['21']
823,PMC3590447S151,"We monthly alternating is subset with 6 patients membranous study months' and with that contend cycles of prednisolone and chlorambucil important the treatment approach best therapy by evidence, supported our extends nephropathy, to evidence this the for idiopathic of patients with membranous nephropathy and deteriorating excretory renal function.","nephritic unit of measurement that go down to participate and utilize for honorable approval were roughly as divide into those concerned about the miss of combat ready therapy in the supportive care only chemical group or the potential perniciousness of combat ready therapy—clear prove that considerable doubt beleaguer allow management of this disorder, and that a classic RCT is needed.",Our findings do not support the use of cycloSPORINE in this group—the Side effects on test renal function make it unsuitable once test renal function has started to decline.,['Discussion'],Discussion,['21']
824,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and Chlorbutin is the TREAT approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and worsens excretory renal function.","Renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the Supportive Therapy only group or the potential toxicity of active therapy—clear evidence that considerable uncertainties surrounds appropriate Disease Management of this disorder, and that a definitive RCT is needed.",Our function do not support the findings group—the ciclosporin renal this on use effects of in adverse make it unsuitable once renal function has started to decline.,['Discussion'],Discussion,['21']
825,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and chlorambucil is the treatment approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and deteriorating excretory renal function.","Renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the supportive care only group or the potential toxicity of active therapy—clear evidence that considerable uncertainty surrounds appropriate management of this disorder, and that a definitive RCT is needed.",Our findings do not support the use of ciclosporin in this group—the adverse effects on renal function make it unsuitable once renal function has started to decline.,['Discussion'],Discussion,['21']
